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The emergence and global spread of antimicrobial resistance (AMR) is an increasingly serious 
threat to human and veterinary medicine. Driven by the misuse and overuse of antibiotics, 
resistance to our antibiotic armoury is rapidly outpacing our current efforts to discover and 
develop novel agents. In light of this, there is restimulated interest in exploiting metals for novel 
antibacterial strategies. Zinc is an essential metal ion for various cellular pathways in bacterial 
physiology, yet excess amounts are toxic. The involvement of zinc in modulating antibiotic 
efficacy and resistance pathways is also becoming increasingly evident. Zinc ionophores, 
molecules that transport zinc into cells, offer a strategy to capitalize on the anti-infective 
potential of this metal. The zinc ionophore PBT2, an 8-hydroxyquinoline derivative, has 
recently been discovered to potentiate zinc toxicity and antibiotic efficacy against several AMR 
pathogens, suggesting possibilities for zinc ionophores as a novel class of standalone antibiotic 
or antibacterial adjuvant in either animal or human medicine. A molecular understanding of 
these actions, however, is currently lacking. This body of work examines the bactericidal action 
of PBT2 against the veterinary pathogen Streptococcus uberis, and the underlying mechanism 
of synergy between PBT2 and β-lactam antibiotics against methicillin-resistant Staphylococcus 
aureus (MRSA).  
 A combination of bacterial physiology, biochemistry, genetics, and chemical biology 
approaches were utilised to investigate the mechanisms of zinc ionophores in both lines of this 
research. We revealed PBT2-mediated intracellular zinc accumulation disrupts zinc and 
manganese homeostasis and cellular redox balance in S. uberis, ultimately exerting its 
bactericidal action through intracellular zinc accumulation and manganese starvation, ROS 
accumulation, and the impairment of manganese-dependent antioxidant activity. We further 
demonstrated that β-lactam antibiotic resensitization in MRSA by PBT2 and related structural 
analogues is likewise associated with a destabilization of cellular zinc and manganese 
homeostasis. Mechanistic investigations revealed this zinc ionophoric activity perturbs multiple 
elements involved in β-lactam resistance in MRSA, including the expression of key resistance 
determinants, cell wall and membrane integrity, and the proton motive force (PMF). Further, 
PBT2 and β-lactam combination treatment significantly improved animal survival rates and 
pathogen clearance in a murine model of invasive MRSA infection. This study provides novel 
mechanisms of intracellular zinc toxicity and demonstrates a targetable overlap between metal 
homeostasis, cell wall and membrane metabolism and β-lactam resistance. Overall, this data 
contributes and adds to the field of bacterial metal homeostasis and exemplifies how it can be 
exploited for novel antibacterial strategies in veterinary and human medicine.  
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 Antimicrobial resistance (AMR) 
1.1.1 The AMR crisis 
The discovery of penicillin in 1928 marked the beginning of the golden age of antibiotic 
discovery, an era that revolutionized medicine (1). Bacterial infections that once accounted 
for significant morbidity and mortality could suddenly be treated effectively with these 
‘magic bullets’, contributing to significant improvements in human life expectancy. The 
continued efficacy of antibiotics in treating common infections, however, is threatened by 
the global spread of pathogens that have evolved mechanisms to resist inhibition or killing 
by specific drugs. This threat of antimicrobial resistance (AMR) severely undermines the 
many advances in modern medicine that depend upon effective antimicrobial treatments, 
including routine surgeries and immunosuppressive treatments for organ transplants and 
cancer chemotherapy (2, 3). Currently, AMR infections cause an estimated 700,000 deaths 
globally a year (3). While estimates of the current and projected burden of AMR on global 
health and economics are difficult to quantify reliably (4, 5), extensive evidence indicates 
that unless global coordinated efforts are immediately taken, we are heading towards a ‘post-
antibiotic’ era with dire medical and economic consequences (6).  
Most antibiotics in use today are either compounds discovered in the ‘golden era’ of 
antibiotic discovery during the 1940s to 1960s, or synthetic derivatives of these compounds 
(1). During this time, the Waksman platform of screening soil microorganisms for 
antibacterial activity discovered the large majority of clinically important antibiotic classes, 
including tetracyclines, macrolides, β-lactams, and aminoglycosides, among others (7) 
(Figure 1.1). Unfortunately, this natural source of antibacterial compounds became 
overmined, and the emergence of resistance outpaced the short-term success of its synthetic 
derivatives. Despite the anticipated success of the modern drug discovery platform 
developed in the late 1990s, based on a combination of genomics, proteomics, combinatorial 
chemistry and high-throughput screening, intensive efforts to develop novel antibiotics 
proved unsuccessful (8). Although inhibitors of essential bacterial proteins were discovered, 
this approach failed to generate compounds that sufficiently met the necessary antibacterial 
and pharmacological requirements to progress the pharmaceutical pipeline (1, 8, 9). 
Consequently, since the end of the golden era, only four new classes of antibiotics have 
successfully progressed to clinical practice (7) (Figure 1.1). The current paradigm of 
antibiotic development is insufficient to counter rising resistance, and if we are to preserve 
our achievements in modern medicine, innovation in antibacterial research and development 




Figure 1.1. Timeline of antibiotic discovery. Year of discovery (top) and clinical 
introduction (bottom) of novel antibiotic classes. The ‘golden era of antibiotic discovery’ is 
highlighted. Adapted from Lewis et al, 2020 (7) and Hutchings et al, 2019 (11). 
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1.1.1.1 Mechanisms of AMR 
Antibiotic resistance is broadly achieved by either the enzymatic inactivation or 
modification of the antibiotic, modification of the bacterial target site, or reduced antibiotic 
penetration or accumulation (12). Resistance to antibiotics can be intrinsic, where the 
underlying mechanism of resistance is an innate feature of the bacterium. The outer 
membrane of Gram-negative species, for example, provides an additional permeability 
barrier that confers intrinsic resistance to many antibiotic classes (13). Bacteria are also able 
to acquire resistance through chromosomal mutations or via the acquisition of genetic 
determinants of resistance from other bacteria. In the latter case, the primary mechanisms of 
horizontal gene transfer – conjugation, transformation and transduction – mediate the 
acquisition of resistance and are largely responsible for the rapid and global dissemination 
of multi-drug resistant pathogens that threaten human health (12).   
 
1.1.2 Methicillin-resistant Staphylococcus aureus (MRSA) 
The Gram-positive bacterium Staphylococcus aureus is both a widespread commensal and 
a major human pathogen. An estimated one-third of the human population are colonized 
with S. aureus as part of the normal microbiota in the nasal mucosa, and accordingly, carriers 
have an increased risk of infection with this opportunistic pathogen (14, 15). Transmission 
occurs primarily through direct skin-to-skin contact with a carrier or infected individual, 
although fomites in contact with the skin can become contaminated and serve as 
environmental reservoirs for transmission (16, 17). S. aureus infection typically requires a 
breach in the skin or mucosal barriers – for example, as a result of wounds or surgery – to 
facilitate pathogen invasion into the underlying tissue or bloodstream (15). Most common 
are skin and soft tissue infections, particularly in community settings, although  
S. aureus is also a leading cause of invasive infections including bacteremia, pneumonia, 
endocarditis and osteomyelitis (18).  
S. aureus infections have historically been associated with high mortality and 
morbidity. In the pre-antibiotic era, the case fatality rate of S. aureus bacteremia exceeded 
80% (19). The introduction of penicillin in the early 1940s dramatically reduced mortality 
associated with S. aureus infections, however, its success was short-lived. Penicillin resistant 
strains emerged as early as 1942 (20), quickly becoming widespread in both hospitals and 
communities (21). Resistance is mediated by β-lactamase – an enzyme that inactivates 
penicillin by hydrolysis of the β-lactam ring – and is acquired via horizontal gene transfer 
of a plasmid or transposon encoding the β-lactamase gene, blaZ (22, 23). In 1959, the first 
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β-lactamase-resistant penicillin derivative, methicillin, was introduced into the clinic as an 
effective treatment for penicillin-resistant S. aureus. Methicillin is a semisynthetic derivative 
of benzylpenicillin with an alternative, bulkier side chain that protects the β-lactam ring from 
β-lactamase by steric hindrance (24). The success of methicillin soon led to the discovery of 
the β-lactamase-resistant isoxazolyl penicillins with improved activity and oral absorption – 
oxacillin, cloxacillin, dicloxacillin, flucloxacillin and nafcillin (25).  
Resistance to methicillin emerged rapidly after its introduction. Unlike penicillin 
resistance, methicillin resistance was not mediated by enzymatic inactivation of the 
antibiotic but rather the acquisition of an alternative protein, thereby replacing the antibiotic 
target. In methicillin-sensitive S. aureus (MSSA), β-lactams exert their antibacterial activity 
by mimicking the D-Ala-D-Ala substrate of penicillin-binding proteins (PBPs), enzymes 
responsible for the final steps in the synthesis of peptidoglycan in the cell wall (26). β-
lactams specifically bind the transpeptidase domain of PBPs with high affinity and prevent 
the cross-linking of peptidoglycan, thereby weakening the cell wall and leading to lysis (27) 
(Figure 1.2A). S. aureus carries four native PBPs: PBP1, PBP3 and PBP4 are 
monofunctional transpeptidases while the bifunctional PBP2 facilitates both the 
transpeptidation and transglycosylation steps of peptidoglycan biosynthesis (28) (Figure 
1.2A). In methicillin-resistant S. aureus (MRSA), an alternative PBP (PBP2a) with a lower 
binding affinity for β-lactams permits continued transpeptidation. In coordination with PBP2 
transglycosylase activity, PBP2a enables cell-wall biosynthesis in the presence of methicillin 








Figure 1.2. Mechanism of β-lactam inhibition of peptidoglycan biosynthesis and 
resistance in MRSA. (A) The peptidoglycan precursor (lipid II) is composed of a N-
acetylglucosamine (NAG)-N-acetylmuramic acid (NAM)-pentapeptide monomer anchored 
to the lipid carrier undecaprenyl pyrophosphate (UPP). After membrane translocation, the 
precursors are incorporated into peptidoglycan by PBPs. The transglycosylase (TG) domain 
of PBP2 attaches the incoming NAG to a NAM in the growing end of the peptidoglycan 
chain. PBP transpeptidase (TP) activity catalyzes the release of the terminal D-Ala residue 
on the incoming pentapeptide and cross-links the remaining D-Ala to the pentaglycine bridge 
linked to L-Lys on the acceptor strand peptide stem. β-lactam antibiotics mimic the D-Ala-
D-Ala substrate for the TP domain, inhibiting peptidoglycan biosynthesis. (B) MRSA 
expresses an additional PBP, PBP2a, with reduced affinity for β-lactams. β-lactams therefore 
bind and inhibit the TP activity of other PBPs (PBP1-4), but PBP2a permits continued TP 
activity necessary for peptidoglycan biosynthesis (30, 31).  
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Since the first reported outbreaks of MRSA in hospitals in the 1960s (32), a series of 
epidemic waves have occurred as a result of the dissemination of highly successful clones 
harboring staphylococcal cassette chromosome mec (SCCmec), a mobile genetic element 
encoding the gene for PBP2a (mecA or mecC) (15). Outbreaks were largely confined to 
hospital settings (hospital-associated MRSA (HA-MRSA)) in many parts of the world up 
until the late 1990s when rapid evolutionary changes facilitated the emergence of MRSA 
strains in general populations (referred to as community-associated MRSA (CA-MRSA)) 
(21). The CA-MRSA strain USA300 is perhaps the most infamous, emerging in the United 
States as the dominant cause of community-acquired skin and soft tissue infections 
throughout the early 2000s. USA300 strains initially only harbored resistance to methicillin, 
but have since acquired resistance to macrolides, clindamycin and tetracycline (33). Both 
HA- and CA-MRSA continue to cause a significant number of infections worldwide, and 
compared to MSSA, infections with MRSA are associated with higher mortality rates and a 
greater economic burden (6, 34, 35).  
In recent years, some MRSA strains have additionally acquired resistance to 
vancomycin, the current drug of choice in treating invasive MRSA infections. Although 
vancomycin-resistant S. aureus (VRSA) strains are rare, MRSA strains with reduced 
susceptibility to vancomycin, so-called vancomycin-intermediate-resistant S. aureus 
(VISA), have a comparatively higher burden and are often associated with treatment failures 
(36). With few alternatives for treatment, coupled with the notorious ability of S. aureus to 
rapidly become resistant, an epidemic of vancomycin resistance is of serious concern. 
Although MRSA infections have stabilized in some regions in recent years, the continued 
threat of MRSA is well recognized (37, 38). Indeed, the World Health Organization (WHO) 
has identified MRSA as a high-priority pathogen for which efforts into the research and 
development of novel antibiotics are urgently needed (39).  
 
1.1.3 AMR in agriculture 
Although the emergence of AMR through natural selection is inevitable, the misuse and 
overuse of antibiotics accelerates this process (40). Antimicrobial use in agriculture is a 
considerable threat to rising AMR, as the majority (>70%) of antimicrobials sold worldwide 
are used in food-producing animals for disease prevention, treatment or growth promotion 
(41, 42). A significant proportion of antibiotics used in livestock are considered medically 
important for humans (42) and the extensive use of last-resort antibiotics such as colistin for 
animal husbandry is of particular concern. In China, a plasmid-encoded gene conferring 
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resistance to colistin (mcr-1) was recently reported in Escherichia coli from livestock and 
subsequently detected in E. coli cultured from humans (43). This study is not alone; a 
growing body of evidence documents the transmission of AMR from animals to humans 
(44-46).  
Antimicrobial use and levels of resistance within food-producing animals have 
increased over the past two decades (47, 48). As global populations increase and livestock 
farming intensifies to meet the demand for animal protein, antimicrobial consumption and 
its accompanying resistance are predicted to rise (49). Such a scenario poses a threat to both 
animal and human health. In recognition of this, the WHO has recently made 
recommendations to dramatically reduce the overall consumption of medically important 
antimicrobials in food-producing animals and end their use for disease prevention and 
growth promotion (50). These initiatives of antimicrobial stewardship are crucial in 
prolonging the efficacy of our current antimicrobial armoury; however, antimicrobials for 
the prevention and treatment of disease are necessary to maintain animal health and 
productivity in agriculture. Depleting the options for disease prevention and treatment in 
animals may have significant animal welfare and economic consequences in the future. This 
calls for the discovery and development of novel antimicrobials to be exclusively used in 
animals, thus eliminating antimicrobial crossover while securing the future of veterinary 
medicine.  
 
1.1.4 Bovine mastitis 
Mastitis, an inflammatory disease of the mammary gland primarily caused by bacterial 
infections, is a prevalent disease affecting dairy cattle worldwide. Bovine mastitis has a 
significant economic impact within the dairy industry, with financial losses resulting from 
reduced milk quality and yield, in addition to the costs associated with treatment and culling 
(51, 52). As the world leader in the export of dairy products, mastitis is of particular 
significance to New Zealand and is associated with an economic burden of more than 
$NZ180 million/year (53, 54).  
Mastitis represents the main cause for antimicrobial use in the dairy industry, and in 
New Zealand, nearly all prophylactic and therapeutic antimicrobials for mastitis control are 
deemed medically important (55-57) (Figure 1.3). Prophylactic antibiotic treatment, which 
involves the intramammary infusion of long-acting antibiotics at the end of lactation, is 
routinely used in the dairy industry as an effective measure for preventing infections arising 
during the dry period (58). In recognition of the pressing need for antimicrobial stewardship 
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and the existence of effective alternatives (e.g. internal teat sealants and improved mastitis 
management practices), the New Zealand Veterinary Association (NZVA) has called to 
restrict this “dry cow therapy” for the treatment of existing clinical cases only, thereby 
ending its prophylactic use (59).  
 The bacterial pathogens that cause bovine mastitis are classified as either contagious 
or environmental, based on their primary reservoir and mode of transmission (60). 
Contagious mastitis-causing pathogens are adapted to survive within the host, primarily 
within the bovine mammary gland, and are transmitted cow-to-cow during the milking 
period through shared milking cups. In contrast, environmental pathogens occupy the cow’s 
habitat (e.g. bedding, pasture, bovine faeces and body sites), and contamination and 
colonization of the teat skin with environmental pathogens from these reservoirs predispose 
the mammary gland to opportunistic invasion and infection (61). The main contagious 
pathogens are S. aureus and Streptococcus agalactiae, whereas E. coli, Streptococcus uberis 
and Streptococcus dysgalactiae are the major environmental pathogens (62). Of these,  
S. uberis is the leading cause of mastitis in New Zealand dairy herds and is a significant 






Figure 1.3. Antimicrobials used in bovine mastitis prevention and treatment in New 
Zealand. Antimicrobials are classified by the New Zealand Veterinary Association 
according to a three tier (traffic light) system based on WHO guidelines (57, 66). Critically 
important antimicrobials for human medicine are in bold. All others are classed as “highly 
important”.   
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1.1.4.1 Antibiotic resistance in S. uberis 
Streptococcal pathogens have long-been considered universally susceptible to β-
lactam antibiotics, despite the extensive use of these drugs as frontline antibiotics for 
streptococcal infections in both humans and animals, as is the case for bovine mastitis. 
Recently, however, various studies investigating the antimicrobial susceptibility of S. uberis 
isolates have revealed increased tolerance to β-lactam antibiotics (67-70). Reduced 
susceptibility to β-lactams in S. uberis is linked to alterations in genes for several PBPs (67, 
70), of which several are associated with poorer treatment outcomes (67). Mutations within 
PBP2X are the most common, in particular the Q554E substitution, a well-described 
substitution associated with reduced β-lactam susceptibility in other streptococcal pathogens 
(71, 72). Structural characterization of the corresponding substitution in Streptococcus 
pneumoniae PBP2X (Q552E) has revealed this modification both closes the active site and 
introduces a negative charge at its entrance, hindering β-lactam access (71). Such mutations 
are considered the first step in eventual complete penicillin resistance, as has been observed 
in S. pneumoniae (73, 74). Despite the fact that these S. uberis isolates are still considered 
sensitive to β-lactams, there is mounting evidence of a slow but clear shift towards decreased 
susceptibility. This trend appears to be occurring in parallel within human streptococcal 
pathogen populations (69, 75). The continued reliance on β-lactam antibiotics for bovine 
mastitis control, therefore in principle, imposes a selective pressure that encourages the 
spread of resistance determinants within this animal reservoir and potentially into human 
pathogens.  
 
1.1.4.2 Antiseptic use for mastitis control 
In addition to antimicrobial usage, disinfection of teats following the milking process 
is critical in effective mastitis management (76). Chlorhexidine and iodine, both broad-
spectrum biocides, are the most commonly used antiseptics in teat disinfectants worldwide 
(77). Both of these antiseptics, however, are listed in the WHO Model List of Essential 
Medicines which recognizes their importance in preventing infections in human medicine 
(78). While both chlorhexidine and iodine are routinely used as skin disinfectants in health-
care settings, chlorhexidine is considered the superior antiseptic due to its longer-lasting 
residual activity and greater efficacy in preventing surgical site infections (79-81). Skin 
decolonization by chlorhexidine bathing is a key strategy in the prevention and control of 
MRSA outbreaks (82) and is recommended for reducing rates of infection with other multi-
drug-resistant pathogens in intensive care patients (83). While the need for antimicrobial 
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stewardship is well recognized, measures to preserve the effectiveness of antiseptic biocides 
are comparatively overlooked. Indeed, increased tolerance to chlorhexidine has been 
reported in both Gram-positive and Gram-negative hospital-associated pathogens, including 
MRSA (82, 84-86). Recently, several isolates of S. aureus from bovine mastitis cases were 
demonstrated to have an increase in chlorhexidine tolerance (87). This highlights the 
possibility of an eventual shift towards chlorhexidine resistance in both hospital- and 
livestock-associated settings, driven by extensive chlorhexidine use.  
Taken together, the use of medically important antibiotics and antiseptics for bovine 
mastitis control raises concerns of the potential for the emergence and spread of resistance 
to human pathogens by horizontal gene transfer. Indeed, this is becoming increasingly 
realized, and governments are beginning to implement measures to reduce or eliminate the 
use of essential antimicrobials in animals, leaving few alternatives for veterinary medicine 
(42, 88). Given that dairy is New Zealand’s largest export sector (53), the effective 
prevention and treatment of bovine mastitis is vital to the New Zealand economy. In order 
to sustain productivity within the dairy industry, both in New Zealand and worldwide, the 
development of novel, animal-only antimicrobials and antiseptics is urgently needed.  
 
1.1.5 Alternatives to de novo antibiotic development  
Despite the urgency for novel antibiotics, investment in the research and development of 
antibiotics from the pharmaceutical industry has paradoxically receded. This stems from the 
significant scientific challenges and economic barriers surrounding de novo antibiotic 
development, combined with poor financial returns on investment (12). Interest is growing 
in pursuing alternative strategies for drug development that are more economically viable, 
such as repurposing existing drugs as antibiotics, or discovering antibiotic adjuvants that 
augment antibiotic efficacy.  
Repurposing existing, clinically approved drugs as antibacterials represents a 
powerful alternative to de novo drug discovery. The primary advantage of drug repurposing 
is an accelerated drug development process as extensive safety and pharmacological studies 
have already been completed. As such, the associated costs and risks of drug development 
are substantially reduced (89). To date, the success of drug repurposing approaches for new 
antimicrobials has been limited to new antiparasitic and antiviral treatments, rather than new 
antibacterials. Nevertheless, several promising candidates with antibacterial activity have 
been identified and reviewed (12, 89), and highlight the potential of this approach in fast-
tracking new antibiotics into the clinic. 
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Antibiotic adjuvants provide a means to restore the efficacy of antibiotics against 
formerly susceptible pathogens that have acquired resistance, or alternatively, to enhance 
antibiotic activity against intrinsically resistant pathogens and thereby broaden the spectrum 
of clinically important antibiotics (90). Adjuvants therefore have the potential to expand the 
current range of treatment options while bypassing many of the challenges faced with 
discovering new drugs. The only clinically approved examples of antibiotic adjuvants, the 
β-lactamase inhibitors (e.g. clavulanic acid, tazobactam and sulbactam), have been 
successfully combined with β-lactam antibiotics for over 30 years to treat infections caused 
by various β-lactamase-producing Gram-positive and Gram-negative pathogens that are 
otherwise resistant (90, 91). Despite the success of β-lactamase inhibitors, research into 
identifying and developing adjuvants that inhibit other mechanisms of resistance has been 
relatively underexplored in contrast to the extensive efforts for novel antibiotic discovery. 
Expanding our research efforts to exploit essential targets responsible for resistance, 
alongside those essential for survival, can therefore open up new opportunities for drug 
discovery (90). 
 
1.1.6 Novel zinc-dependent antibacterial strategies 
In light of the failure of modern drug discovery platforms, interest has renewed in reviving 
the once-successful Waksman platform of searching natural sources for antibacterial 
potential (92). Through the use of modern techniques to screen previously unculturable soil 
bacteria, the revival of screening soil microorganisms has shown recent success with the 
discovery of the novel cell wall inhibitor teixobactin (93). Opportunities for antibiotic 
discovery need not be limited to soil microorganisms; natural antibacterial products and 
strategies are universal in biology, representing untapped sources for drug discovery. 
Zinc is an essential transition metal ion for bacterial physiology, yet excess amounts 
are toxic, and bacteria must strictly regulate intracellular levels to avoid starvation or 
toxicity. Mammalian immune systems have evolved over millennia to exploit the 
vulnerability of bacterial pathogens to disruptions in zinc homeostasis for host defence, 
sequestering zinc from pathogens to cause deficiency or delivering the metal in excess to 
cause toxicity (94). As discussed below, disrupting bacterial zinc homeostasis through 
developing drugs that transport excess zinc into bacterial cells (zinc ionophores), is 
becoming increasingly appreciated as a potential avenue for novel antibiotics or adjuvants. 
In this review, zinc homeostasis in bacterial physiology and its exploitation for host defence 
strategies is discussed, along with the potential for repurposing existing zinc ionophores as 
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novel chemotherapeutic agents to override bacterial zinc homeostasis in either human or 
veterinary pathogens. Further, we highlight the emerging evidence of the impact of zinc in 
antibiotic resistance, and zinc ionophores as potential antibiotic adjuvants.  
 
 Zinc in bacterial physiology 
1.2.1  Metal ions in biology  
Metal ions are essential to the biochemistry of all forms of life. Each and every cell on Earth 
is composed almost entirely of the elements carbon, hydrogen, oxygen, nitrogen, sulphur 
and phosphorus, which constitute biology’s major macromolecules: carbohydrates, lipids, 
proteins and nucleic acids (95). However, many crucial biological processes would be 
impossible if cells relied solely upon these elements. Throughout evolution, biology has 
exploited the distinct chemical nature of selected transition (or d-block) metals iron, zinc, 
manganese, copper, nickel, cobalt and molybdenum to perform the fundamental chemical 
transformations of life (95). Biology has additionally capitalized on the specific chemistries 
of the alkali/alkaline earth metals sodium, potassium, magnesium and calcium, utilising 
these essential cations as carriers of electrical charge and regulators of osmotic pressure. In 
addition, the importance of magnesium and calcium as structural and catalytic cofactors in 
proteins, and as secondary messengers in eukaryotic signalling, is well recognised (95, 96). 
Indeed, so integral are metals in biology that an estimated one-third of all proteins require 
metal cofactors for structure or function (97). When considering only enzymes, almost half 
of all those with predicted or known catalytic function require metals (98, 99).  
Transition metals serve either structural, redox catalysis or non-redox catalysis roles 
(94). Iron is the predominant redox metal in biological systems, most notably serving this 
role of electron transfer within iron-sulfur clusters and haem (95). The biological redox 
activity of transition metals relates to their ability to exist in a range of oxidation states; 
however, zinc exists in only one oxidation state (Zn2+) in biological systems and is therefore 
the only essential transition metal to lack redox activity (96). This feature of zinc, among its 
other chemical characteristics, make it a particularly prominent cofactor in metalloproteins. 
While unable to participate in redox catalysis, zinc drives catalysis for several classes of 
enzymes by acting as a strong Lewis acid (98). Relative to other metals, zinc is more versatile 
in its coordination chemistry and interacts with ligands in various geometries (with 
coordination numbers from four to six), exhibits fast ligand exchange, and forms stronger 
protein complexes (98, 100). As a result, zinc can be found in diverse chemical environments 
and is a cofactor for an estimated 5% of all bacterial proteins (101).  
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While metal ions are indispensable for all living cells, excess metal ions can be toxic. 
A fundamental principle of biological chemistry is that some metal ions tend to bind organic 
molecules more strongly than others. The affinity of divalent metal ions for  ligands follows 
a natural order of stability, called the Irving-Williams series (Mg2+, Ca2+ < Mn2+ < Fe2+ < Co2+ 
< Ni2+ < Cu2+ > Zn2+) (102). This states that weaker binding, less-competitive metals, such 
as magnesium and calcium, are vulnerable to displacement from their metal-binding sites on 
ligands by stronger binding, more-competitive metal ions further up the series, such as 
copper and zinc. Further, elevated levels of redox-active metals (in particular, iron and 
copper) can facilitate the overproduction of reactive oxygen species (ROS), causing 
oxidative damage to various essential biological macromolecules and ultimately cell death 
(96, 103). The maintenance of each essential metal within an optimal concentration range, 
with levels sufficient for cellular requirements but low enough to avoid toxicity, is therefore 
an absolute requirement for cellular survival.  
 
1.2.2 Bacterial zinc homeostasis 
Bacterial cells have evolved complex, coordinated systems to ensure metal ion homeostasis. 
That is, the maintenance of metal concentrations within a narrow, tolerable range despite 
fluctuating conditions in the extracellular space (96, 104). The particular chemical 
characteristics of zinc make it favourable as a catalytic or structural cofactor in a diverse 
range of proteins. Zinc metalloproteins have roles in various crucial processes including 
DNA replication, protein synthesis, peptidoglycan turnover, carbon metabolism and the 
biosynthesis of amino acids and folate (105-110). Disturbances to normal zinc homeostasis 
can therefore have pleiotropic effects on bacterial physiology, involving changes in the 
activities of both zinc-dependent and zinc-independent metalloproteins (111).  
Based on the natural order of stability for metal-ligand complexes, in a simplistic 
model where all metal ions are in equal abundance and availability within a bacterial cell, 
all metalloproteins would be bound to copper or zinc (112). In reality, this is not the case; 
bacterial metalloregulatory systems have evolved such that, as a general rule, the more 
competitive the metal ion, the lower its intracellular bioavailability (113). While the total 
zinc content (the zinc quota) in bacterial cells is in the 0.1 – 1 mM range, the amount of 
bioavailable zinc (the labile pool) that is readily incorporated into nascent metalloproteins, 
storage proteins or sensed by metalloregulators is buffered to a sub-picomolar range (~10-12 
– 10-14 M) (114-116). This estimate is several orders of magnitude below the concentration 
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of a single zinc atom within an E. coli cell, indicating that there are virtually no ‘free’ 
intracellular zinc ions (i.e. not associated with any ligand except water) (114, 117).  
 
1.2.2.1 Bacterial mechanisms of intracellular zinc buffering  
Such extreme restriction of zinc availability is achieved through an abundance of 
cytoplasmic metal-chelating ligands with affinities tight enough to sequester free zinc ions, 
yet labile enough to permit metal transfer to apoproteins (96). The metal-ligands constituting 
this labile pool are only beginning to be defined, with evidence suggesting that an abundance 
of small molecules (low-molecular-weight thiols, amino acids), specific buffering proteins, 
and metallochaperones serve to buffer zinc (104) (Figure 1.4). In many Gram-negative 
bacteria, reduced glutathione (GSH) is the dominant low-molecular-weight thiol that buffers 
zinc and other transition metals (118). GSH is considered rare among Gram-positive 
bacteria, although several species of Streptococcus, Lactobacillus, Enterococcus and 
Listeria encode the machinery to either synthesize or acquire GSH from their environment 
(119-123). In Bacillus subtilis, bacillithiol (BSH) functions as a zinc buffer and is thought 
to serve this role in other species that accumulate BSH as the major low-molecular-weight 
thiol (e.g. S. aureus) (116). The amino acid histidine has also been identified as a labile zinc 
pool in Acinetobacter baumannii. Under conditions of zinc starvation, A. baumannii 
mobilizes zinc from these complexes through histidine degradation (124). Further 
contributing to zinc sequestration are bacterial metallothioneins, small cysteine-rich metal-
binding proteins that serve as zinc storage proteins and facilitate zinc transfer to apoproteins 
(125, 126).  
Intracellular zinc restriction means proteins must compete with other molecules for 
a limited supply of zinc, rather than allowing zinc to outcompete other metals for limited 
metal-binding sites (99). Zinc becomes kinetically unavailable once complexed with target 
metalloproteins, owing to the tighter stability of metal-protein complexes than the metal-
ligand complexes within the labile pool (96). In addition, the metal-binding site can become 
buried within the folded, mature holoprotein upon metallation and this prevents competition 
from other molecules for the metal, or from other metals for the binding site (99, 112). While 
most proteins are assumed to acquire zinc from the exchangeable pool, in certain cases 
delivery proteins termed metallochaperones are required for metal acquisition. Metal 
transfer from metallochaperones to target proteins requires specific protein-protein 
interactions and ligand-exchange reactions (99). Members of the COG0523 subfamily of 
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G3E GTPases have putative roles as zinc metallochaperones, with recent evidence that the 
B. subtilis COG0523 family protein ZagA facilitates zinc delivery to high-priority 
metalloenzymes under conditions of zinc limitation (127) (Figure 1.4).  
 
1.2.2.2 Zinc-sensing metalloregulators 
As with all other essential metals, intracellular zinc levels are defined by zinc-sensing 
metalloregulators that precisely coordinate zinc import, mobilization and export in 
accordance with physiological needs (104) (Table 1.1). The DNA binding affinity of these 
zinc sensors is allosterically modulated by direct metal ion binding; therefore, the metal 
affinities of the sensors of zinc deficiency and zinc excess are particularly important in 
defining the window of bioavailable zinc (128). In E. coli, the sensors of zinc deficiency 
(Zur) and zinc excess (ZntR) have affinities estimated at ~5 × 10-15 M and ~1 × 10-15 M, 
respectively (114). When intracellular zinc exceeds the high-set point of ~1 × 10-15 M, zinc-
bound forms of Zur and ZntR coordinate the expression of genes involved in zinc 
detoxification and repress those involved in zinc acquisition (Figure 1.4). Conversely, as 
zinc falls below the low set-point, apo-forms of Zur and ZntR coordinate the response to 
zinc deficiency (129, 130). The zinc sensors of deficiency and excess utilised by bacteria 
vary among species, and the set points of these metalloregulators are attuned to the specific 
physiological needs of the individual. In any case, however, the zinc affinities of these 
sensors create the boundaries that free intracellular zinc must be buffered within to avoid 





Figure 1.4. Bacterial intracellular zinc buffering and homeostasis. Bacteria buffer 
intracellular zinc through small molecule ligands, e.g. glutathione (GSH), bacillithiol (BSH), 
histidine (His) and metallothioneins (MT), that serve as zinc stores and the primary source 
for nascent metalloproteins to acquire zinc. Metallochaperones ensure zinc is delivered to 
high-priority zinc-requiring proteins during conditions of zinc limitation through specific 
protein-protein interactions. In B. subtilis, the metallochaperone ZagA interacts with and 
presumably metallates the zinc-dependent folate biosynthetic enzyme FolE to enable 
continued functioning of this essential pathway (127). Intracellular zinc levels are defined 
by a pair of zinc-sensing metalloregulators, a sensor of deficiency (e.g. Zur) and excess (e.g. 
ZntR). Zinc-binding to metalloregulators modulates gene expression. As shown here, zinc-
bound Zur represses expression of the ZnuABC uptake system while zinc-bound ZntR 
activates expression of the ZntA export system. The balance of zinc uptake and export 
defines the intracellular zinc concentration.  
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Table 1.1. Bacterial sensors of zinc deficiency and excess.






Sensors of zinc 
deficiency 
    
Zur Fur Repressor E. coli, B. subtilis (128, 131) 
AdcR MarR Repressor Streptococcus sp. (132) 
Sensors of zinc 
excess 
    
ZntR MerR Activator E. coli (130) 
SczA TetR Activator Streptococcus sp. (133, 134) 
CzrA ArsR Derepressor  B. subtilis,  
S. aureus 
(135, 136) 
SmtB ArsR Derepressor  M. smegmatis, 
Synechococcus sp. 
(137, 138) 








1.2.3 Zinc acquisition 
In most bacteria, the Fur family metalloregulator Zur functions as the sensor of zinc 
deficiency. Under the regulation of Zur is the high-affinity ATP-binding cassette (ABC) type 
transporter ZnuABC, of which homologues are ubiquitous throughout the bacterial kingdom 
(131). The metal specificity of this system is provided by zinc-specific metal-coordinating 
residues within the solute-binding protein (SBP, subunit A), which enables high-affinity zinc 
acquisition from environments with limited availability (142, 143). The SBP is typically 
located either in the periplasm of Gram-negative bacteria or present as a cell-surface 
lipoprotein in Gram-positive bacteria (Figure 1.5). Upon metal acquisition, the SBP delivers 
zinc to the transmembrane channel (subunit B), and ATP hydrolysis via the associated 
cytoplasmic ATPase (subunit C) provides the energy required for zinc import (144, 145). 
Whilst the ZnuABC system is the most widespread, an orthologous ABC transporter for 
high-affinity zinc import, the AdcABC system, is prevalent among streptococci and several 
other Gram-positive species (145-149). AdcR, a MarR family metalloregulatory protein, is 
the functional equivalent of Zur for this system (132) (Table 1.1).  
In the case of Gram-negative bacteria, Zur also regulates energy-coupled active 
transporters at the outer membrane. In environments where zinc is abundant, zinc and other 
metal ions are thought to passively diffuse through the outer membrane of Gram-negative 
bacteria via pore-forming channels called porins (111). Once in the periplasm, low-affinity 
transport systems such as the ZIP (Zrt-Irt-like protein) family protein ZupT facilitate zinc 
import across the cytoplasmic membrane (150). In addition, zinc can be transported into 
cells as a metal-phosphate complex via the constitutively-expressed inorganic phosphate 
uptake system (PitA) (151). Under a state of zinc deficiency, Zur induces the expression of 
the TonB-dependent receptor family protein, ZnuD, at the outer membrane (142, 152, 153). 
ZnuD is energised by the TonB/ExbB/ExbD cytoplasmic membrane complex, which 
effectively couples the proton motive force to active zinc transport (153). Upon reaching the 
periplasm zinc is likely then imported by the high-affinity ZnuABC system (Figure 1.5).  
Additional zinc-recruiting proteins which function to “supercharge” zinc delivery to 
SBPs are also expressed by Zur in response to zinc deficiency. In several bacteria, the Zur-
regulated ZinT acquires zinc and forms a complex with the ZnuA SBP, facilitating zinc 
transfer to the primary zinc-binding site (154-156). Intriguingly, the orthologous AdcA 
consists of two distinct domains with clear structural homology to ZnuA and ZinT (157). 
Given that Gram-positive bacteria lack an outer membrane to compartmentalise ZinT, this 
fusion is speculated to have arisen to preserve the efficient acquisition of zinc achieved by 
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transient ZnuA/ZinT interactions in the periplasm (143). In many streptococcal species, an 
additional homologue of AdcA (AdcAII) exists that lacks the ZinT-like domain. Mirroring 
the ZinT-ZnuA interaction, the cell surface-associated protein PhtD (polyhistidine triad 
protein D) functions to deliver zinc to AdcAII in S. pneumoniae (143, 157) (Figure 1.5). 
This has led to the proposal that Pht proteins such as PhtD serve as ‘zinc sinks’ at the cell-
surface, facilitating efficient zinc transfer to AdcAII/AdcA by direct or indirect protein 




Figure 1.5. Bacterial zinc acquisition systems. In Gram-positive bacteria (left), 
extracellular zinc is bound by zinc-specific SBPs (AdcA/ZnuA, AdcAII) and delivered to 
the cognate ABC importer (exemplified by AdcABC, or ZnuABC). Under zinc limitation, 
S. pneumoniae PhtD scavenges and delivers zinc to AdcAII for import (157). In Gram-
negative bacteria (right), extracellular zinc enters the periplasm through outer membrane 
porins under zinc replete conditions. Zinc then enters the cytoplasm via low-affinity 
transporters (e.g. ZupT, PitA). During zinc deficiency, zinc is actively transported across the 
outer membrane via the TonB-ExbB-ExbD-dependent ZnuD transporter in N. meningitidis 
(153). Active zinc transport in the periplasm is facilitated by the high-affinity ZnuABC 
system and ZinT. CW, cell wall; CM, cytoplasmic membrane; OM, outer membrane. Figure 
adapted from (128).  
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1.2.4 The adaptive response to zinc deficiency 
When intracellular zinc falls below the low set-points defined by zinc metalloregulators, the 
bacterial cell enters a state of zinc deficiency. Zinc deficiency initiates an adaptive response, 
notably characterised by the derepression of high-affinity zinc uptake systems and the 
redistribution of zinc from nonessential stores (158). The transition from a state of 
sufficiency to deficiency within a bacterial cell is gradual, rather than immediate. The 
intracellular pool is gradually depleted as cellular demand outweighs supply, and 
consequently, metalloregulators are thought to precisely sense the degree of metal deficiency 
and respond accordingly (104). Indeed, detailed investigations in B. subtilis and 
Streptococcus species have revealed graded responses of Zur and AdcR to increasing zinc 
deprivation (143, 159, 160). In both cases, a stepwise derepression of target genes occurs 
such that bacteria first mobilize zinc from intracellular stores before investing in 
energetically expensive high-affinity zinc import. This degree of control is provided by the 
varying affinities of Zur and AdcR for DNA binding depending on their metallation status 
(143, 159-161).  
Given the high abundance of ribosomes (~2000 – 70,000 per cell) (106), zinc-
dependent ribosomal proteins are major intracellular stores of zinc. The derepression of zinc-
independent paralogues of ribosomal proteins is a characteristic of the first wave of gene 
derepression by both Zur and AdcR to effectively reduce cellular demand for zinc and 
provide a substantial increase to the bioavailable zinc pool (159, 160). Further zinc 
deprivation initiates subsequent waves of gene derepression, characterised by the expression 
of high-affinity zinc uptake systems and zinc metallochaperones, as well as the derepression 
of zinc-independent isozymes of essential zinc-dependent proteins (e.g. GTP cyclohydrolase 
and alcohol dehydrogenase) (159, 160). Despite these adaptations, conditions of severe zinc 
limitation (zinc starvation), where zinc is insufficient for the continuation of essential zinc-
dependent processes, are ultimately lethal for the bacterial cell (104). 
 
1.2.5 Zinc detoxification 
The known sensors of zinc excess are varied between species and belong to several different 
protein families (Table 1.1). In E. coli, the MerR family metalloregulatory protein ZntR 
regulates the response to zinc excess (130), whereas the TetR family protein SczA functions 
as the equivalent metalloregulator in S. pneumoniae and related streptococci (133, 134). 
Further still, the adaptive response to zinc excess is coordinated by the ArsR family proteins 
CzrA of B. subtilis and S. aureus (135, 136), and SmtB of M. smegmatis and Synechococcus 
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(137, 138). Zinc binding to the sensors of zinc excess induces a conformational change in 
the metalloregulatory protein that generally results in either derepression through the 
dissociation of the sensor from the DNA, or transcriptional activation through DNA twisting 
(104, 112). In addition, the response to zinc excess can occur through a two-component 
phosphotransfer from a zinc-sensing histidine kinase to a response regulator, such as the case 
of CzcRS that regulates expression of the zinc exporting CzcABC system in Ralstonia 
metallodurans and Pseudomonas aeruginosa (139-141). 
The sensors of zinc excess regulate an assortment of zinc exporters belonging to either 
the P1B-type ATPase, cation diffusion facilitator-type (CDF) or resistance nodulation-
division (RND) protein families (162) (Figure 1.6). Whereas P1B-type ATPases utilise ATP 
hydrolysis for zinc export, CDF proteins are proton-coupled antiporters that use the proton 
motive force to export zinc outside the cell or into the periplasm (163). Representative 
members of zinc-exporting P1B-type ATPases include the E. coli ZntA (164) and B. subtilis 
CadA (165), for which numerous homologues exist in other bacterial species. Similarly, the 
most well-characterized zinc-exporting CDF, Yiip from E. coli (166), has many functional 
homologues in various species including S. pneumoniae CzcD and S. aureus CzrB, among 
others (163). In contrast, RND type zinc exporters (e.g. CzcABC from R. metallodurans and 
P. aeruginosa) have only been identified in a few Gram-negative species, functioning as 
tripartite proton-driven “efflux guns” that export metals across both the cytoplasmic and 
outer membranes (163).  
The induction of zinc exporters is the predominant mechanism of zinc detoxification in 
bacteria. However, strategies that function to amplify zinc sequestration have been described 
as part of the adaptive response to excess zinc in some bacteria. For example, in 
Synechococcus, elevated zinc levels induce the expression of a SmtB-regulated 
metallothionein, SmtA (138). Similarly, E. coli upregulates the expression of a set of genes 
involved in cysteine biosynthesis following the sudden exposure to elevated extracellular 
zinc (167).  
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Figure 1.6. Bacterial zinc efflux systems. In Gram-positive bacteria (left), efflux across the 
cell membrane is mediated by P1B-type ATPases (e.g. B. subtilis CadA) and CDF-type 
transporters (e.g. S. pneumoniae CzcD). In Gram-negative bacteria (right), zinc exported 
into the periplasm by P1B-type ATPases (e.g. E. coli ZntA) or CDF-type transporters (e.g. E. 
coli Yiip) crosses the outer membrane via porins. RND type zinc exporters (e.g. P. 
aeruginosa CzcABC) additionally export zinc across both the cytoplasmic and outer 
membranes. CW, cell wall; CM, cytoplasmic membrane; OM, outer membrane. Figure 
adapted from (128). 
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1.2.6 Mechanisms of zinc toxicity 
In response to most situations of sudden zinc influx, cytoplasmic zinc buffering and the 
coordinated activities of the sensors of zinc deficiency and excess are sufficient to maintain 
a viable intracellular zinc concentration range for growth (96). Zinc intoxication, however, 
has long been recognised in bacteria with numerous studies describing the mechanisms of 
its toxicity (Figure 1.7). The basis of zinc’s toxicity is largely attributed to its capacity to 
outcompete other metals for catalytic, structural or regulatory binding sites on various 
proteins. Metal-binding sites with tetrahedral coordination environments (e.g. many iron and 
manganese mononuclear enzymes) appear particularly sensitive to zinc mismetallation, 
given the preference of zinc for this coordination chemistry (98, 168). Ribulose-5-phosphate 
3-epimerase (Rpe), a member of the pentose phosphate pathway, is an example of a 
mononuclear iron enzyme that becomes mismetallated by zinc in E. coli. Upon displacement 
of iron by zinc, the enzymatic activity of Rpe diminishes by > 95% and the pentose 
phosphate pathway fails as a result (169). The toxic effect of zinc in E. coli has also been 
attributed to the mismetallation and destruction of exposed iron-sulfur clusters on 
dehydratases, enzymes crucial for key metabolic pathways (170). Additional intracellular 
targets of zinc toxicity have been recognised, including two key glycolytic enzymes that are 
inhibited under zinc stress in Group A Streptococcus (GAS), impairing growth on glucose 
(171). Consistent with this finding, zinc impairs glucose metabolism in several oral 
streptococci (172, 173). Further, zinc has recently been implicated in the dysregulation of 
haem biosynthesis in B. subtilis via mismetallation of the metalloregulator PerR, presumably 
contributing to the bactericidal mechanism of zinc through redox cycling between 
accumulated haem and reduced quinone, consequently generating toxic ROS (165). 
At the bacterial cell membrane, high concentrations of zinc in the extracellular (or 
periplasmic) environment can mismetallate membrane proteins. Early biochemical 
experiments have established the role of zinc as a potent inhibitor of membrane-bound 
electron transport chain components in bacteria, including succinate dehydrogenase and 
terminal oxidases (174-176). Recently, the B. subtilis cytochrome bd terminal oxidase has 
been associated with increased resistance to zinc (165). Under zinc stress, cells appear to 
switch from using the zinc-sensitive major terminal oxidase, cytochrome aa3, to the 
relatively zinc-insensitive cytochrome bd. Cytochrome bd is also derepressed in S. 
coelicolor in response to zinc, suggesting a similar mechanism of remodelling the respiratory 
chain to withstand extracellular zinc stress (177). High extracellular zinc also exerts a toxic 
effect by antagonizing the uptake of other metals. In S. pneumoniae, excess exogenous zinc 
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outcompetes manganese for binding to the extracellular manganese SBP, PsaA, of the 
PsaABC manganese import system (178). Zinc binding is irreversible, and as a result, 
manganese uptake is blocked. Manganese-starved S. pneumoniae are unable to appropriately 
metallate the manganese-dependent superoxide dismutase (SOD), and consequently become 
hypersensitive to oxidative stress (178).   
As illustrated by the collective findings of these studies, zinc toxicity is likely a 
consequence of the simultaneous inactivation of a multitude of essential processes. Although 
these studies have been successful in uncovering targets of zinc mismetallation, our 
knowledge of the exact molecular mechanisms of zinc toxicity that contribute to the 
cessation of growth or cell death is still far from complete. As yet unidentified mechanisms 
are likely at play, and the specific mechanisms of toxicity are presumed to vary between 
species and growth conditions (e.g. energy sources, availability of other competing metals, 
anaerobic or aerobic environment) (96). In light of the global spread of antibiotic resistance, 
expanding our understanding of the mechanisms of zinc toxicity could prove invaluable in 




Figure 1.7. Antibacterial mechanisms of zinc toxicity. (A) Excess zinc causes the 
mismetallation of metal-binding sites. Zinc mismetallation can displace essential structural, 
catalytic or regulatory cofactors (as depicted here for E. coli Rpe) and destroy iron-sulfur 
clusters in metalloproteins. (B) Zinc exerts toxicity at extracellular and intracellular levels. 
At the bacterial cell membrane, zinc inhibits respiration and antagonizes manganese uptake. 
Within the cytoplasm, protein mismetallation by zinc disrupts metabolic and regulatory 
pathways. See main text for details. Abbreviations: Rpe; ribulose-5-phosphate-3-epimerase, 
Cys; cysteine, ETC; electron transport chain, PFK; phosphofructokinase, GADPH; 
glyceraldehyde-3-phosphate dehydrogenase.  
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1.2.7 Zinc at the host-pathogen interface 
The idea of exploiting bacterial metal ion homeostasis to fight important pathogens is not a 
novel one; in fact, over evolutionary time the mammalian immune system has developed 
strategies to exploit the vulnerability of bacterial pathogens to shifts in metal homeostasis, 
in a concept termed ‘nutritional immunity’ (94, 179). Nutritional immunity is most well 
understood in the context of iron limitation (94), although mechanisms of zinc restriction 
and intoxication by the host are becoming increasingly recognized (179, 180). During the 
course of infection, the success of bacterial zinc homeostasis therefore becomes absolutely 
vital for pathogen survival within the host.   
 
1.2.7.1 Mechanisms of host-mediated zinc restriction 
The sequestration of zinc from invading pathogens can occur extracellularly on a 
systemic level, at the local site of infection, or within the intracellular environment (Figure 
1.8). Systemically, serum zinc is substantially reduced (hypozincemia) during the vertebrate 
response to infection. Proinflammatory cytokines such as IL-6, produced in response to 
bacterial lipopolysaccharide (LPS), induce the expression of the zinc transporter ZIP14 on 
hepatocytes, triggering uptake of circulating zinc (181). Within hepatocytes, the 
simultaneous expression of host metallothionein ensures the newly accumulated zinc is 
sequestered intracellularly (181).  
 Several members of the S100 protein family have been implicated in the 
sequestration of extracellular zinc within infected tissue (179). S100 proteins are EF-hand 
calcium-binding proteins that can dimerize either as homodimers or heterodimers and bind 
two metal ions at the dimer interface (182). Calprotectin, a heterodimer of S100A8 and 
S100A9, exerts antibacterial function through the chelation of zinc and manganese (183). 
The role of calprotectin in nutritional immunity was first recognized as a mechanism of 
inhibiting the growth of S. aureus within tissue abscesses (183) and has since been 
implicated as a key innate defense strategy against numerous other pathogens (184-188). 
Calprotectin makes up 40 – 50% of the protein constituent of the neutrophil cytoplasm, 
although due to the requirement of calcium for metal binding, active zinc sequestration by 
calprotectin likely only occurs upon secretion into the extracellular environment in 
neutrophil extracellular traps (NETs) (189). The homodimeric S100 proteins psoriasin 
(S100A7) and calgranulin C (S100A12) have similar roles to calprotectin in nutritional 
immunity, providing zinc sequestration at epithelial surfaces and the gastrointestinal tract, 
respectively (190-192). 
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At the intracellular level, the fungal pathogen Histoplasma capsulatum is starved of 
zinc within macrophage phagolysosomes as zinc transporters mobilize zinc from 
phagolysosomes to the cytoplasm and Golgi apparatus (193). Similarly, T cells upregulate 
the expression of the ZIP8 zinc transporter on lysosomal membranes when stimulated by 
IFN-ɣ, a critical cytokine for the clearance of intracellular pathogens, reducing the lysosomal 
zinc concentration (194). Although these mechanisms are anticipated to play a role in 
starving engulfed bacterial pathogens of zinc, intracellular zinc alterations additionally play 
an important role in T cell and dendritic cell activation. Additional studies are needed to 
further understand the impact of host-cell zinc deprivation during infection with bacterial 
pathogens (179).  
 
1.2.7.2 Mechanisms of host-mediated zinc toxicity 
The delivery of metals to invading pathogens in excess quantities has only recently 
been appreciated as another branch of nutritional immunity. Mycobacterium tuberculosis 
experiences zinc intoxication within macrophage phagolysosomes, as macrophages release 
zinc stored within metallothioneins and shuttle the metal into phagolysosomes upon 
infection (195). Mutants lacking a zinc-exporting P1-type ATPase show reduced intracellular 
survival of M. tuberculosis, highlighting the importance of effective zinc detoxification for 
this pathogen (195). Similarly, human neutrophils accumulate zinc within phagolysosomes 
to intoxicate GAS, and zinc export mutants (ΔczcD) have reduced survival within 
neutrophils in a mouse model of infection (196). In addition, deletion of the putative zinc 
exporter (cznABC) in Helicobacter pylori reduces its virulence in a gerbil model of gastric 




Figure 1.8. Zinc mobilization strategies by the innate immune system during infection. 
(A) At the systemic level, serum zinc levels drop (hypozincemia) as pro-inflammatory 
cytokines produced in response to bacterial infection stimulate increased expression of zinc 
importers (ZIP14) and metallothionein (MT) in hepatocytes, causing increased uptake of 
circulating zinc and intracellular sequestration (181). (B) At local sites of infection, metal-
chelating S100 proteins (e.g. calprotectin (CP), S100A7 and S100A12) reduce zinc 
availability. CP sequesters both zinc and manganese, while the S100A7 homodimer 
(psoriasin) sequesters zinc and S100A12 (calgranulin C) binds both zinc and copper (180). 
(C-D) At the intracellular level, microbial pathogens can experience zinc starvation or 
toxicity. (C) Macrophages starve the fungal pathogen H. capsulatum of zinc through 
mobilizing zinc from phagolysosomes into the cytoplasm via the ZNT4/ZNT7 zinc 
exporters. Cytoplasmic zinc is then mobilized to the Golgi apparatus or MTs (193). (D) GAS 
experiences zinc toxicity within neutrophils as zinc-rich lysosomes and azurophilic granules 
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fuse with the phagosome to create a phagolysosome with a high-zinc environment (196). 
Similarly, M. tuberculosis is poisoned by zinc within macrophage phagosomes (195).  
1.2.7.3 Pathogen subversion of nutritional immunity 
Nutritional immunity imposes a selective pressure on invading pathogens for 
efficient zinc acquisition and detoxification systems. As mentioned, zinc exporters are key 
virulence determinants for numerous bacterial pathogens, and likewise, ZnuABC/AdcABC 
import systems are crucial in enabling a multitude of pathogens to effectively compete with 
the host for limited zinc (184, 187, 196, 198-202). Similarly, the secretion of small-molecule 
zinc-binding metallophores (zincophores), such as the S. aureus staphylopine (148), is 
important for virulence in several pathogens (202-204). In another mechanism of subverting 
nutritional immunity, Neisseria meningitidis has evolved to subvert calprotectin-mediated 
zinc sequestration by hijacking and utilizing calprotectin as a zinc source. This mechanism 
is dependent on a calprotectin-specific outer membrane receptor, called CbpA, which  
N. meningitidis expresses under zinc deprivation (198). Neisseria gonorrhoeae has recently 
been shown to possess this mechanism of evading nutritional immunity, wherein the CbpA 
homolog TdfH binds and facilitates zinc internalization from calprotectin (187).  
 
1.2.7.4 Clinical implications of nutritional immunity 
The current understanding of nutritional immunity is that immune cells can exploit 
either zinc starvation or toxicity to defend against invading pathogens, depending on the site 
of infection, whether the pathogen has an intracellular or extracellular lifestyle, and the 
specific physiological requirements of the invading pathogen for zinc (94). Indeed, while 
zinc deficiency is associated with a suppressed immune system and increased susceptibility 
to diarrheal and respiratory bacterial infections, clinical studies investigating the benefits of 
zinc supplementation in preventing infection have had variable results (205, 206). In a 
murine model of Clostridium difficile infection, high dietary zinc leads to perturbations in 
the gut microbiota and antagonizes the inhibitory action of calprotectin, predisposing 
individuals to infection (207). Conversely, a diet sufficient in zinc is important in resisting 
infection with S. pneumoniae via zinc intoxication (208). Murine nasopharynx and lung 
tissue are enriched with zinc during S. pneumoniae infection, and the depletion of zinc within 
these microenvironments during dietary zinc deficiency promotes invasive pneumococcal 
lung infection (208). Although the precise situations where zinc starvation and intoxication 
are utilized by the host are yet to be fully elucidated, the importance of such strategies at the 
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host-pathogen interface highlights a vulnerability of pathogens that novel antimicrobial 
therapeutics could capitalize upon.  
 
 Zinc ionophores as novel antibacterials 
1.3.1 General properties of ionophores 
One potential strategy of exploiting the vulnerability of pathogens to dysregulated zinc 
homeostasis is through the use of zinc ionophores that enhance the toxicity of zinc. 
Ionophores are a class of molecules that bind specific ions and facilitate their transport across 
cell membranes. The hydrophobic nature of the lipid bilayer means cell membranes are 
naturally extremely impermeable to charged species (209). Ionophores are able to overcome 
this barrier by forming a lipid-soluble complex with the transported ion, shielding its charge 
from the hydrophobic bilayer (209). Ionophores are broadly classified as either mobile ion 
carriers or channel carriers, depending on their mode of ion transport (Figure 1.9). Mobile 
carriers (such as valinomycin and nigericin) bind ions on one side of the membrane, diffuse 
across the membrane as a complex, and release the ion on the opposite side (210, 211). These 
mobile carriers may diffuse back and forth between the extracellular and intracellular spaces 
or remain within the membrane while facilitating ion transport between either side (212). 
Channel carriers (such as gramicidin) arrange within the membrane to form transmembrane 
hydrophilic channels that allow ions to flow down their electrochemical gradients (209). In 
contrast to mobile carriers, which are highly selective for particular ions, channel carriers 
show less discrimination between ions but greater activity, as ion transport is not limited by 




Figure 1.9. Mechanisms of ion transport by ionophores.Valinomycin and nigericin are 
examples of mobile carrier ionophores. Valinomycin selectively carries potassium ions (and 
therefore a charge) across the cell membrane by forming a cyclic structure that shields the 
positive charge of the metal ion. Nigericin is a hydrophobic carboxylic acid that exchanges 
potassium ions for protons, equilibrating proton and potassium concentration gradients in an 
electroneutral process. Channel-forming ionophores such as gramicidin form cell membrane 
pores that have less selectively than mobile carriers, facilitating the diffusion of a variety of 
monovalent cations (X+). Adapted from (211). 
 
1.3.2 Ionophores in agriculture 
Ionophores are most well known for their applications in agriculture as antimicrobial growth 
promotants or prophylactics for the prevention of coccidiosis in poultry and other farm 
animals (213). As growth promotants, ionophores are proposed to increase feed efficiency 
in beef cattle and sheep by altering the ruminal gut microbiome, and consequently ruminal 
fermentation, to promote weight gain (214). The ionophores used in agriculture include, 
among others, monensin, lasalocid, narasin, maduramycin and salinomycin, all of which 
belong to the carboxylic polyether class of compounds that are naturally produced by 
Streptomyces bacteria (213). Structurally, polyether ionophores are molecules with a lipid-
soluble alkyl backbone exterior and an oxygen-rich interior that permits cation binding and 
transport across the cell membrane (210). Cation preference varies between different 
polyethers, although most display a high affinity for sodium, hydrogen, calcium or 
potassium ions. The maintenance of transmembrane concentration gradients for these ions 
is essential for bacterial physiology, and thus, the ionophore-mediated perturbation of 
intracellular cation balance is ultimately lethal (215). To date, ionophore use in agriculture 
is generally excluded from regulations regarding antibiotic use on the basis that, despite 
decades of extensive use, they are not associated with cross-resistance to medically 
important antimicrobials (214). 
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1.3.3 Zinc ionophores 
Given zinc is universal in biology, the capacity of zinc ionophores to facilitate zinc influx 
confers these drugs a wide range of biological activities. Zinc ionophores have long been 
used as therapeutic agents in humans, or investigated as potential therapeutics, for a broad 
spectrum of medicinal applications, including neurodegenerative diseases, cancer, and 
bacterial, fungal, parasitic or viral infections (216, 217). Perhaps the most well-known is 
zinc pyrithione (ZPT) (Figure 1.10A and 1.10B), the active agent in most over-the-counter 
dandruff treatments (218). ZPT inhibits the main cause of dandruff, Malassezia yeast, via a 
mechanism of zinc toxicity (219). In addition, ZPT has broad-spectrum activity against both 
Gram-positive and Gram-negative bacteria (219, 220), and shows potential as a safe and 
effective topical skin antiseptic (218). The quinoline-based drug chloroquine (Figure 
1.10C), previously used as an antimalarial, exhibits zinc ionophore activity and has sparked 
recent interest due to its ability to inhibit the recently emerged novel coronavirus (SARS-
CoV-2) (221). As the RNA dependent RNA polymerase (RdRp) of the related SARS-CoV 
is inhibited by ZPT in a zinc-dependent mechanism (222), it has been proposed that the zinc 
ionophore properties of chloroquine, and presumably its derivative hydroxychloroquine 




Figure 1.10. Chemical structures of the pyrithione, chloroquine and 
hydroxychloroquine zinc ionophores. (A) Pyrithione. (B) Zinc pyrithione complex (ZPT). 




The antimicrobial activity of 8-hydroxyquinoline (8-HQ) (Figure 1.11A), a subclass 
of quinoline, and its derivatives has long been recognized; in fact, as early as 1895 a mixture 
of 8-HQ and potassium pyrosulphate (‘Chinosol’) was used as a topical antiseptic (224). 
Several 8-HQ derivatives (e.g. clioquinol, nitroxoline) have since become available for 
clinical use as antimicrobials, and the 8-HQ scaffold has continued to be an active area of 
interest for drug development and repurposing (9). 8-HQ and its derivatives are lipophilic, 
metal-chelating heterocycles, and it is this ability to chelate metals that was established to 
confer antibacterial activity (225). 8-HQ molecules selectively bind transition metals 
through the pyridine nitrogen and phenolate oxygen atoms, with relative metal affinities 
closely following the Irving-Williams series (216). The stoichiometry of 8-HQ-metal 
complexes depends upon the ratio of metal (M) to ligand (L): at low ligand concentrations, 
positively charged 1:1 (ML) complexes form (Figure 1.11B); at excess ligand 
concentrations, two 8-HQ molecules chelate a single metal in an electroneutral 1:2 (ML2) 
complex (226) (Figure 1.11C). It has not yet been fully elucidated which of the two 
complexes contributes to its bactericidal action, although several studies suggest the lipid-
soluble 1:2 ML complex serves to carry the positively charged metal across the cell 
membrane, enabling the release of free metal or water-soluble 1:1 ML complexes on the 
opposite side (226, 227) (Figure 1.11D).  
Up until 1950, the mode of antimicrobial action was considered to be through 
bacterial metal starvation. Experiments investigating the toxicity of 8-HQ against 
staphylococci and streptococci in metal-depleted media established that neither 8-HQ nor 
metal ions alone were toxic, however; a combination of the two was required for lethality, 
supporting a mechanism of ionophore-mediated metal accumulation (226, 228). 8-HQ has 
since been implicated as an ionophore in numerous bacterial pathogens, more recently as a 
bactericidal copper ionophore against M. tuberculosis (227, 229, 230). Mechanistically, the 
bactericidal activity of 8-HQ-metal complexes is related to the intrinsic toxic properties of 




Figure 1.11. Chemical structure of 8-hydroxyquinoline-metal complexes and proposed 
mode of action. (A) 8-Hydroxyquinoline (8-HQ). (B) 8-HQ-zinc complex with a 1:1 ML 
ratio. (C) 8-HQ-zinc complex with a 1:2 ML ratio. (D) Proposed bactericidal mechanism of 
8-HQ-metal complexes. In the absence of metal ions, 8-HQ lacks antibacterial activity (226, 
228). Upon ionization of the phenolate hydroxyl group to an anion, 8-HQ chelates transition 
metal ions via its oxygen and nitrogen ligands to form either 1:1 or 1:2 ML complexes. The 
1:1 complex is positively charged, freely soluble in water and almost insoluble in lipids, 
whereas the 1:2 complex is electrochemically neutral, practically insoluble in water but 
freely soluble in lipids. The 1:2 complex is proposed to act as a metal carrier across cell 
membranes, dissociating in the cytoplasm into the 1:1 complex, and then into a free 8-HQ 
anion and metal cation. Protonation of the 8-HQ anion in the cytoplasm enables the neutral 
complex to recross the cell membrane, ultimately causing the net exchange of extracellular 
metal for intracellular protons. Presumably, excess intracellular metal or 1:1 ML complexes 
exert bactericidal action through the mismetallation of metal-binding groups on essential 
intracellular ligands (226, 227).  
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1.3.3.2 PBT2 
PBT2 (8-quinolinol,5,7-dichloro-2-[(dimethylamino)methyl]) (Figure 1.12B) is a 
derivative 8-HQ molecule originally developed as a potential therapeutic for Alzheimer’s 
and Huntington’s disease. PBT2 is the successor to clioquinol (5-chloro-7-iodo-8-
hydroxyquinoline) (Figure 1.12A), which was once widely used as an antiseptic and 
antimicrobial for various gastrointestinal and skin infections (231, 232), and was 
subsequently resurrected for its potential in the treatment of neurodegenerative diseases. As 
a zinc and copper ionophore, clioquinol facilitates the transport of these metals into neuronal 
cells from the interstitial space, inhibiting the metal-induced aggregation of the interstitial 
amyloid-beta (Aβ) and huntingtin (Htt) proteins that cause the pathologies of Alzheimer’s 
and Huntington’s disease respectively (233-235). Clioquinol treatment effectively reduced 
the associated symptoms and pathology of these diseases in mouse models (233, 236, 237). 
Although preliminary clinical trials with clioquinol were promising (238), subsequent trials 
were stalled by the inability to prevent a toxic impurity of clioquinol (di-iodo-8-
hydroxyquinoline) forming during large-scale manufacturing, necessitating the development 
of PBT2 as a next-generation derivative with easier chemical synthesis (239). PBT2 showed 
promise in preclinical studies, even exceeding the ionophoric activity of clioquinol (239), 
but in recent phase II clinical trials for Alzheimer’s (240, 241) and Huntington’s disease 
(242), PBT2-treated patients failed to show significant cognitive or functional 
improvements. Importantly, however, all preclinical and clinical studies to date demonstrate 
PBT2 is safe and well-tolerated in animal models (mouse) and humans. In one trial, patients 
received doses of 250 mg/day of PBT2 for 12 months with no adverse side effects (241). 
This opens up possibilities for repurposing this zinc ionophore as an antibiotic.  
The ability of PBT2 to potentiate zinc toxicity in bacteria via ionophore function has 
recently been investigated. PBT2 in combination with zinc (PBT2-zinc) was found to exhibit 
potent antibacterial activity against the Gram-positive multi-drug-resistant pathogens 
MRSA, vancomycin-resistant Enterococcus faecium (VRE) and erythromycin-resistant 
GAS (243). Antibacterial activity was observed in vitro and in vivo in murine wound 
infection models of these pathogens, and, consistent with a zinc ionophore mechanism of 
action, PBT2-zinc facilitated bacterial intracellular zinc accumulation (243). Transcriptional 
profiling of the response to PBT2-zinc revealed changes in the expression of various genes 
involved in virulence, metabolism, oxidative stress and metal transport, fitting a global 
mechanism of zinc toxicity in which multiple cellular pathways are perturbed by excess zinc 
(243). Resistance to PBT2-zinc was unable to be generated in any of the pathogens, further 
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supporting the existence of multiple bactericidal mechanisms which thereby reduces the 
likelihood of resistance developing (243). Although various pathways are expected to be 
targeted by accumulated zinc, an exact definition of the underlying bactericidal mechanisms 
of PBT2 remains unresolved.  
Given the safety profile of PBT2, both as an oral and topical drug in humans, this 
zinc ionophore shows promise as a novel antibacterial for important multi-drug-resistant 
pathogens, although further research is needed to determine if systemic administration of 
PBT2 is effective for invasive infections. On the other hand, as ionophores have almost 
exclusively been used in agriculture for over 30 years, preserving this class for animal-only 
medicine should also be considered. The established efficacy of PBT2 as a topical 
antibacterial suggests a possible niche of this compound, or structural analogues, as novel 




Based on the premise that zinc ionophores could serve roles as animal-only 
antibacterials, a series of novel derivatives of 8-HQ (termed 8-sulfonamidoquinolines) have 
recently been developed in a collaborative medicinal chemistry project between our 
laboratory and the Brimble laboratory (School of Chemical Sciences, University of 
Auckland) (244). The 8-sulfonamidoquinolines are characterized by the substitution of the 
8-HQ phenol group with a sulfonamide moiety (Figure 1.12C) (245). Similar to other 8-
HQ-based molecules, these compounds have zinc-dependent antibacterial activity, with 
bactericidal activity demonstrated against the major mastitis-causing pathogens, S. uberis, 
S. aureus and E. coli (245, 246), as well as human pathogens (unpublished data). It is 
therefore hypothesised that these compounds function as zinc ionophores in a similar manner 





Figure 1.12. Chemical structures of 8-hydroxyquinoline derivatives. (A) Clioquinol (or 
PBT1). (B) PBT2. (C) 8-Sulfonamidoquinoline scaffold showing substitution of the 8-HQ 
phenol group with a sulfonamide moiety. Derivatives have modifications at indicated 
functional groups. Clioquinol and PBT2 form 1:1 and 1:2 ML complexes with zinc as shown 
for 8-HQ in Fig. 1.11 (247, 248).  
 
 The impact of zinc on antibiotic resistance 
1.4.1 Co-selection of zinc and antibiotic resistance and zinc-antibiotic antagonism 
The complicated role of zinc in antibiotic resistance is becoming increasingly clear; on one 
side, various studies implicate zinc as a driver of antibiotic resistance (249, 250), and on the 
other, a growing body of research describes synergy between zinc and various antibiotics 
(250-257), and several reports even describe the zinc-dependent inhibition of resistance 
development (257, 258). A consequence of its tendency to form metal-complexes with 
proteins and molecules in a multitude of cellular pathways, and its capacity to activate or 
inactivate transcriptional regulators, zinc can positively or negatively impact antibiotic 
activity. The exact situations in which zinc enhances or hinders antibiotic efficacy is likely 
dependent on the antibiotic, the pathogen, and the nature of its mobile genetic elements and 
resistance mechanisms.  
Cross-resistance, in which a single resistance determinant provides resistance to 
multiple compounds, is considered a key mechanism of metal-driven co-selection (249). 
Cross-resistance has mostly been attributed to efflux pumps capable of transporting both 
antibiotics and metals (259). In the case of zinc, a multi-drug efflux transporter of Listeria 
monocytogenes, MdrL, that provides increased resistance to zinc, also provides resistance to 
the antibiotics erythromycin, josamycin and clindamycin (260). Similarly, marine bacterial 
communities exposed to antifouling paints containing zinc have increased resistance to both 
zinc and tetracycline, and an enrichment of RND efflux system genes with cross-resistance 
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potential within these communities is thought to underlie this mechanism of co-selection 
(261).  
If zinc resistance determinants co-reside on mobile genetic elements with antibiotic 
resistance genes, or the two are physically linked on chromosomes, zinc exposure can 
simultaneously select for both zinc and antibiotic resistance (249). This mechanism of co-
resistance has been well-described for zinc and methicillin in the livestock-associated 
MRSA (LA-MRSA) clonal complex (CC) 398 (262, 263). Indeed, the zinc-resistance 
determinant czrC, a putative zinc-exporter, is co-located with mecA on the SCCmec element 
(263). As such, the use of zinc supplementation in animal feed has been proposed to 
contribute to the persistence of methicillin resistance through co-selection. A significant 
proportion of LA-MRSA lack an SCCmec element containing czrC, however, thus zinc 
resistance is not the only contributing factor behind the emergence and spread of LA-MRSA 
(262, 264).  
Metal stress activates various transcriptional responses, and in some cases, these 
responses can indirectly enhance antibiotic resistance. Co-regulatory resistance between 
zinc and the carbapenem antibiotic imipenem has been described in P. aeruginosa, where 
zinc activation of the CzcRS two-component system leads to the simultaneous upregulation 
of the CzcABC zinc efflux system and downregulation of the carbapenem-specific OprD 
porin, consequently resulting in imipenem resistance (141). Further, selection for zinc-
resistance in P. aeruginosa frequently generated mutations in the CzcS sensor protein that 
additionally co-selected for carbapenem resistance (141). Similarly, zinc activates the 
envelope-stress-responsive two-component system AmgRS in P. aeruginosa (265), which 
has previously been shown to promote resistance to aminoglycoside antibiotics (266). 
Mutations in amgS which cause the constitutive activation of the AmgRS system result in 
both zinc tolerance and increased resistance to aminoglycosides (265, 266).  
In addition to these mechanisms of zinc-antibiotic co-selection, zinc can antagonize 
antibiotic efficacy in certain situations. Metallo-β-lactamases (MBLs), a subset of β-
lactamases requiring zinc in their active site for β-lactam hydrolysis, represent a clinically 
significant group of enzymes in several Gram-negative pathogens (267). MBLs confer 
resistance to most β-lactam antibiotics, including last-resort carbapenems (12). Several 
recent studies have demonstrated the efficacy of zinc-chelating compounds in restoring β-
lactam activity against MBL-producing strains by sequestering active site zinc (268-271), 
suggesting a therapeutic potential of zinc chelators as antibiotic adjuvants.  
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1.4.2 Zinc and antibiotic synergy 
Zinc has a broad ability to complex with molecules, including some antibiotics. In the case 
of bacitracin, a divalent metal ion is required for sequestration of its molecular target, the 
lipid carrier undecaprenyl pyrophosphate (UPP) (272). The bacitracin-zinc complex is the 
most stable, and as such, bacitracin is typically formulated as a complex with zinc in 
antibiotic treatments (272). The ability of vancomycin to chelate zinc has been realized from 
its observed capacity to induce a zinc-starvation response in a range of bacteria (273), and 
importantly, zinc potentiates vancomycin activity against resistant strains (256). Zinc 
binding to vancomycin triggers the formation of vancomycin polymers, and in this 
conformation, vancomycin-zinc has enhanced affinity towards the modified D-Ala-D-Lac 
target of cell wall peptidoglycan in vancomycin-resistant Enterococcus faecalis and S. 
coelicolor (256). Quinolone antibiotics are also capable of binding divalent metals, and in 
several studies, zinc-quinolone complexes exhibit greater antibacterial activity than the 
respective free quinolones (253-255).  
 Aside from directly interacting with certain antibiotics and enhancing their activity, 
zinc has been described to potentiate antibiotic efficacy by inhibiting resistance mechanisms. 
Quinolone antibiotics are known to induce hypermutation via the SOS response, a state that 
promotes the development of resistance to quinolones as well as unrelated antibiotics (258, 
274). Zinc prevents hypermutation by inhibiting the ability of RecA to bind single-stranded 
DNA, a necessary step for the initiation of the SOS response (257). Indeed, zinc is effective 
in inhibiting ciprofloxacin-induced hypermutation in E. coli and Klebsiella pneumoniae 
(258), and additionally reduces the emergence of chloramphenicol resistance in 
Enterobacter cloacae (257). Zinc-mediated inhibition of the SOS response in bacteria was 
also found to potentiate the activity of fluoroquinolones against E. coli biofilm persisters 
(275), and block the SOS-induced transfer of an extended-spectrum β-lactamase (ESBL) 
gene from E. cloacae to a susceptible E. coli strain (257). In addition, zinc is a known 
inhibitor of the aminoglycoside-modifying enzyme AAC(6’)-Ib (aminoglycoside 6’-N-
acetyltransferase type Ib), a common resistance determinant for this class of antibiotics 
among Gram-negative clinical isolates (12, 252). Zinc inhibits the acetylation and 
inactivation of aminoglycosides by AAC(6’)-Ib and consistently synergizes with the 
aminoglycoside amikacin against A. baumannii strains harboring this enzyme (252).  
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1.4.3 Reversal of antibiotic resistance by zinc ionophores 
Recent studies have reported on the reversal of antibiotic resistance in both Gram-negative 
and Gram-positive AMR pathogens by the action of zinc ionophores. While zinc alone 
potentiates aminoglycoside activity in A. baumannii, extremely high concentrations are 
required (252). The zinc ionophore ZPT markedly reduces the concentration of zinc required 
to reverse aminoglycoside resistance in A. baumannii, and in addition, ZPT restores 
aminoglycoside sensitivity in E. coli and Klebsiella pneumoniae (252, 276). The 
enhancement of this inhibitory effect is attributed to the ionophore-mediated accumulation 
of zinc within the cytoplasm, which overcomes the low permeability of zinc across cell 
membranes and action of detoxification systems that normally hinder its intracellular 
accumulation, enabling AAC(6’)-Ib inhibition with greater efficiency (252). Although 
effective and safe for topical application, ZPT causes significant toxicity in mammals when 
administrated orally, and therefore its potential as an antibiotic adjuvant is restricted for only 
topical treatments (277). The 8-HQ class of zinc ionophores have a more favourable safety 
profile for oral administration, and indeed, zinc complexes of 8-HQ and several of its 
analogs, including clioquinol, restore aminoglycoside susceptibility in A. baumannii and  
E. coli (278, 279). 
Besides aminoglycosides, ionophore-mediated zinc accumulation is implicated in the 
reversal of resistance to multiple other classes of antibiotics against a range of multi-drug-
resistant pathogens. In the same work that described PBT2 as an antibacterial, sub-inhibitory 
PBT2-zinc complexes were demonstrated to resensitize GAS HKU16, VRE RBWH1 and 
CA-MRSA USA300 strains to several clinically relevant antibiotics (243). The effect of 
PBT2-zinc on antibiotic resistance varied between pathogens; for example, PBT2-zinc 
reversed erythromycin resistance in MRSA but not in GAS or VRE, potentially relating to 
the different mechanisms of erythromycin resistance operating in MRSA USA300 
(inducible resistance via ermC) compared to GAS HKU16 and VRE RBWH1 (constitutive 
resistance via ermB) (243). While ineffective in reversing erythromycin resistance in GAS 
and VRE, PBT2-zinc resensitized these pathogens to another macrolide antibiotic 
(clindamycin) and tetracycline. Further, PBT2-zinc restored vancomycin susceptibility in 
VRE and additionally resensitized MRSA to the β-lactam antibiotics ampicillin and oxacillin 
(243). Synergy between zinc and β-lactams against S. aureus has been reported previously 
(251), although the underlying molecular mechanism by which excess intracellular zinc 
augments β-lactam susceptibility has not yet been defined. In addition, it is not yet known 
whether other related zinc ionophores similarly restore β-lactam sensitivity in MRSA.  
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PBT2-zinc has also been demonstrated to sensitize N. gonorrhoeae to tetracycline and 
two polymyxin antibiotics, polymyxin B and colistin (280). N. gonorrhoeae is intrinsically 
resistant to polymyxins because of the presence of a positively charged 
phosphoethanolamine (PE) modification on the lipid A of lipooligosaccharides in the cell 
wall, which reduces polymyxin binding affinity (280). In a mutant strain lacking the enzyme 
responsible for lipid A modification, LptA, N. gonorrhoeae becomes sensitive to 
polymyxins (281). Mechanistic studies have revealed a significant reduction in PE-modified 
lipid A from PBT2-zinc treated cells, and given LptA requires metal cofactors, LptA 
mismetallation has been proposed as a mechanism of polymyxin sensitization in  
N. gonorrhoeae by PBT2-zinc (280).  
The reversal of resistance in numerous AMR pathogens to multiple antibiotic classes by 
zinc ionophores highlights the potential therapeutic use of these compounds as antibiotic 
adjuvants. Given the severe shortage of novel antibacterial drug candidates and the 
unrelenting rise in antibiotic resistance, there is great value in combining existing antibiotics 
with adjuvants that restore their activity against AMR pathogens.  
 
 Aims and chapter overviews 
Zinc undoubtedly has a complex role in bacterial systems; the same ligand-binding 
properties of this metal that have been exploited over evolutionary time for various 
fundamental biological processes also permit the inappropriate metallation of ligands by zinc 
when in excess, disturbing various cellular pathways and ultimately leading to the cessation 
of growth or cell death. Zinc toxicity is becoming increasingly appreciated as an important 
mechanism of host innate defence, and recent explorations into novel chemotherapeutic 
agents against AMR pathogens have drawn inspiration from this natural antibacterial 
strategy. The potentiation of zinc toxicity and antibacterial efficacy by PBT2 opens up 
possibilities for the development of zinc ionophores as either a novel class of standalone 
antibiotics or adjuvants to combat bacterial infections in either veterinary or human 
medicine. Both applications offer significant benefits in light of the AMR crisis, however, 
mechanistic understandings of the bactericidal action of PBT2 or its synergism with β-
lactams against MRSA are lacking.  
The proven efficacy of PBT2 against streptococcal pathogens as a topical antimicrobial, 
along with the near exclusive use of ionophores in agriculture, are all points that argue in 
favour of repurposing PBT2 as an animal-only antibacterial for use in veterinary medicine. 
Indeed, as we have discussed, novel animal-only antibacterials for the control of bovine 
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mastitis is of substantial medical and economic importance (section 1.1). Chapter II 
investigates the bactericidal mechanism of action of PBT2 against the bovine mastitis-
causing pathogen S. uberis. This published chapter demonstrates that PBT2 causes lethality 
through multiple mechanisms: intracellular zinc accumulation and manganese depletion, the 
production of toxic ROS, and the impairment of manganese-dependent antioxidant 
functions.  
In terms of their favourable pharmacological properties, bactericidal mechanism of 
action and therapeutic safety, β-lactams are arguably one of the most important classes of 
antibiotics among our current armoury (282). The ability of PBT2 to break β-lactam 
resistance in MRSA, along with its recognized safety in humans (240-242), offers an 
opportunity to resurrect this important class of antibiotics for the treatment of MRSA 
infection. Chapter III aims to explore the underlying mechanism of PBT2-mediated β-
lactam resensitization in MRSA and examines if the related 8-sulfonamidoquinolines 
similarly display antibiotic adjuvant activity. Furthermore, the efficacy of PBT2 and β-
lactam synergy in vivo is investigated following systemic administration in a murine model 
of invasive MRSA infection.  
A discussion of this doctoral work, along with suggested future directions for the 
exploration of the bactericidal and adjuvant activities of zinc ionophores for veterinary or 
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Globally more antimicrobials are used in food-producing animals than humans, and the 
extensive use of medically important human antimicrobials poses a significant public health 
threat in the face of rising antimicrobial resistance (AMR). The development of novel 
ionophores, a class of antimicrobials used exclusively in animals, holds promise as a strategy 
to replace or reduce essential human antimicrobials in veterinary practice. PBT2 is a zinc 
ionophore with recently demonstrated antibacterial activity against several Gram-positive 
pathogens, although the underlying mechanism of action is unknown. Here, we investigated 
the bactericidal mechanism of PBT2 in the bovine mastitis-causing pathogen,  
Streptococcus uberis. In this work, we show that PBT2 functions as a Zn2+/H+ ionophore, 
exchanging extracellular zinc for intracellular protons in an electroneutral process that leads 
to cellular zinc accumulation. Zinc accumulation occurs concomitantly with manganese 
depletion and the production of reactive oxygen species (ROS). PBT2 inhibits the activity 
of the manganese-dependent superoxide dismutase, SodA, thereby impairing oxidative 
stress protection. We propose PBT2-mediated intracellular zinc toxicity in S. uberis leads to 
lethality through multiple bactericidal mechanisms: the production of toxic ROS and the 
impairment of manganese-dependent antioxidant functions. Collectively, these data show 
that PBT2 represents a new class of antibacterial ionophore capable of targeting bacterial 
metal ion homeostasis and cellular redox balance. We propose this novel and multitarget 
mechanism of PBT2 makes the development of cross-resistance to medically important 




More antimicrobials are used in food-producing animals than humans, and the extensive use 
of medically important human antimicrobials poses a significant public health threat in the 
face of rising antimicrobial resistance. Therefore, the elimination of antimicrobial crossover 
between human and veterinary medicine is of great interest. Unfortunately, the development 
of new antimicrobials is an expensive, high-risk process fraught with difficulties. 
Repurposing chemical agents provides a solution to this problem, and while many have not 
been originally developed as antimicrobials, they have been proven safe in clinical trials. 
PBT2, a zinc ionophore, is an experimental therapeutic that met safety criteria but failed 
efficacy checkpoints against both Alzheimer’s and Huntington’s disease. It was recently 
found that PBT2 possessed potent antimicrobial activity, although the mechanism of 
bacterial cell death is unresolved. In this body of work, we show that PBT2 has multiple 




The widespread emergence of antimicrobial resistance (AMR) threatens the security of 
modern medicine. Antimicrobial use in food-producing animals is recognised as an 
important driver of AMR, raising concerns in light of the considerable overlap of 
antimicrobials used in both humans and animals (42). With food consumption rising to meet 
the demands of a growing global population, antimicrobial use in food-producing animals is 
consequently set to increase (49). This intensification of antimicrobial use comes with a 
greater risk of resistance emerging (283, 284), and warrants the elimination of antimicrobial 
crossover between human and veterinary medicine.  
Bovine mastitis, an inflammatory disease of the bovine mammary gland, is the 
leading cause for antimicrobial use in the dairy industry worldwide (55, 56). The Gram-
positive pathogen, Streptococcus uberis, is a common environmental cause of bovine 
mastitis (285). Due to the ubiquity of environmental pathogens such as S. uberis in the dairy 
environment, prevention of environmental mastitis is particularly challenging and relies 
heavily on antimicrobial sanitisers (60, 62). Chlorhexidine and iodine, which the World 
Health Organisation (WHO) recognises as essential antiseptics for human medicine (78), are 
among the most common antiseptics used in teat disinfectants (77). Increased tolerance to 
chlorhexidine has been reported in both Gram-positive and Gram-negative hospital-
associated pathogens (84-86), illustrating the pressing need to discover novel animal-only 
antimicrobials for mastitis prevention and treatment.  
Ionophores represent a class of molecules capable of binding and transporting 
protons or other cations across biological membranes (211). With the exception of the 
mycobactericidal drug bedaquiline, with recently demonstrated H+/K+ ionophoric activity 
(286), ionophoric drugs (e.g. monensin, lasalocid, salinomycin, narasin) are exclusively used 
in agriculture (214). Despite the routine use of ionophores in agriculture for over 35 years, 
there is little indication of increasing resistance to these drugs, nor of cross-resistance to 
medically important classes of antimicrobials (214). Developing novel antimicrobials with 
ionophoric mechanisms of action for veterinary-only medicine satisfies the requirement for 
antimicrobials in food-producing animals without risking cross-over with human medicine.  
PBT2, a derivative of the 8-hydroxyquinoline (8-HQ) scaffold, has been 
demonstrated to act as a zinc and copper ionophore in mammalian cells (239). PBT2 
facilitates the intracellular accumulation of these metals, and showed promise as a 
therapeutic for targeting the abnormal metallo-chemistry in Alzheimer’s and Huntington’s 
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disease (239, 287). In phase II clinical trials, however, efficacy endpoint criteria were not 
met in PBT2-treated patients of these neurodegenerative diseases (240-242). Despite this, 
extensive pre-clinical and clinical data demonstrate PBT2 is safe and well-tolerated in 
humans and animal (mouse) models (240-242).  
In bacterial cells, zinc is an essential micronutrient for normal physiology, yet can 
mediate significant toxicity in excess (134, 288). The essentiality and toxicity of zinc in 
bacterial pathogens has been exploited by host defence mechanisms that starve cells of zinc, 
in a concept termed ‘nutritional immunity’ (94, 179), or deliver the metal in excess toxic 
quantities (178, 196). Given the vulnerability of bacterial cells to zinc stress, and the safety 
profile of PBT2 in mammalian hosts, the antimicrobial potential of this zinc ionophore was 
recently investigated. Indeed, PBT2 in combination with zinc (PBT2-zinc), has potent 
antibacterial activity against multiple Gram-positive pathogens (243). Antibacterial activity 
was observed in vitro and in vivo in a murine wound infection model, highlighting the 
potential of PBT2 to be repurposed as a topical antimicrobial in veterinary medicine (243).   
While PBT2 was shown to increase cytosolic zinc and disrupt metal ion homeostasis 
in bacteria (243), a defined molecular mechanism of killing remained unresolved and is key 
to the development of effective next generation derivatives. In this study, we show that PBT2 
is a Zn2+/H+ ionophore and exerts bactericidal activity in S. uberis through intracellular zinc 
toxicity, which leads to the accumulation of toxic reactive oxygen species (ROS) and 
dysregulates manganese homeostasis, causing cells to become hypersensitive to oxidative 
stress. Our work builds on the current knowledge of the coordinated relationship between 





2.4.1 Bacterial strain and growth conditions 
Streptococcus uberis strain NZ01 (289) was isolated from a clinical bovine mastitis case in 
the Manawatu-Wanganui region of New Zealand. S. uberis NZ01 was grown in Todd Hewitt 
Broth (THB) (Sigma-Aldrich) or on THB agar (THA) containing 1.5% (w/v) agar for all 
experiments. Bacteria were routinely grown at 37°C with agitation (200 rpm). All 
inoculations were performed from overnight cultures (16 hrs) to a final optical density at 
600 nm (OD600) of 0.05.  
 
2.4.2 Chemical and radiochemical reagents  
PBT2 was synthesised as described previously (243). All stocks of PBT2 (2 mg/mL) were 
prepared in 100% DMSO unless otherwise stated. ZnSO4•7H2O (zinc) and MnSO4•H2O 
(manganese) stocks were prepared in filter-sterilised dH2O. The following radiochemicals 
were obtained from Moravek Inc.: [7-14C]benzoate (54.1 mCi/mmol), [14C]methyltriphenyl 
phosphonium iodide (TPP+) (57 mCi/mmol), [14C]polyethylene glycol 4000 (PEG) and 
[3H]water (1mCi/g).  
 
2.4.3 Determination of cell growth inhibition  
The antibacterial activities of PBT2 and zinc, both alone and in combination, were assessed 
by a checkerboard broth microdilution assay. Varying concentration combinations of PBT2 
(0 – 10 mg/L [0 – 29 µM]) and zinc (0 – 800 µM) were arrayed in a 96-well flat bottom 
microtiter plate and resuspended in THB inoculated with S. uberis NZ01 (OD600 0.05) at a 
final volume of 200 µL. After 24 hrs incubation, cell growth (OD600) was determined by a 
Varioskan Flash microplate reader (Thermo Scientific). The PBT2 and zinc MIC and CIC 
were determined as the lowest concentrations that showed no visible growth. The interaction 
effects were derived from calculation of the FICI, the sum of the FIC for each compound, 
which is in turn defined as the quotient of the MIC of the inhibitor in combination (CIC) and 
the MIC of the inhibitor alone, as follows (290): 





FICI analysis was interpreted according to threshold values described previously (291), 
whereby synergism between two inhibitors is regarded at an FICI ≤ 0.5, antagonism at an 
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FICI ≥ 4.0, and no interaction at an FICI between 0.5 and 4.0. Checkerboard assays were 
undertaken in biological triplicate. 
For susceptibility testing of PBT2 in bovine milk, overnight cultures of S. uberis 
NZ01 were harvested by centrifugation and washed twice in PBS (3,220 × g for 10 min at 
4°C) before inoculation into pasteurised whole-fat (3.8%) cow milk at an OD600 of 0.1.  
S. uberis cells were then inoculated 1:2 into milk containing 2-fold serial dilutions of PBT2 
with various concentrations of Zn in a 96-well flat bottom microtiter plate. After 24 hrs 
incubation at 37°C, 10 µL aliquots were spot plated on to THA plates according to the Miles-
Misra drop plate method (292). Bactericidal activity was examined after 24 hrs incubation 
at 37°C, in which a >3-log10 reduction in CFU/mL was determined as bactericidal. As a 
measure of sterility, the absence of CFUs in uninoculated milk was verified by plating on to 
THA.   
 
2.4.4 Bacterial time-dependent cell killing assays  
S. uberis NZ01 was inoculated at OD600 0.05 in THB only, THB containing the MIC of PBT2 
(5.0 mg/L) or zinc (800 µM), or THB containing a CIC of PBT2 and zinc (0.5 mg/L PBT2 
and 10 µM zinc) in biological triplicate. Aliquots of cultures were taken at 0, 2, 4, 6 and 24 
hrs post-challenge, serially diluted in 1 X phosphate buffered saline (PBS), and spot plated 
on THA plates. The surviving CFU/mL of cultures was determined after 24 hrs incubation 
at 37°C.  
 
2.4.5 Examination of resistance development 
Serial passaging experiments to generate resistance to PBT2+Zn/antibiotics were undertaken 
as described in Bohlmann et al (243). Broth (THB) 2-fold microdilution assays of PBT2 in 
the presence of 100 µM Zn, ciprofloxacin and rifampicin were first set up in a 96-well flat-
bottom microtiter plate with an initial inoculum of S. uberis NZ01 at OD600 0.05. Cells from 
the highest PBT2+Zn or antibiotic concentrations that showed growth after 24 hrs incubation 
were subcultured into a new microtiter plate with 2-fold dilutions of PBT2+Zn or antibiotics. 
Serial passaging was repeated for 30 days in biological duplicates.  
 
2.4.6 Inductively coupled plasma mass spectrometry (ICP-MS) 
Overnight cultures of S. uberis were diluted to OD600 0.05 in THB and grown to mid-log 
phase (OD600 0.3). Aliquots (45 mL) of mid-log phase cells were separated into individual 
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flasks and challenged for 1 hr with PBT2 (0.25, 0.5 or 1.0 mg/L) with or without zinc (100 
µM) or untreated. Samples were prepared for ICP-MS analysis according to the protocol 
used by Bohlmann et al (243). The metal contents of samples were determined using an 
Agilent 7500ce ICP-MS (Centre for Trace Element Analysis, Department of Chemistry, 
University of Otago). Three biological replicates were analysed. For analysis of THB, a 2 
mL aliquot of the media was sent for analysis.  
 Metal ion concentrations (mg/L) of samples were converted to molar units, whereby 
the intracellular metal ion concentrations of bacterial samples were calculated from the  
S. uberis NZ01 protein content (111 mg protein/OD600/L) and internal cell volume (3.76 ± 
0.78 µL/mg protein). Protein content was determined by a BCA assay and the internal cell 
volume was estimated from the difference between the intracellular and extracellular 
partitioning of 3H2O and the non-metabolizable [14C]PEG, as in a previously described 
method (293).  
 
2.4.7 Transmembrane pH (∆pH) and membrane potential (∆Ψ) measurements 
Overnight cultures of S. uberis were diluted to OD600 0.1 in THB (50 mL) at pH 7.5 and 
grown to an OD600 between 0.5 and 1.0. For ∆pH experiments, cells were harvested by 
centrifugation (3,220 × g for 20 min at 4°C), washed twice in THB (pH 5.0) and resuspended 
to OD600 1.0. For ∆Ψ experiments, cells were harvested under the same centrifugation 
conditions and then resuspended to OD600 1.0 in THB (pH 7.5). In both experiments, cultures 
were then energized by incubating with glucose (20 mM) for 1 hr at 37°C and 200 rpm. 
Aliquots of energized cells were either untreated or treated with membrane permeabilising 
toluene (0.4% v/v), or PBT2+Zn at 1× or 10× the CIC (0.5 mg/L PBT2 + 10 µM zinc) for a 
further 20 min (37°C, 200 rpm). Following this, 1 mL aliquots were incubated in glass tubes 
with either [7-14C]benzoate (11 µM final concentration) or [14C]TPP+ (5 nM final 
concentration) for 5 min at 37°C. Radio-isotope measurements, and calculations of the ∆pH 
and ∆Ψ, were performed as previously described (293). Assays were undertaken in 
biological triplicate.  
 
2.4.8 Preparation of pyranine-containing liposomes 
Pyranine-containing liposomes were prepared according to the previously described method 
by Hards et al (286). Liposomes were prepared in an incorporation buffer (5 mM Mes-Mops-
Tris in required proportions for desired pH) with or without zinc sulfate (1 mM).  
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2.4.9 Quantification of internal pH by pyranine fluorescence 
The internal pH of liposomes was measured as previously described (286). A standard curve 
of the pyranine fluorescence ratio to pH was determined for each incorporation buffer, in the 
presence of 0.5 µM pyranine, at known pH values. Kinetic traces were measured on a 
Varioskan Flash plate reader (Thermo Scientific), and data was presented from the 15 min 
endpoint measurements. CCCP (1 µM) equilibrated the internal pH of liposome preparations 
with the external pH (Fig. S2.8), confirming the responsiveness of our preparations to pH 
gradients. 
 
2.4.10 Isothermal titration calorimetry (ITC) 
ITC (isothermal titration calorimetry) experiments were performed at 30◦C with continuous 
stirring using a VP-ITC (GE Healthcare). ZnSO4•7H2O (zinc) and PBT2 were dissolved in 
100 mM Mops-Tris buffer (pH 7.7, 1% DMSO). The zinc sample (0.3 mM) was injected 
(30×10 µL) into PBT2 (0.035 mM) and the data was analysed using Origin 7 software and 
fitted to a single site-binding model.  
 
2.4.11 RNA extraction and real-time PCR (RT-qPCR) 
A biological triplicate of S. uberis NZ01 cells were grown to mid-log phase (OD600 0.3) in 
THB (45 mL) and treated for 1 hr with either PBT2 (1.0 mg/L), zinc (100 µM), PBT2 and 
zinc combined, or untreated. Total RNA was isolated using TRIzol-chloroform extraction as 
described previously (294) and purified using the RNA clean and concentrator™-5 
extraction kit (ZYMO research). Following elution of RNA into DNase/RNase-free H2O, 
RNA was DNase-treated using the TURBO DNA-free kit (Invitrogen) according to the 
manufacturer’s instructions, and RNA was quantified on a NanoDrop instrument (Thermo 
Scientific).  
 cDNA for each sample was synthesised using a SuperScript™ III Reverse 
Transcriptase kit (Invitrogen). Primers used for qPCR were designed on Primer-BLAST and 
are detailed in Table S2.2. Primer optimization and efficiency assays were performed, and 
qPCR experiments were conducted in a ViiA7 real-time PCR system (Applied Biosystems) 
using the PowerUp™ SYBR™ Green Master Mix (Applied Biosystems) according to the 
manufacturer’s instructions. Results were normalized to the gene pflC using the ΔΔCT 
method (295).  
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2.4.12 SOD activity assays 
Overnight cultures were inoculated to OD600 0.05 in THB and grown to OD600 0.3. Cultures 
were split into 50 mL aliquots and treated for 1 hr with PBT2 (1.0 mg/L), zinc (100 µM) or 
manganese (800 µM), individually or in combination, or were untreated. Cultures were then 
harvested by centrifugation (3,220 × g for 10 min at 4°C), washed with HEPES buffer (50 
mM, pH 7.4), resuspended in 1 mL of HEPES buffer, and lysed mechanically by beadbeating 
three times (48,000 rpm, 30 sec). Lysates were centrifuged (17,000 × g, 2 min, 4°C) and 
assayed for SOD activity using a SOD assay kit (Invitrogen) following manufacturers’ 
instructions. Protein concentrations in the lysates were determined by a BCA assay and SOD 
activity was normalised for total protein content.  
 
2.4.13 H2O2 measurement 
H2O2 was measured using the Amplex® Red Hydrogen Peroxide/Peroxidase Assay kit 
(Invitrogen) according to the manufacturer’s instructions. An overnight culture of S. uberis 
cells was diluted to OD600 0.05 in THB and grown to mid-log phase (OD600 0.3). Mid-log 
phase cells were separated into aliquots (10 mL) and were treated for 1 hr with PBT2 (1.0 
mg/L), zinc (100 µM) or manganese (800 µM), individually or in combination, or H2O2 (1 
mM) or untreated. Cells were then harvested by centrifugation (3,220 × g for 7 min at 4°C). 
Cell pellets were washed twice in PBS under the same centrifugation conditions and 
resuspended in 1´ Reaction Buffer at OD600 ~3.5. For analysis, samples were diluted to 
OD600 ~0.4 in 1´ Reaction Buffer and Amplex Red reagent®/HRP working solution in a 
black-walled, clear-bottomed 96-well microplate. Amplex Red fluorescence was then 




 Results  
2.5.1 PBT2 and zinc exhibit antibacterial synergy 
We examined if the reported antibacterial activity of PBT2 extended to the bovine pathogen 
S. uberis. A checkerboard assay was undertaken to determine the minimum inhibitory 
concentration (MIC) and combined inhibitory concentrations (CIC) of PBT2 and zinc. Both 
PBT2 and zinc individually displayed antibacterial activity against S. uberis, with MICs of 
5.0 mg/L (14.5 µM) and 800 µM respectively (Table S2.1, Fig. S2.1). Combining PBT2 and 
zinc dramatically increased the antibacterial effectiveness of both compounds, with a CIC 
of 0.5 mg/L PBT2 (1.45 µM) in the presence of 10 µM zinc or 0.05 mg/L PBT2 (0.145 µM) 
with 100 µM zinc. The fractional inhibitory concentration indexes (FICI) of 0.113 and 0.135 
indicates PBT2 and zinc interact synergistically (FICI ≤ 0.5). A time-dependent cell-killing 
assay revealed >3-log10 reductions in CFU/mL of initial inocula following treatment with 
the MIC of either PBT2 or zinc, indicating a bactericidal mechanism of action (Fig. 2.1A). 
The observed bactericidal activity of PBT2 alone may be attributable to the concentration of 
23 µM zinc in the growth medium, Todd Hewitt Broth (THB), which was determined by 
inductively-coupled plasma mass spectrometry (ICP-MS). However, the extent to which 
PBT2 mobilises the bioavailable proportion of medium zinc was not determined. 
Remarkably, treatment with the CIC of PBT2 and zinc (PBT2-zinc) was bactericidal, even 
at 10-fold and 80-fold lower concentrations of PBT2 and zinc MICs, respectively (Fig. 
2.1A).  
We next sought to compare the ability of S. uberis to develop resistance to PBT2+Zn 
and two medically important antibiotics, rifampicin and the fluoroquinolone antibiotic 
ciprofloxacin, by serial passaging through progressively increasing drug concentrations over 
a course of 30 days. Whilst the rifampicin and ciprofloxacin MICs increased by 4608-fold 
and 72-fold respectively, the PBT2+Zn MIC increased by only 4-fold (Fig. 2.1B).  
Because antimicrobial activity can be negatively affected by proteins and lipids 
present in milk (296), assessing the antimicrobial efficacy in bovine milk is important for 
the development of potential new therapeutics for mastitis prevention or treatment. We 
tested the bactericidal efficacy of PBT2+Zn in whole cow’s milk and observed that PBT2 
remained bactericidal against S. uberis (MIC 32 mg/L PBT2 + 0 µM Zn, 16 mg/L PBT2 + 




Figure 2.1. Bactericidal action and resistance development of PBT2 and zinc against  
S. uberis.  
(A) Time-dependent cell killing of S. uberis in response to MICs of PBT2 and zinc, alone 
(5.0 mg/L PBT2, 800 µM zinc) and in combination (0.5 mg/L PBT2 + 10 µM zinc). THB 
contains a background concentration of 23 µM zinc. Error bars represent the standard 
deviation of the mean from a biological triplicate. (B) Development of resistance to 
PBT2+Zn compared to rifampicin and ciprofloxacin. S. uberis was serially passaged for 30 
days in the presence of subinhibitory concentrations of PBT2 (+100 µM Zn), rifampicin or 
ciprofloxacin in THB. Data represent the mean of two biological replicates. 
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2.5.2 PBT2-zinc disrupts metal ion homeostasis  
ICP-MS analysis was used to determine the metal ion content of S. uberis cells in response 
to PBT2 treatment. Consistent with the ionophore activity of PBT2, a concentration-
dependent increase in whole cell zinc accumulation was observed in response to increasing 
concentrations of PBT2 (Fig. 2.2A). While 0.25 mg/L PBT2 alone had no effect on cellular 
zinc abundance, in the presence of zinc (100 µM), cells treated with 0.25 mg/L PBT2 
accumulated >3-fold more zinc than untreated cells (P = 0.006) (Fig. 2.2A). Additional 
PBT2 did not increase cellular zinc further, with zinc plateauing at a similar level to cells 
treated with the highest tested concentration of PBT2 alone (1.0 mg/L) (Fig. 2.2A). This 
suggests zinc accumulated by higher concentrations of PBT2 may exceed tolerated cellular 
levels and either induces mechanisms to maintain zinc homeostasis or causes cell death. 
Previous evidence in mammalian cell models indicates that PBT2 acts as both a zinc and 
copper ionophore (239). However, there were no observable changes in S. uberis copper 
levels in response to PBT2 treatment (Fig. 2.2B). This is likely attributable to the low 
concentration of copper (1 µM) in the growth medium relative to zinc (23 µM). We speculate 
that under our experimental conditions zinc outcompetes copper for chelation to PBT2. 
Treatment with PBT2 and zinc altered the cellular abundances of manganese and iron 
(Fig. 2.2C and 2.2D). Manganese levels decreased by up to 7.5-fold in response to PBT2-
zinc challenge (P = 0.0001) compared to untreated cells (Fig. 2.2C). Decreased manganese 
levels were also observed in cells treated with either PBT2 or zinc alone (Fig. 2.2C). 
Exogenous zinc has previously been reported to deplete cellular manganese in Streptococcus 
pneumoniae, causing cells to become hypersensitive to oxidative stress (178, 297). In 
response to oxidative stress, streptococci restrict cellular iron levels as a strategy to limit the 
generation of ROS through iron-mediated Fenton chemistry (298-300). Similarly, S. uberis 
treated with either PBT2 (0.5 and 1.0 mg/L) or zinc had significantly lower cellular iron than 
untreated cells (P = 0.0387, 0.0335, 0.0498, respectively) (Fig. 2.2D). Collectively, these 
data suggest that PBT2-mediated zinc accumulation perturbs normal metal ion homeostasis 





Figure 2.2. PBT2-zinc alters intracellular metal ion homeostasis. Intracellular (A) zinc, 
(B) copper, (C) manganese and (D) iron concentrations as determined by ICP-MS of mid-
log phase S. uberis NZ01 cells (OD600 0.3) treated with various concentrations of PBT2 with 
or without additional zinc (100 µM), or untreated. Error bars represent the standard deviation 
of the mean from a biological triplicate (*, P < 0.05; **, P < 0.005; *** P < 0.001; **** P 
< 0.0001, one-way ANOVA).  
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2.5.3 PBT2 exchanges zinc ions for protons  
Ionophores are compounds with the ability to translocate either cations, protons, or both, and 
are therefore capable of dissipating either the ∆ψ (membrane potential) (e.g. valinomycin) 
or ΔpH (transmembrane pH gradient) (e.g. nigericin) components of the proton motive force 
(PMF) (211). To examine if the bactericidal mechanism of PBT2 is explained by dissipation 
of the PMF, we measured the ∆ψ and ∆pH of S. uberis cells in response to PBT2-zinc, using 
the radioisotopes [14C]TPP+ and [7-14C]benzoate, respectively. No observable differences in 
either component of the PMF occurred in response to treatment with PBT2-zinc at either 1× 
or 10× the CIC (0.5 mg/L PBT2 + 10 µM zinc) (Fig. S2.2). 
As we observed an increase in cellular zinc, but no effect on the membrane potential 
of whole cells (Fig. S2.2C), we hypothesised that a counter-ion (either protons or other 
cations) might be moved to make the process electroneutral. To test this, we assessed the 
ability of PBT2 to move protons in phosphatidylcholine liposomes loaded with the non-
membrane-permeable and pH-sensitive probe, pyranine (Fig. 2.3). Pyranine-containing 
liposomes have previously been used as a controlled system for measuring internal pH 
changes in response to protonophoric or ionophoric drugs (286, 301) where finite, 
(electro)chemical gradients are artificially established and used to assess proton movement 
across artificial lipid bilayers. Changes in the liposome luminal pH (internal pH) are detected 
by measuring the fluorescence of the acidic and basic forms of pyranine, the ratio of which 
is dependent on pH (Fig. 2.3A).   
 In response to external zinc addition, PBT2 was able to cause a concomitant increase 
(alkalisation) of the liposome internal pH (Fig. 2.3B, 2.3C and Fig. S2.3). As PBT2-zinc 
does not alter the cell membrane permeability of GAS, VRE or MRSA (243), we attribute 
this effect to a direct interaction of PBT2 with protons rather than proton leakage through 
damaged liposomal membranes. This effect was not observed in the absence of zinc (Fig. 
S2.4), suggesting it is dependent on the formation of a PBT2-zinc complex. Using isothermal 
titration calorimetry (ITC), we confirmed the formation of 2:1 PBT2:Zn complexes, as 
previously observed (Fig. S2.5) (247). Collectively this suggests PBT2 exchanges zinc for 
protons in an antiport-like process. Inverting the gradient, by incorporating zinc inside the 
liposome during preparation, resulted in a concomitant internal acidification upon PBT2 
addition (Fig. 2.3C and Fig. S2.6). This suggests the process is not direction specific and is 
driven purely by the Zn2+ concentration gradient. Notably, acidification of the assay buffer 
to pH 6.5 enhanced this antiport activity up to 7.5-fold, compared to pH 8.5 (Fig. 2.3B, 2.3C, 
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and Fig. S2.3). Given the apparent absence of a biological effect from PBT2-mediated 
proton translocation, we continued this work with a focus on the consequences of zinc 




Figure 2.3. PBT2 is a Zn2+/H+ ionophore. (A) Schematic for measuring internal pH using 
pyranine-containing liposomes: pyranine is a non-membrane-permeable pH indicator where 
the ratio of the acidic to basic forms of pyranine is pH dependent. Excitation of acidic (λex 
405 nm) and basic (λex 455 nm) pyranine generates detectable fluorescence (λem 510 nm). 
The internal pH of liposomes equilibrates over time with the external pH, and internal pH 
can be determined using a standard curve of pH to pyranine fluorescence ratios. In these 
experiments, pyranine fluorescence was measured and internal pH was determined after 
addition of PBT2 and/or zinc to liposomes from a 15 min endpoint. Changes to internal pH 
by PBT2-zinc were normalised for the effect of external zinc (10-3 M) alone. (B) Changes in 
internal pH of pyranine-containing liposomes with matching internal and external pH values 
following addition of PBT2 (10-6 M) in combination with zinc (10-3 M). (C) Relative change 
in internal pH of liposomes suspended in Mes-Mops-Tris buffer (pH indicated) containing 
PBT2 (10-6, 10-7 or 10-8 M), where zinc (10-3 M) is either external to liposomes (plain bars) 






































































2.5.4 PBT2-zinc induces transcriptional changes to metal ion transporter genes  
To further understand the effect of PBT2 and zinc on metal ion homeostasis, changes in the 
expression of genes involved in metal ion transport were investigated. Consistent with the 
observed changes in metal ion levels, several metal ion transporters were differentially 
expressed in response to PBT2-zinc challenge (Fig. 2.4). S. uberis contains the ATP-binding 
cassette (ABC) permease AdcABC, a conserved zinc acquisition system among streptococci 
(302). We observed that the zinc-specific solute binding protein (SBP), adcA 
(CGZ53_03345), was downregulated 4.5-log2 fold in response to PBT2-zinc (Fig. 2.4). 
Consistent with previous work on cadA homologs demonstrating function in zinc export,  
S. uberis cadA (CGZ53_06375) was upregulated 3.7-log2 fold in response to PBT2-zinc 
(Fig. 2.4). In another demonstration of increased zinc export in response to PBT2-zinc, 
expression of a putative homolog of the czcD zinc efflux pump (CGZ53_05790) increased 
1.8-log2 fold (Fig. 2.4).  
 S. uberis contains a homolog of the S. pneumoniae PsaABC manganese importer, 
termed MtuABC, with an established role in manganese uptake (303). Consistent with the 
observed depletion in manganese upon PBT2-zinc treatment (Fig. 2.2C), transcriptional 
profiling revealed that mtuA (CGZ53_02610) was strongly downregulated (3.5-log2 fold) in 
response to PBT2-zinc treatment (Fig. 2.4). The upregulation of fetB, a putative iron export 
ABC transporter permease, following PBT2-zinc treatment, together with our previous 
finding of decreased cellular iron in PBT2-zinc treated wild-type cells (Fig. 2.4 and Fig. 
2.2D), supports the inference that cells must tightly regulate iron to avoid iron toxicity under 




Figure 2.4. PBT2-zinc alters the expression of metal ion transport genes. Relative 
expression of selected genes in mid-log phase S. uberis cells (OD600 0.3) after 1 hr treatment 
with or without PBT2 (1.0 mg/L) and zinc (100 µM), individually or in combination. 
Relative expression (expressed as log2-fold change) was calculated relative to the untreated 
control and normalized to the reference gene (pflC) using the ∆∆CT method. Error bars 
represent the standard deviation of the mean from a biological triplicate.  
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2.5.5 PBT2-mediated zinc toxicity sensitises cells to killing by ROS 
If excess zinc in S. uberis exerts toxicity through manganese starvation, as previously 
observed in S. pneumoniae (178), then supplementing cells with manganese should rescue 
the observed lethality associated with PBT2-zinc treatment. We found cultures pre-treated 
with manganese (800 µM) were completely protected against cell killing by PBT2, zinc and 
PBT2-zinc (Fig. 2.5A, 2.5B and 2.5C).  
 Manganese has prominent roles in oxidative stress protection in biological systems, 
from serving as a cofactor for manganese-dependent superoxide dismutase to forming ROS-
scavenging Mn-organic acid complexes (304-306). As in related streptococcal species (297, 
299), S. uberis relies solely on a manganese-dependent superoxide dismutase (SodA) for the 
conversion of accumulated O2•- to H2O2 and O2. To determine if oxidative stress contributes 
to the lethality of PBT2 and zinc, we tested whether an antioxidant could prevent cell killing. 
Pre-treatment with reduced glutathione (GSH) (50 mM) added extracellularly, an 
antioxidant capable of neutralising ROS in bacteria (307), provided protection against the 
bactericidal action of PBT2 and zinc (Fig. 2.5A, 2.5B and 2.5C). Because zinc is able to 
bind to the sulfhydryl group of the GSH cysteine moiety and form GSH-Zn complexes (308), 
which may explain the observed protective effect of GSH, we undertook further 
experimentation to clarify the role of oxidative stress in the PBT2-zinc bactericidal 
mechanism.  
We hypothesised that by depleting intracellular manganese, PBT2-zinc would inhibit 
SodA enzyme activity. As anticipated, cultures treated with PBT2-zinc showed a 2.7-fold 
reduction in SodA activity compared to untreated cells (P = 0.0156) (Fig. 2.6A). Treatment 
with PBT2 alone reduced SodA activity by 2.6-fold (P = 0.0179), but zinc alone had no 
effect (Fig. 2.6A). Transcriptional profiling of sodA revealed no changes in expression 
following PBT2, zinc or PBT2-zinc treatment, suggesting PBT2 does not interfere with 
normal sodA regulation (Fig. S2.7). Provision of excess exogenous manganese significantly 
increased the SodA activity (P = 0.0041), and when in combination with PBT2-zinc, 
manganese partially restored SodA function (P = 0.0345) (Fig. 2.6A). 
 To examine if ROS accumulate as a consequence of PBT2-mediated zinc toxicity 
and manganese starvation, we specifically measured the production of H2O2. We found that 
PBT2 or zinc alone had no effect on H2O2 levels compared to untreated cells (Fig. 2.6B). 
However, cells treated with PBT2-zinc showed increased H2O2 (P = 0.0380) (Fig. 2.6B).  
S. uberis encodes an alkyl hydroperoxidase (ahpC and ahpF) for the detoxification of H2O2, 
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yet no changes in expression of either ahpC or ahpF were observed in response to PBT2-
zinc (Fig. S2.7). As a critical test of the hypothesis that manganese abolishes PBT2-zinc 
lethality through restoring antioxidant function, we examined the effect of manganese on 
H2O2 production. The addition of exogenous manganese to PBT2-zinc treated cells 
dramatically increased detectable H2O2 (P = 0.0001) (Fig. 2.6B). This finding supports the 
notion that providing excess manganese enables the sole superoxide dismutase, the 
manganese-dependent SodA, to convert accumulated O2•- to H2O2 and O2, ultimately 
increasing detectable H2O2. Treatment with manganese alone also demonstrated an increase 
in H2O2, although this was not statistically significant (P = 0.4742) (Fig. 2.6B). This supports 





Figure 2.5. Manganese and reduced glutathione (GSH) protect against PBT2-zinc 
killing. Pre-treatment of S. uberis cells (OD600 0.05) with manganese or GSH before the 
addition of (A) PBT2, (B) PBT2+Zn or (C) zinc at respective MICs and CICs prevents cell 
killing. Error bars represent the standard deviation of the mean from a biological triplicate.  
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Figure 2.6. PBT2-zinc impairs SodA activity and generates ROS. (A) Superoxide 
dismutase (SOD) activity of mid-log phase S. uberis cells (OD600 0.3) treated with 
PBT2 (1.0 mg/L), zinc (100 µM), or manganese (800 µM), individually or in combination. 
Cell lysates were analysed for SOD activity and normalised for total protein. (B) H2O2 
generation of mid-log phase S. uberis cells (OD600 0.3) treated with PBT2 (1.0 mg/L), zinc 
(100 µM), or manganese (800 µM), individually or in combination, as detected by Amplex 
Red fluorescence (560 λex, 590 λem). Untreated and H2O2-treated controls are included for 
comparison. Error bars represent the standard deviation of the mean from a biological 
triplicate (ns, P > 0.05; *, P < 0.05; **, P < 0.005; *** P < 0.001; **** P < 0.0001, one-




 Discussion  
In this work, we show that the bactericidal mechanism of PBT2 is mediated by intracellular 
zinc toxicity, which disrupts manganese homeostasis and leads to the accumulation of toxic 
ROS. In this global bactericidal mechanism of action, S. uberis was unable to generate 
significant resistance to PBT2+Zn in comparison to the single-target antibiotics 
ciprofloxacin (309) and rifampicin (310). In addition, this work provides a molecular 
mechanism for PBT2 ionophoric activity in bacterial cells, whereby PBT2 translocates 
across the bacterial cell membrane acting as a Zn2+/H+ ionophore. The absence of an effect 
on the membrane potential indicates PBT2 functions as an electroneutral ionophore, in 
support of an exchange of one Zn2+ ion for two H+ ions. While there was a pronounced 
alkalisation of pyranine-containing liposomes from PBT2-mediated proton translocation, no 
changes in internal pH were found in whole cells. Bacterial cells employ multiple 
homeostatic mechanisms to maintain intracellular pH in a narrow, tolerable range (311) and 
such regulatory mechanisms likely protect cells from intracellular pH alterations by PBT2. 
We observed an enhancement of PBT2 ionophoric activity at lower pH, suggesting 
that protonation of PBT2 is required for efficient zinc transport. A detailed structural analysis 
by Nguyen et al (247) has revealed zinc chelation by PBT2 occurs through the pyridine 
nitrogen and deprotonated phenoxide. Protonation of the PBT2-zinc complex at low pH may 
therefore promote the release of zinc according to the membrane potential and zinc 
concentration gradient. Given that cytosolic ‘free’ zinc in bacterial cells is in the picomolar 
to nanomolar range (312) and PBT2 binds zinc with an affinity of ~2 µM, it is unlikely PBT2 
is capable of moving zinc ions out of bacterial cells. Collectively, these data, along with the 
finding of PBT2-mediated zinc accumulation, provide a novel molecular model for PBT2 
ionophoric activity in which PBT2 exchanges extracellular zinc for intracellular protons in 
an electroneutral process (Fig. 2.7).  
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Figure 2.7. Proposed bactericidal model of action of PBT2. PBT2 has Zn2+/H+ ionophore 
activity and mediates intracellular zinc accumulation by exchanging extracellular Zn2+ for 
intracellular 2H+ in an electroneutral process. Excess zinc leads to ROS accumulation and 
additionally dysregulates manganese homeostasis through inappropriately downregulating 
expression of the MtuABC manganese import system. The resulting cellular manganese 
depletion pre-disposes cells to oxidative stress through limiting manganese-dependent 
antioxidant activity. The manganese-dependent SodA may be inhibited by two mechanisms: 
depletion of the essential manganese cofactor and zinc mismetallation. Cell death results 
when ROS accumulate beyond a tolerable threshold and induce excessive oxidative damage 
to essential cellular proteins and genomic DNA. 
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Similar to previous work investigating zinc toxicity in S. pneumoniae (178, 297, 
313), we show exogenous zinc significantly depletes cellular manganese in S. uberis. 
Consistently, addition of manganese (800 µM) protects against zinc toxicity. In these 
previous studies, the proposed mechanism of zinc-mediated manganese-starvation is 
through zinc competitively binding to the extracellular PsaA, the manganese SBP of the 
PsaABC manganese importer, thereby limiting manganese uptake. Given the identical 
composition of the metal-binding sites in the S. uberis PsaA homolog (MtuA) and  
S. pneumoniae PsaA (303), zinc may similarly impede manganese import in S. uberis by 
mismetallation of MtuA. While this may be the case under conditions of excess exogenous 
zinc, manganese depletion occurred concomitantly with PBT2-mediated intracellular zinc 
accumulation. This indicates the existence of an alternative mechanism whereby 
intracellular zinc intoxication interferes with normal manganese homeostasis. The depletion 
of mtuA transcripts following PBT2-zinc treatment indicates excess intracellular zinc 
dysregulates mtuA expression, thereby preventing manganese import. Consistently, 
Bohlmann et al (243) found expression of the GAS mtuA homolog (mtsA) is reduced 2.3-
log2 fold in response to PBT2-zinc. The molecular target of this zinc mismetallation was not 
identified in our study, however mismetallation of metalloregulators, which sense specific 
metal ions and modulate transcription of regulated genes in accordance with physiological 
needs, has previously been observed under conditions of cytosolic metal intoxication (104). 
In Bacillus subtilis intracellular zinc intoxication leads to mismetallation of the peroxide 
response regulator PerR, which when bound to zinc, cannot repress heme biosynthesis and 
consequently leads to toxic heme accumulation (165). Similarly, under conditions of 
manganese intoxication, the ferric-uptake regulator Fur is mismetallated with manganese 
and inappropriately represses iron uptake (314).  
 Given that exogenous zinc (100 µM) does not affect intracellular zinc content nor 
SodA activity yet depletes manganese to similar levels as PBT2 alone, PBT2-mediated zinc 
accumulation may inhibit SodA function through zinc mismetallation. Reduced SodA 
activity as a result of the zinc ionophoric activity of PBT2 may therefore result from a 
combination of depleting the essential manganese cofactor and mismetallation of SodA with 
zinc. Mismetallation of the GAS SodA with iron reduces the enzyme activity (299), however 
investigations into the functionality of the Zn-SodA enzyme are lacking.  
 The accumulation of H2O2 in PBT2-zinc treated cells indicates a bactericidal 
mechanism whereby intracellular zinc intoxication leads to the generation of ROS, in 
addition to impairing the ability to manage oxidative stress. Zinc lacks biological redox 
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activity but may perturb the intracellular redox status indirectly through protein 
mismetallation and inactivation. Indeed, heme accumulation following zinc mismetallation 
of PerR causes toxic superoxide generation as a result of redox cycling between heme and 
menaquinone (165). Because the provision of manganese to PBT2-zinc treated cells 
increased cellular H2O2, we infer that intracellular zinc intoxication accumulates O2•- in 
addition to H2O2. In addition to providing protection against O2•- , manganese can 
catalytically scavenge H2O2 and replace iron in the active sites of iron-containing enzymes, 
thereby preventing iron oxidation by H2O2 and subsequent protein inactivation (108, 315). 
Our data suggest that providing sufficient manganese restores the activity of Mn-SodA and 
non-enzymatic manganese-based antioxidants that scavenge ROS, thereby re-establishing 
redox balance under conditions of zinc toxicity.  
We propose a model for the bactericidal mechanism of action of the zinc ionophore 
PBT2 (Fig. 2.7): PBT2 binds extracellular zinc as a complex and dissociates in the 
cytoplasm, releasing zinc in exchange for intracellular protons in an electroneutral process 
that leads to cellular zinc accumulation. Excess intracellular zinc perturbs normal metal ion 
homeostasis and dysregulates expression of mtuABC, causing manganese depletion. Zinc 
intoxication additionally disrupts the intracellular redox balance and ROS accumulate. 
Antioxidant activity is compromised under these manganese-starved conditions leaving the 
cell vulnerable to toxic O2•- and H2O2. Ferrous iron (Fe2+) may potentiate this oxidative 
stress by reacting with H2O2 in the Fenton reaction, generating damaging hydroxyl radicals 
(•OH). Extensive oxidative damage to DNA by •OH and to cellular proteins by O2•- and 
H2O2 (316) ultimately proves lethal to the bacterial cell.  
 Here, we have demonstrated the original intended ability of PBT2 in altering the 
metallo-chemistry in Alzheimer’s and Huntington’s disease can be used to destabilize metal 
ion and redox homeostasis in S. uberis, sensitizing cells to oxidative stress in a global 
bactericidal mechanism. Given the essentiality of manganese acquisition for S. uberis to 
infect the bovine mammary gland (303), and the observed bactericidal activity of PBT2 in 
bovine milk, the therapeutic potential of PBT2 as an antimicrobial for mastitis prevention or 
treatment is promising. Indeed, the importance of manganese for virulence extends to other 
pathogens including S. pneumoniae, GAS, Staphylococcus aureus and Bacillus anthracis 
(178, 317-319). PBT2 represents a new class of antibacterial capable of targeting bacterial 
metal ion homeostasis, and through understanding the molecular basis of zinc ionophoric 
toxicity, this work serves as a platform for designing future lead compounds with potential 
for veterinary-only medicine.  
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 Supplementary information 
Table S2.1. PBT2 and zinc exhibit antibacterial synergy against S. uberis. 
 MIC of each compound 
PBT2 5.0 mg/L 
ZnSO4•7H2O 800 µM 
 CIC FICPBT2 FICZn FICI 
PBT2+ZnSO4•7H2O 
0.05 mg/L PBT2  
+ 100 µM Zn 
0.01 0.125 0.135 
0.5 mg/L PBT2  
+ 10 µM Zn 
0.1 0.0125 0.113 
† MIC, Minimum Inhibitory Concentration; CIC, Combined Inhibitory Concentration; FIC, 




Table S2.2. Real-time qPCR primers used in this study. 
Gene Primer 
direction 
Primer sequence (5’ → 3’) Primer 
efficiency 
mtuA Fwd TGAACCGCTACCTGAAGATGT 92.1% 
Rev TCAACACCATCACTGACAGCA  
fetB Fwd TCAAATGATCCCTGTTGGTGGT 101.8% 
Rev TATCAGCTCCCAAGGCCAAC  
cadA Fwd TGTTCTGGGTTGGACTTGGT 97.24% 
Rev CTTTCTGGCAGCTCGGCTAA  
adcA Fwd GCAAATGAAGCGGGTGTCAA 100.5% 
Rev TTACCTTCGCGTTCGGTTGT  
czcD Fwd TCGATGCACACTTGGTGAGT 110.7% 
Rev TCCAATCCATCTGCCGACAA  
sodA Fwd TTGCTAATGCCAATGCTGCG 96.1% 
Rev TGGTTAAGATGTCCGCCTCC  
ahpC Fwd AAGCTTGGCATGATGACTCC 90.9% 
Rev TGCTGACGAACGTATTGAGC  
ahpF Fwd GTCTTTCATTCTGGCCGTGC 108.7% 





Figure S2.1. Checkerboard analysis of PBT2 and Zn synergy.  
Growth of S. uberis NZ01 in response to various concentrations of PBT2 and Zn, alone and 
in combination, in a checkerboard broth microdilution assay. After 24 hrs incubation, growth 
(OD600) was determined by spectrometric measurement on a microplate reader. Data 




Figure S2.2. Effect of PBT2-zinc on components of the protonmotive force (PMF).  
(A) Internal pH, (B) transmembrane pH gradient (∆pH) and (C) membrane potential (∆Ψ) 
(mV) of S. uberis cells following treatment with PBT2-Zn at 1×CIC (0.5 mg/L PBT2 + 10 
µM zinc) or 10×CIC (5.0 mg/L PBT2 + 100 µM zinc) for 20 min. As a control, cells were 
treated with toluene (0.4% v/v) to permeabilise cell membranes and dissipate the ∆pH and 
∆Ψ. In (A) and (B), cells were suspended in THB at pH 5.2 to establish a large ∆pH, while 
cells in (C) were suspended in THB at pH 7.5. The ∆pH was calculated from the distribution 
of [14C]benzoate using the Henderson-Hasselbalch equation, and the ∆Ψ was determined 
from the uptake of [14C]TPP+ according to the Nernst relationship. Internal pH was 
determined from the ∆pH. Error bars represent the standard deviation of the mean from a 
biological triplicate (ns, P > 0.05; **** P < 0.0001, one-way ANOVA).  
 78 
 
Figure S2.3. Effects of PBT2-zinc on internal pH of empty liposomes. Pyranine-
containing liposomes with an internal pH of (A) 6.5, (B) 7.7 or (C) 8.5 were suspended in 
Mes-Mops-Tris buffer of matching pH and treated with PBT2 and zinc. Actual measured 
internal pH values of liposomes, including untreated and vehicle (DMSO) treated controls, 
are shown on the left. The relative change in internal pH of liposomes treated with PBT2 is 
shown on the right and is normalised for the effect of zinc alone on internal pH. Error bars 




Figure S2.4. Effect of PBT2 on internal pH of liposomes in the absence of zinc. Pyranine-
containing liposomes with an initial internal pH of 6.5, 7.7 or 8.5 were suspended in buffer 
of matching pH and treated with varying concentrations of PBT2. Untreated and vehicle 





Figure S2.5. PBT2 binds zinc in a 2:1 stoichiometry. Titration curve and binding isotherm 
of 0.3 mM zinc injected into 0.035 mM PBT2 at pH 7.7 and 37°C, with best-fit 
thermodynamic parameter estimates of KD = 1.97 × 10-6 ± 3.12 × 10-5 M and ∆H = −7.48 ± 




Figure S2.6. Effects of PBT2 on internal pH of zinc-containing liposomes. (A) Internal 
pH of untreated zinc-containing liposomes following suspension in buffer at pH 6.5, 7.5 or 
8.5. Initial internal pH of liposome preparations was pH 7.5. (B) Internal pH of pyranine-
containing liposomes loaded with zinc (10-3 M) following suspension in buffer at pH 6.5, 
7.7 or 8.5 with varying concentrations of PBT2. (C) Change in internal pH of zinc-
containing liposomes suspended in buffer of pH 6.5, 7.7 or 8.5 with varying concentrations 
of PBT2, relative to internal pH of untreated controls. Error bars represent the standard 




Figure S2.7. Expression of oxidative-stress response genes following PBT2 and zinc 
treatment. Relative expression of ahpF, ahpC and sodA genes in mid-log phase S. uberis 
cells (OD600 0.3) after 1 hr treatment with or without PBT2 (1.0 mg/L) and zinc (100 µM), 
individually or in combination. Relative expression (expressed as log2-fold change) was 
calculated relative to the untreated control and normalized to the reference gene (pflC) using 





Figure S2.8. Response of liposome preparations to a pH gradient. Pyranine-containing 
liposomes were prepared with an internal pH of 7.7 and suspended in Mes-Mops-Tris buffer 
at pH 7.7, 6.5, or 6.5 with carbonyl cyanide m-chlorophenylhydrazone (CCCP) and 
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The World Health Organization recognises methicillin-resistant Staphylococcus aureus 
(MRSA) as a high-priority pathogen for which novel drug treatment strategies are urgently 
needed. Antibiotic adjuvants that break resistance in drug-resistant pathogens offer a strategy 
to bypass the costly and timely drug discovery platform by resurrecting once-successful 
antibiotics. Recently, the safe-for-human-use zinc ionophore PBT2 was discovered to 
reverse β-lactam resistance in MRSA through an undefined mechanism of action. Here, we 
report that the zinc ionophoric activity of PBT2 and structurally related 8-
sulfonamidoquinoline compounds reverses β-lactam resistance in both hospital- and 
community-associated MRSA strains by dysregulating cellular zinc and manganese 
homeostasis. Restoring manganese homeostasis through exogenous manganese 
supplementation could abolish the β-lactam adjuvant activity of PBT2. Investigations into 
the physiological effects of PBT2-zinc-oxacillin combination therapy in MRSA point to a 
disruption of multiple elements involved in resistance, including mecA expression, cell wall 
and membrane structural integrity, autolysis and the proton motive force. Further, MRSA 
treated with PBT2-zinc had suppressed expression of the SaeRS global regulator of 
virulence. Whereas neither PBT2 nor oxacillin treatment alone protected mice from lethality 
in a murine model of MRSA peritonitis, PBT2-oxacillin combination therapy significantly 
improved survival rates and bacterial clearance from the kidneys. Collectively, our findings 
indicate zinc ionophores disrupt the connections between metal homeostasis, cell wall and 
membrane metabolism, and β-lactam resistance in MRSA through a multi-faceted 
mechanism of action. Zinc ionophores may serve as important agents for β-lactam adjuvant 




Methicillin-resistant Staphylococcus aureus (MRSA) has emerged globally as a major multi-
drug resistant bacterial pathogen in both hospital and community settings (15). MRSA 
causes a variety of clinical manifestations including skin, soft tissue and bone infections, 
endocarditis, pneumonia and sepsis (18). Infections with this pathogen are associated with 
significant mortality, morbidity, and prolonged hospital stays (34, 35). In the United States 
alone, more than 300,000 cases, 10,000 deaths and $1.7 billion in associated healthcare costs 
were attributed to MRSA in 2017 (37). Vancomycin has long been relied upon as a front-
line antibiotic treatment for invasive MRSA infections; however, MRSA isolates have 
emerged with decreased susceptibility to vancomycin, and in rare cases, complete 
vancomycin resistance (36). Moreover, resistance has also been described for alternative 
treatment options, including teicoplanin, daptomycin and linezolid (15). In light of the 
limited and depleting repertoire of effective antibiotics for the treatment of invasive MRSA 
infections, new therapeutic options for this high-priority pathogen are urgently needed (39).  
In MRSA, β-lactam resistance is mediated by the acquisition of an alternative 
penicillin binding protein (PBP), PBP2a, encoded by the mecA gene of the mobile genetic 
element SCCmec (15). Unlike the native PBPs, the transpeptidase domain of PBP2a has an 
extremely low affinity for β-lactams (29). Cooperative PBP2a transpeptidase and PBP2 
transglycosylase function enables continued peptidoglycan cross-linking in the presence of 
almost all β-lactam antibiotics (28). Prior to the widespread emergence of resistance, the 
bactericidal mechanism and favourable pharmacological and safety profiles of β-lactams 
made them the drugs of choice for the treatment of staphylococcal infections (282). An 
adjuvant that restores the clinical efficacy of β-lactams against MRSA would therefore add 
valuable treatment options and bypass many of the challenges in novel antimicrobial 
discovery and development (89). Indeed, the most successful antibiotic adjuvants ever 
introduced to the clinic are the β-lactamase-inhibitors (clavulanic acid, tazobactam and 
sulbactam) that restore penicillin sensitivity against β-lactamase-producing methicillin-
susceptible S. aureus (91). This has served as motivation for the research and development 
of agents capable of reversing PBP2a-mediated resistance in MRSA.  
We have recently demonstrated that PBT2, an 8-hydroxyquinoline (8-HQ) derivative 
originally developed as a therapeutic for neurodegenerative diseases, resensitizes several 
drug-resistant Gram-positive pathogens to multiple classes of antibiotics in the presence of 
zinc (243). Importantly, a sub-inhibitory concentration of PBT2-zinc restored the activity of 
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the β-lactam antibiotics ampicillin and oxacillin against the epidemic community-associated 
MRSA (CA-MRSA) strain USA300 in vitro (243). PBT2 acts as a zinc ionophore, 
facilitating zinc transport across cell membranes (239), and accumulates zinc in MRSA 
(243). Investigations into the bactericidal activity of PBT2 against the bovine pathogen 
Streptococcus uberis point to a mechanism of intracellular zinc toxicity, which consequently 
causes lethality through the dysregulation of manganese homeostasis and production of toxic 
reactive oxygen species (ROS) (320). The molecular mechanism by which subinhibitory 
PBT2-zinc resensitizes MRSA to β-lactams, however, is currently unclear.  
Although PBP2a is the key genetic determinant for resistance, a network of 
interdependent processes contributes to PBP2a-mediated resistance in MRSA. Genetic 
screens and biochemical analyses have identified a large number of auxiliary genes required 
for resistance that are involved in processes such as peptidoglycan precursor biosynthesis, 
cell wall turnover, mecA regulation and PBP2a localization at the division septum (282, 321-
323). Several compounds that inhibit these targets act synergistically with β-lactams against 
MRSA (282, 323-325). As excess intracellular zinc promotes the nonspecific mismetallation 
of cellular ligands (168), it is plausible that one or more of the pathways necessary for 
PBP2a-mediated resistance becomes dysregulated by zinc ionophore activity. Several 
clinical trials have found PBT2 a safe therapeutic for human use (240-242), and thus, there 
is considerable interest in understanding the mechanism of β-lactam resensitization by PBT2 
and its therapeutic potential as a β-lactam adjuvant against invasive MRSA infections.  
In this work, we investigated the underlying biological mechanism of β-lactam 
resensitization in MRSA by PBT2. In addition, 8-sulfonamidoquinolines, substituted 
sulfonamide analogues of PBT2 with zinc-dependent antibacterial activity (245) were 
investigated for zinc ionophoric and β-lactam-potentiating activities. Further, we examined 
the efficacy of PBT2 as an antibacterial adjuvant in vivo in a peritonitis model of invasive 
MRSA infection. Our results indicate zinc ionophores dysregulate zinc and manganese 
homeostasis in MRSA, with broad-reaching consequences on the expression of key 
resistance and virulence determinants, cell membrane and wall integrity, and the proton 
motive force (PMF).  
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 Materials and Methods 
3.3.1 Bacterial strains, media, and growth conditions 
All bacterial strains used in this study are listed in Table S3.1. MRSA strains were all grown 
in Tryptic Soy broth (TSB) (Sigma-Aldrich) or cation-adjusted Mueller-Hinton broth 
(CAMHB) (Sigma-Aldrich). GAS and VRE strains were grown in CAMHB. Bacteria were 
routinely grown in broth at 37°C with agitation (200 rpm). For growth on solid medium, 
1.5% (w/v) agar was added to make either Tryptic Soy agar (TSA) or cation-adjusted 
Mueller-Hinton agar (CAMHA).  
 
3.3.2 Chemical and radiochemical reagents 
PBT2, ZDR090 and ZDR115 were all synthesised as described previously (243, 246). The 
chemical structures of PBT2, ZDR090 and ZDR115 are shown in Table S3.2. PBT2 stocks 
(2 mg/mL) were prepared in 10% DMSO, and ZDR090 and ZDR115 stocks (20 mg/mL) 
were prepared in 100% DMSO. ZnSO4•7H2O (zinc) and MnSO4•H2O (manganese) stocks 
were prepared in filter-sterilised dH2O. The radiochemicals [7-14C]benzoate (54.1 
mCi/mmol) and [14C]methyltriphenyl phosphonium iodide (TPP+) (57 mCi/mmol) were 
obtained from Moravek Inc.  
 
3.3.3 Minimum inhibitory concentration (MIC) determination 
MICs were determined by broth microdilution in accordance with CLSI guidelines (326). 
MIC assays were undertaken in either CAMHB or TSB as stated, with test compounds 
serially diluted 2-fold in 50 µL volumes within 96-well round-bottom plates. Bacterial 
inocula equal to a 0.5 MacFarland turbidity standard were prepared by direct colony 
suspension in phosphate buffered saline (PBS). The suspensions were then diluted 1:150 in 
broth and added 1:2 to each microtiter well at a final volume and inoculum of 100 µL and  
5 × 105 CFU/mL per well, respectively. The MIC was determined after 16 – 24 hrs 
incubation at 37°C as the lowest concentration of the antibiotic/compound that showed no 
visible growth. MIC assays were undertaken in biological triplicate.  
 
3.3.4 Bacterial time-dependent cell killing assays 
Overnight cultures of MRSA USA300 were inoculated to OD600 0.05 in TSB and grown to 
mid-log phase (OD600 0.5). For time-kill experiments investigating the restoration of 
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oxacillin susceptibility by PBT2 and ZDR compounds, cells were diluted to a starting OD600 
of 0.05 in TSB only, TSB containing oxacillin (8 µg/mL or 16 µg/mL, as stated), PBT2+zinc 
(3 µM PBT2 + 50 µM zinc), ZDR090 (24 µM), ZDR115 (16 µM), PBT2+zinc+oxacillin, 
ZDR090+oxacillin, or ZDR115+oxacillin. For experiments with cardiolipin (CL) (C0563; 
Sigma-Aldrich) and phosphatidylglycerol (PG) (63371; Sigma-Aldrich), cells were diluted 
to OD600 0.05 in TSB containing PBT2+zinc+oxacillin and either 100 µM or 25 µM of CL 
or PG. Aliquots of cultures were taken at 0, 4, 8, 12 and 24 hrs post-challenge, serially diluted 
in PBS, and spot plated (10 µL) on TSA plates. The surviving CFU/mL of cultures was 
determined after 24 hrs incubation at 37°C. Assays were performed in biological triplicate.  
For time-kill experiments investigating the synergistic concentration of 
PBT2+zinc/ZDR090 with oxacillin at a higher cell density, aliquots of USA300 cells at 
OD600 0.5 were treated with oxacillin (8 µg/mL), PBT2+zinc (9 µM PBT2 + 50 µM zinc), 
ZDR090 (72 µM), PBT2+zinc+oxacillin (9 µM PBT2 + 50 µM zinc + 8 µg/mL oxacillin), 
ZDR090+oxacillin (72 µM ZDR090 + 8 µg/mL oxacillin), or were untreated. The OD600 of 
cultures was measured at various time-points up until 24 hrs post-challenge, and experiments 
were performed in biological duplicate.    
For manganese rescue experiments, MRSA USA300 cultures were grown to mid-log 
phase and diluted to OD600 0.05 (~5 × 106 CFU/mL) in TSB containing various 
concentrations of subinhibitory manganese (0, 0.1, 0.5, 1.0 or 5 mM) alone, or with the 
addition of oxacillin (16 µg/mL), PBT2+zinc (3 µM PBT2 + 50 µM zinc), or PBT2+zinc 
and oxacillin in combination. The surviving CFU/mL of cultures was determined after 24 
hrs incubation at 37°C, and experiments were performed in biological duplicate.  
 
3.3.5 Inductively coupled plasma mass spectrometry (ICP-MS) 
Overnight cultures of MRSA USA300 were inoculated at OD600 0.05 in TSB and grown to 
mid-log phase (OD600 0.5). Aliquots (10 mL) of mid-log phase cells were separated into 
individual 50 mL falcons and challenged for 4 hrs with oxacillin (8 µg/mL), PBT2 (9 µM), 
zinc (50 µM), PBT2+zinc (9 µM PBT2 + 50 µM zinc), PBT2+zinc+oxacillin (9 µM PBT2 
+ 50 µM zinc + 8 µg/mL oxacillin) or untreated. For experiments with ZDR090, aliquots 
(50 mL) of mid-log phase cells were separated into individual 250 mL flasks and challenged 
for either 1 hr or 4 hrs with oxacillin (8 µg/mL) or ZDR090 (72 µM), alone or in 
combination, or untreated. Samples were prepared for ICP-MS analysis as previously 
described (243). The metal contents of samples were determined using an Agilent 7500ce 
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ICP-MS (Centre of Trace Element Analysis, Department of Chemistry, University of 
Otago). Three biological replicates were analysed.  
 Metal ion concentrations (mg/L) of samples were converted to molar units as 
previously described (320) (Chapter II, section 2.4.6). The OD600 of each sample and the 
MRSA USA300 protein content (94.62 mg protein/OD600/L) were used to determine cellular 
metal ion concentrations based on an intracellular volume of 5 µL/mg protein (327). Protein 
content was determined by a BCA assay of cell lysates (lysed by 1 M NaOH, 95°C and 
neutralized with 1 M HCl) using bovine serum albumin (BSA) as the standard.  
 
3.3.6 Transmembrane pH (ΔpH) and membrane potential (ΔΨ) measurements 
Overnight cultures of MRSA USA300, GAS HKU16 and VRE RBWH1 were grown to mid-
log phase (OD600 0.6) in CAMHB and challenged with PBT2 and zinc for 1 hr  
(MRSA, 2 µM PBT2 + 50 µM zinc; GAS, 4.75 µM PBT2 + 128 µM zinc; VRE, 1.75 µM 
PBT2 + 128 µM zinc). Aliquots of cells (2 mL) were then incubated in glass tubes for 5 min 
at 37°C with [7-14C]benzoate (11 µM final concentration) or [14C]TPP+ (5 nM final 
concentration) for determination of the ΔpH and ΔΨ, respectively. All MRSA and GAS 
replicates included a 1% toluene control to dissipate the ΔΨ and ΔpH components for 
analysis, while 20 µM nigericin combined with 20 µM valinomycin was used for this 
purpose for VRE. Radioisotope measurements and calculations of the ΔpH, internal pH, and 
ΔΨ, were performed as previously described based on an intracellular volume of 5 µL/mg 
protein (293, 327). Assays were conducted in biological triplicate.  
 
3.3.7 RNA extraction and real-time quantitative PCR (RT-qPCR) 
MRSA USA300 cells were grown to mid-log phase (OD600 0.5) in TSB (50 mL) and 
separated into individual 10 mL aliquots in 50 mL falcon tubes. The cells were then treated 
for 4 hrs with oxacillin (8 µg/mL), PBT2+zinc (9 µM PBT2 + 50 µM zinc), 
PBT2+zinc+oxacillin combined, or untreated. Total RNA was isolated using TRIzol-
chloroform extraction as described previously (294) and purified using the RNA clean and 
concentrator™-5 extraction kit (ZYMO research). Following elution of RNA into 
DNase/RNase-free H2O, RNA was DNase-treated using the TURBO DNA-free kit 
(Invitrogen) according to the manufacturer’s instructions, and RNA was quantified on a 
NanoDrop instrument (Thermo Scientific). cDNA was synthesised from DNA-free samples 
using a SuperScript™ III Reverse Transcriptase kit (Invitrogen). Primers used for qPCR 
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were designed on Primer-BLAST and are detailed in Table S3.3. cDNA optimization and 
primer efficiency assays were performed, and qPCR experiments were undertaken in a 
ViiA7 real-time PCR system (Applied Biosystems) using the PowerUp™ SYBR™ Green 
Master Mix (Applied Biosystems) according to the manufacturer’s instructions. Results 
were normalized to the gyrB gene using the ΔΔCT method (295) and experiments were 
undertaken in biological triplicate.  
 
3.3.8 Autolysis assay 
Autolysis was measured as described previously (328). A biological triplicate of mid-log 
phase MRSA USA300 cells (OD600 0.5) were treated for 4 hrs with oxacillin (8 µg/mL), 
PBT2 (9 µM), zinc (50 µM), PBT2+zinc (9 µM PBT2+ 50 µM zinc), PBT2+zinc+oxacillin 
(9 µM PBT2 + 50 µM zinc + 8 µg/mL oxacillin), or were untreated. Cells were then 
harvested by centrifugation (3,220 × g, 4°C, 10 min), washed twice in mQ H2O, and then 
resuspended to an OD600 of 1.0 in 50 mM Tris-HCl (pH 7.5) buffer (unstimulated autolysis) 
or 50 mM Tris-HCl (pH 7.5) buffer containing 0.1% (w/v) Triton-X-100 (stimulated 
autolysis). Cells were incubated stationary at 37°C in spectrophotometer cuvettes and the 
OD600 was recorded every 30 min for 4 hrs.  
 
3.3.9 Measuring turbidity of PBT2-lipid mixtures 
Measurements of the turbidity of PBT2-lipid mixtures were performed as previously 
described by Johnston et al (329). CL and PG were dissolved in methanol at a concentration 
of 10 mM. In a 96-well plate, PBT2 (1 mM) and/or zinc (0.1 mM), or oxacillin (16 µg/mL) 
were mixed with CL or PG (at concentrations ranging from 0.125 to 5 mM) in mQ at a final 
volume of 50 µL. The optical density at 490 nm (OD490) was measured after a 10 min 
incubation at RT.  
 
3.3.10 Transmission electron microscopy (TEM) 
Mid-log phase MRSA USA300 (OD600 0.5) were treated for 4 hrs with either oxacillin (8 
µg/mL), PBT2 (9 µM), zinc (50 µM), PBT2+zinc (9 µM + 50 µM), PBT2+zinc+oxacillin 
(9 µM + 50 µM + 8 µg/mL), or were untreated. Cell pellets were then harvested by 
centrifugation (3,220 × g, 4°C, 20 min), washed twice in PBS, and suspended in primary 
fixative solution (2.5% glutaraldehyde in 0.1 M cacodylate buffer). Following overnight 
incubation at 4°C, fixed cells were washed in ddH2O and further treated with 1% osmium 
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tetroxide in 0.1 M cacodylate buffer for 1 hr, washed and stained with 1% uranyl acetate in 
ddH2O for 1 hr, serially dehydrated in ethanol, then embedded in EMbed 812 resin. Sections 
were viewed with a Philips CM 100 transmission electron microscope. Sample processing 
and microscopy were performed at the Otago Micro and Nanoscale Imaging (OMNI) 
Electron Microscopy Centre at the University of Otago.  
 
3.3.11 Murine intraperitoneal infection model 
For preparation of MRSA USA300 frozen stocks for infection, cells were grown to mid-log 
phase (OD600 0.5) in TSB, harvested by centrifugation (7,000 × g, 20 min, 4°C), washed 
twice in ice-cold TSB, resuspended in TSB + 15% glycerol and then snap-frozen in liquid 
nitrogen for storage at –80°C. The lethal dose of MRSA USA300 was determined by 
infection of 6-week-old female BALB/c mice (n = 5) with either saline (0.9% NaCl), 5 × 106 
CFU, 5 × 107 CFU, 5 × 108 CFU or 1 × 109 CFU via intraperitoneal injection (100 µL). 
Inocula were determined by CFU enumeration following serial dilution in PBS, plating on 
TSA and incubation 16 – 24 hrs at 37°C. For peritonitis survival experiments with PBT2 and 
oxacillin treatments, 6-week-old female BALB/c mice (n = 10) were infected with 5 × 108 
CFU via intraperitoneal injection (100 µL). At 0.5, 6, 24, 30 and 48 hrs post-infection, mice 
were treated with either an intraperitoneal injection (100 µL) of saline, PBT2 (1.5 mg/kg), 
oxacillin (15 mg/kg), or PBT2 and oxacillin in combination. Infected mice were housed in 
individual cages based on treatment and the survival and morbidity was monitored over a 
period of 10 days. Statistical significance was calculated by the log-rank test.  
Tissue (kidneys) and blood dissemination of MRSA USA300 was determined 
following intraperitoneal infection of mice with 1 × 108 CFU. Infected mice were treated at 
0.5 and 5 hrs post-infection with saline (0.9% NaCl), PBT2 (1.5 mg/kg) and/or oxacillin (15 
mg/kg) in cohorts of 10, and a blood sample (5 µL) was taken by tail bleeding at 6 hrs. At 
24 hrs, mice were culled by inhalation of CO2. The kidneys of mice were then surgically 
extracted and a blood sample (300 µL) was taken by cardiac puncture. Autopsied kidneys 
were homogenised by lysing matrix F tubes using a FastPrep instrument (MP biomedicals). 
Homogenised kidneys and blood samples were serially diluted in PBS and plated on TSA to 
determine viable bacteria. Statistical significance was calculated by one-way ANOVA using 
log-transformed values.  
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3.3.12 Ethical approval 
Animal experiments were undertaken in accordance with the Australian code of practice for 
the care and use of animals for scientific purposes. Permission was obtained from the 




3.4.1 PBT2 and 8-sulfonamidoquinoline derivatives restore β-lactam antibiotic 
susceptibility in various MRSA strains.  
Building on our previous work describing the resensitization of the CA-MRSA strain 
USA300 to β-lactam antibiotics by PBT2 (243), we examined if PBT2 resensitizes other 
MRSA strains of unique genetic backgrounds to this class of antibiotics. We first assessed 
the antibacterial potential of PBT2 and zinc, alone and in combination, against the hospital-
associated MRSA (HA-MRSA) strains NCTC10442 (SCCmec type I (330)) and EMRSA-
15 (SCCmec type IV (331)), and the laboratory MRSA strain RA120 (MSSA strain BB255 
transformed with SCCmec type I) alongside USA300 (332). PBT2 and zinc individually 
displayed antibacterial activity against all MRSA strains tested with MICs of 8 µM PBT2 
and 1.5 – 3 mM zinc (Table 3.1). The combination of PBT2 and zinc showed antibacterial 
synergy in all strains, as indicated by an inverse relationship between the PBT2 MIC and 
increasing zinc concentration (Table 3.1). In the presence of the highest zinc concentration 
tested (0.5 mM), a 4-fold reduction in the PBT2 MIC was observed for strains USA300 and 
RA120, while 2-fold and 8-fold reductions were observed for NCTC10442 and EMRSA-15, 
respectively (Table 3.1).  
The ability of subinhibitory PBT2 and zinc (PBT2+zinc) to restore sensitivity to 
penicillins (oxacillin, ampicillin and penicillin G) was next investigated in EMRSA-15 and 
RA120, alongside USA300. All strains exhibited resistance to all three antibiotics (MIC ≥ 4 
µg/mL oxacillin/ampicillin; MIC ≥ 0.25 µg/mL penicillin G (326)), and as previously 
described (243), a subinhibitory combination of PBT2+zinc restored the sensitivity of 
USA300 to oxacillin and ampicillin (MIC ≤ 2 µg/mL) (Table 3.2). Subinhibitory PBT2+zinc 
substantially reduced the USA300 penicillin G MIC from 64 µg/mL to 0.5 µg/mL (128-fold) 
(Table 3.2), although this value still exceeds the CLSI breakpoint for penicillin G sensitivity 
(MIC ≤ 0.125 µg/mL) (326). EMRSA-15 and RA120 were also resensitized to oxacillin in 
the presence of subinhibitory PBT2+zinc concentrations (Table 3.2). This combination of 
PBT2+zinc also decreased ampicillin and penicillin G resistance in both strains, with 4-fold 
and 8-fold reductions in the ampicillin MIC for EMRSA-15 and RA120, respectively, and 
16-fold reductions in the penicillin G MIC for both strains (Table 3.2). In all MRSA strains, 
neither PBT2 nor zinc had any effect on antibiotic susceptibility when added individually 
(Table 3.2).  
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Table 3.1. Minimum inhibitory concentrations (MIC) of zinc and PBT2, ZDR090 and 
ZDR115 in combination with zinc against MRSA strains 
 MRSA strain 
 USA300 NCTC10442 EMRSA-15 RA120 
 Zinc MIC (mM) 
 1.5 1.5 3 1.5 
Zinc (µM) PBT2 MIC (µM) 
0 8 8 8 8 
50 4 8 4 4 
100 4 4 2 4 
200 4 4 2 2 
500 2 4 1 2 
Zinc (µM) ZDR090 MIC (µM) 
0 64 64 64 32 
50 32 32 16 32 
100 32 32 16 16 
200 16 32 8 16 
500 16 16 4 8 
Zinc (µM) ZDR115 MIC (µM) 
0 16 16 16 16 
50 16 16 16 16 
100 16 16 16 16 
200 16 16 16 16 
500 8 16 8 8 
a MIC values were determined by broth microdilution in cation-adjusted Mueller-Hinton 
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Given the observed synergy of 8-sulfonamidoquinolines with zinc (245, 246), we 
hypothesised these substituted 8-HQs may also restore β-lactam sensitivity in MRSA in a 
similar zinc-dependent mechanism to PBT2. As we had recently demonstrated the bactericidal 
activity of the 8-sulfonamidoquinolines ZDR090 and ZDR115 against an S. aureus strain 
(ATCC 6538) (246), we sought to investigate these two compounds as both standalone 
antibacterials and antibiotic adjuvants in MRSA. Both ZDR090 and ZDR115 inhibited growth 
of MRSA strains USA300, NCTC10442, EMRSA-15 and RA120 (Table 3.1). In the absence 
of supplementary zinc to CAMHB, ZDR090 MICs of 64 µM were observed for USA300, 
NCTC10442 and EMRSA-15, while an MIC of 32 µM was observed for RA120. For ZDR115, 
all strains had an MIC of 16 µM in the absence of additional zinc (Table 3.1). As observed for 
PBT2, ZDR090 became significantly more active in the presence of increasing zinc. In the 
presence of 0.5 mM zinc, the ZDR090 MIC decreased 4-fold in USA300 and NCTC10442, 16-
fold in EMRSA-15, and 8-fold in RA120 (Table 3.1). ZDR115 exhibited less zinc-dependency 
than ZDR090, with only a 2-fold reduction in MIC for USA300, EMRSA-15 and RA120, and 
no change in MIC for NCTC10442 in the presence of 0.5 mM zinc (Table 3.1).  
Subinhibitory concentrations of ZDR090 resensitized all MRSA strains tested 
(USA300, EMRSA-15 and RA120) to oxacillin, ampicillin and penicillin G (MIC ≤ 2 µg/mL 
oxacillin/ampicillin, MIC ≤ 0.125 µg/mL penicillin G (326)) (Table 3.3). While ZDR090 (28 
µM) alone had no effect on the oxacillin MIC, a 4-fold decrease in the ampicillin and penicillin 
G MICs for USA300 was seen. The addition of 10 µM zinc was required to restore oxacillin 
and ampicillin sensitivity while 20 µM zinc was required for penicillin G resensitization (Table 
3.3). ZDR090 (24 µM) alone was sufficient to restore penicillin G and ampicillin sensitivity in 
RA120, but the addition of 10 µM zinc was required to sensitize this strain to oxacillin (Table 
3.3). Compared to USA300 and RA120, EMRSA-15 became susceptible to β-lactams in the 
presence of markedly lower concentrations of ZDR090+zinc (7 µM ZDR090 + 50 µM zinc for 
oxacillin and ampicillin; 7 µM ZDR090 + 75 µM zinc for penicillin G) (Table 3.3). This effect 
may reflect the comparatively greater sensitivity of EMRSA-15 to ZDR090+zinc (Table 3.1).  
PBT2, ZDR090 and ZDR115 also showed antibacterial synergy with zinc against 
various MRSA strains when tested in TSB (Table S3.4), and subinhibitory concentrations of 
these compounds also increased the susceptibility of these strains to oxacillin and ampicillin 
(Table S3.5). To further investigate the synergistic effect between these compounds and β-
lactams, time-dependent cell-killing assays of MRSA USA300 were undertaken. MRSA 
USA300 was able to grow in the presence of up to 128 µg/mL oxacillin alone (Fig. 3.1A), 
although subinhibitory oxacillin concentrations initially prevented growth of this strain for a 
period of at least 8 hrs, as observed previously (333). Interestingly, inhibition of MRSA with 
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≥128 µg/mL oxacillin alone was bacteriostatic whereas 16 µg/mL oxacillin combined with  
3 µM PBT2 + 50 µM zinc (0.375 × the combined inhibitory concentration [CIC] of PBT2 with 
50 µM zinc (Table 3.4)) was bactericidal (≥3-log10 reduction in CFU/mL of the initial inocula) 
(Fig. 3.1B). Similarly, 8 µg/mL oxacillin in the presence of either 24 µM ZDR090 (0.375 × 
MIC) or 16 µM ZDR115 (0.5 × MIC) was also bactericidal (Fig. 3.1C, 3.1D and Table 3.3). 
For both ZDR090 and ZDR115, this resensitization of oxacillin cidality did not require the 
addition of supplementary zinc to the growth media (TSB). We suggest that these compounds 
are effective in forming sufficient complexes with the bioavailable zinc within TSB to exert a 
synergistic effect. Cultures treated with either PBT2+zinc, ZDR090 or ZDR115 alone reached 
a similar CFU/mL as untreated cultures after 24 hrs, although with varying growth kinetics 
(Fig. 3.1B – 3.1D). Whereas ZDR090-treated cultures grew similarly to untreated cultures, 
growth in the presence of PBT2+zinc or ZDR115 was inhibited for 12 hrs and 4 hrs, 
respectively (Fig. 3.1B – 3.1D). These data indicate that PBT2 and 8-sulfonamidoquinolines 
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Figure 3.1. Restoration of oxacillin lethality in MRSA by PBT2 and 8-
sulfonamidoquinolines ZDR090 and ZDR115. (A) Growth of MRSA USA300 (at OD600 
0.05, ~1 × 106 CFU/mL) in the presence of various concentrations of oxacillin after 24 hrs. 
Time-dependent cell killing kinetics of MRSA USA300 in TSB in the presence of (B) 
PBT2+zinc (0.375 × CIC), (C) ZDR090 (0.375 × MIC), and (D) ZDR115 (0.5 × MIC), with 
and without oxacillin (Ox) at indicated concentrations. Dashed lines indicate the limit of 
detection (1 × 102 CFU/mL). Error bars represent the standard deviations of the means from 
biological triplicates.  
 102
3.4.2 Zinc ionophore and oxacillin exposure is associated with changes in metal ion 
abundance in MRSA.  
As a zinc ionophore (239, 243, 320), we hypothesised that PBT2 resensitizes MRSA to β-lactam 
antibiotics by a zinc-dependent mechanism of action. Although we have previously linked zinc 
accumulation to the bactericidal mechanism of action of PBT2 (320), the metal ion content of 
MRSA cells upon resensitization to oxacillin by subinhibitory PBT2+zinc had not previously 
been investigated. To detect cellular metal ions with high sensitivity and reproducibility, 
inductively-coupled plasma mass spectrometry (ICP-MS) analysis was undertaken on mid-log 
phase MRSA USA300 cells (OD600 0.5) treated or untreated with PBT2+zinc in the presence 
or absence of oxacillin. At this cell density, we found 9 µM PBT2 + 50 µM zinc impeded 
growth when combined with 8 µg/mL oxacillin (Fig. S3.1). Given the observed differences in 
growth kinetics by 4 hrs post-treatment with either oxacillin, PBT2+zinc or 
PBT2+zinc+oxacillin under these experimental conditions (Fig. S3.1), this time-point was 
chosen to analyse differences in cellular metal ion abundances. Consistent with previous 
observations, cells treated with PBT2+zinc had significantly higher zinc levels than untreated 
cells (2.5-fold increase, P = 0.0016) (Fig. 3.2A). The addition of oxacillin had no effect on 
PBT2-mediated zinc accumulation, with PBT2+zinc+oxacillin-treated cells accumulating zinc 
to a similar level as PBT2+zinc alone (P = 0.0005 compared to untreated) (Fig. 3.2A). Further, 
treatment with either PBT2, zinc or oxacillin individually did not affect cellular zinc abundance 
(Fig. 3.2A).  
The synergy between 8-sulfonamidoquinolines and zinc strongly suggests that these 
structural analogues of PBT2 also function as zinc ionophores and similarly potentiate β-lactam 
sensitivity in MRSA via a zinc-dependent mechanism. To determine this, ICP-MS analysis was 
undertaken on MRSA cells (OD600 0.5) resensitized to oxacillin (8 µg/mL) by sub-inhibitory 
ZDR090 (72 µM) (Fig S3.1B). As observed for PBT2, cellular zinc levels increased upon 
exposure to both ZDR090 (3.2-fold increase, P = 0.075) and ZDR090+oxacillin (4.4-fold 
increase, P = 0.010), although levels in ZDR090-treated cells were not statistically significant 
(P = 0.075) (Fig. 3.2B). Given that the growth of MRSA appears to recover from ZDR090 
exposure by the 4 hr time-point in which these cells were analysed (Fig. S3.1B), disruptions to 
cellular zinc abundance may be controlled by homeostatic mechanisms. To assess any 
immediate changes in metallostasis by ZDR090, we analysed the metal contents after 1 hr 
treatment. After 1 hr, both ZDR090 and ZDR090+oxacillin significantly increased cellular zinc 
compared to untreated cells (ZDR090: 3-fold increase, P = 0.0037; ZDR090+oxacillin: 2.3-
fold increase, P = 0.0382) (Fig. S3.2). No zinc was added to the growth medium (TSB) along 
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with ZDR090, indicating that ZDR090 translocates bioavailable zinc from the existing pool 
within TSB. ICP-MS analysis of TSB determined the total zinc content in the medium as 10 
µM. Together with their observed synergy with zinc (Table 3.1 and S3.4), these data 
demonstrate 8-sulfonamidoquinolines act as zinc ionophores to transport zinc ions across 
bacterial cell membranes. Furthermore, these data support a zinc-dependent model of 
potentiating β-lactam sensitivity in MRSA. 
Consistent with our previous work demonstrating a link between PBT2-mediated zinc 
accumulation and cellular manganese depletion in the bovine pathogen S. uberis (320), here we 
observed accompanying depletions of manganese in MRSA cells treated with PBT2+zinc or 
ZDR090 (Fig. 3.2A, 3.2B and S3.2). In comparison to untreated cells, PBT2+zinc and 
PBT2+zinc+oxacillin treatments caused 6.2-fold and 7-fold reductions in cellular manganese 
levels, respectively (P < 0.0001) (Fig. 3.2A). Similarly, cellular manganese levels following 
ZDR090 and ZDR090+oxacillin treatment were 1.7-fold (P = 0.3926) and 3.6-fold (P =0.0484) 
lower than untreated cells, respectively (Fig. 3.2B). A stronger depletion of manganese by 
ZDR090 was observed at 1 hr post-treatment, with ZDR090 and ZDR090+oxacillin 
significantly decreasing cellular manganese levels by 4-fold and 7.4-fold, respectively (P < 
0.0001) (Fig. S3.2). Interestingly, analysis of metal contents 1 hr post-treatment revealed 
oxacillin initially decreases cellular manganese (Fig. S3.2). At 4 hrs post-treatment, however – 
which coincides with active growth in the presence of the antibiotic (Fig. S3.1) – manganese 
levels of oxacillin-treated cells were markedly higher than untreated and ionophore-treated cells 
(Fig. 3.2). Several recent studies implicate zinc and manganese homeostasis in cell wall 
metabolism and susceptibility to cell wall-targeting inhibitors, including β-lactam antibiotics 
(334-337). Taken together, these data suggest that manganese plays an important role in β-
lactam resistance in MRSA and that the physiological background of increased cellular zinc 
and decreased cellular manganese induced by zinc ionophores may pre-dispose MRSA to β-
lactam killing.  
Exposure of MRSA to PBT2+zinc and ZDR090, in the presence or absence of oxacillin, 
was also associated with cellular increases in sodium, and decreases in magnesium and 
potassium (Fig. S3.3). Growth in the presence of oxacillin was additionally associated with a 
cellular increase in sodium (1.8-fold) and decrease in potassium (1.3-fold) compared to 
untreated cells (Fig. S3.3). Collectively, these data indicate an overlap between the composition 




Figure 3.2. Oxacillin re-sensitization in MRSA by PBT2 and ZDR090 is associated with 
increased intracellular zinc and decreased intracellular manganese. Cellular zinc and 
manganese concentrations as determined by ICP-MS of mid-log-phase MRSA USA300 cells 
treated for 4 hrs with (A) oxacillin (8 µg/mL) and PBT2+zinc (9 µM PBT2 + 50 µM zinc), 
alone or in combination, or (B) oxacillin (8 µg/mL) and ZDR090 (72 µM), alone and in 
combination. Error bars represent the standard deviations of the means from a biological 
triplicate. ns, P > 0.05; *, P < 0.05; **, P < 0.005; ***, P < 0.001; ****, P < 0.0001 by one-
way analysis of variance (ANOVA).  
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3.4.3 Manganese supplementation alleviates the bactericidal action of PBT2+zinc and 
oxacillin. 
As excess manganese rescues S. uberis cells from killing by PBT2+zinc (320) (Chapter II, 
section 2.5.5), we examined if manganese could inhibit the potentiation of oxacillin by 
PBT2+zinc in MRSA. Indeed, the addition of manganese (5 mM) completely restored growth 
in the presence of PBT2+zinc+oxacillin (Fig. 3.3D). Lower concentrations of manganese (0.1, 
0.5 and 1 mM) also protected MRSA from PBT2+zinc+oxacillin-mediated lethality, although 
normal growth was still inhibited (Fig. 3.3D). All tested concentrations of manganese had no 
effect on the growth of MRSA when added alone (Fig. 3.3A) or in combination with either 
oxacillin or PBT2+zinc individually (Fig. 3.3B and 3.3C). These data indicate manganese 
depletion is a key part of the mechanism of β-lactam resensitization by zinc ionophores, rather 
than a physiological response of MRSA to elevated zinc levels. We propose the existence of a 
potential manganese-dependent resistance determinant(s) that may be mismetallated in the 




Figure 3.3. Manganese supplementation restores growth in the presence of PBT2-zinc and 
oxacillin. Cell viability of MRSA USA300 grown in TSB in the presence of subinhibitory 
manganese (0, 0.1, 0.5, 1.0 and 5.0 mM) alone (A), or in the presence of PBT2+zinc (3 µM 
PBT2 + 50 µM zinc) (0.375 × CIC) (B), oxacillin (16 µg/mL) (C) or the lethal combination 
PBT2+zinc+oxacillin (D). Bactericidal activity (3-log10 reduction) is marked by the dotted line. 
CFU/mL counts were taken before treatment (0 hrs, white bars) and after 24 hrs (blue bars). 
Error bars represent the standard deviations of the means from biological duplicates.  
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3.4.4 PBT2-zinc dissipates the pH gradient (ΔpH) across the cytoplasmic membrane in 
MRSA.  
Furthering our investigations into the physiological effect of zinc ionophores in MRSA, we 
measured the effects of PBT2 on the bacterial proton motive force (PMF). The PMF, generated 
by the respiratory chain, is crucial for energy generation and the uptake or efflux of various 
compounds, including certain antibiotics. Tetracyclines and aminoglycosides, for example, 
depend upon the transmembrane proton gradient (ΔpH, acidic outside) and electrical potential 
(ΔΨ, positive outside) components of the PMF, respectively, for uptake (338, 339), while 
macrolide efflux is known to occur through ΔpH-dependent multidrug efflux systems (340). 
Agents that perturb either component of the PMF consequently alter bacterial susceptibility to 
these classes of antibiotics (341). Intriguingly, 2-aminoimidazole (2-AI) and phenothiazine 
derivatives that target the PMF in MRSA and M. tuberculosis reverse β-lactam resistance in 
these pathogens (333, 342-344). As we recently demonstrated that PBT2 facilitates the 
electroneutral exchange of extracellular zinc for intracellular protons (320), we speculated that 
the ability of PBT2 to resensitize MRSA to various classes of antibiotics might be related to an 
effect on the ΔpH. To assess the effect of PBT2+zinc on the PMF of bacterial cells, ΔΨ and 
ΔpH measurements were undertaken using the radioisotopes [14C]TPP+ and [14C]benzoate, 
respectively. Whereas PBT2+zinc treatment had no effect on the ΔΨ of MRSA cells (Fig. 
3.4A), significant reductions in the ΔpH (presented in mV as ZΔpH, P = 0.0002) and internal 
pH (P = 0.004) were observed (Fig. 3.4B and 3.4D). Overall, the total PMF of MRSA cells 
was lower for PBT2+zinc-treated cells, but this was not statistically significant (P = 0.1194) 
(Fig. 3.4C).  
We further examined if this effect on the PMF extended to GAS and VRE, pathogens 
that PBT2 was additionally shown to resensitize to various classes of antibiotics (243). In GAS 
cells treated with PBT2+zinc, we noted a significant decrease in the ΔpH (P = 0.0297) as well 
as an accompanying increase in the ΔΨ (P = 0.0228) that ultimately maintained the PMF at 
around 150 mV (Fig. S3.4A, S3.4B and S3.4C). Furthermore, PBT2+zinc treated cells had a 
significantly higher external pH than untreated cultures (pH 6.3, PBT2+zinc; pH 5.5, untreated; 
P = 0.023) (Fig. S3.4D). As a lactic acid bacterium, GAS progressively acidifies the medium 
during growth through the production of acidic fermentation end-products (345). The smaller 
ΔpH of PBT2+zinc-treated cells may therefore reflect decreased accumulation and efflux of 
fermentation end-products as a result of a slower growth rate in the presence of PBT2+zinc, or 
the inhibition of zinc-sensitive glycolytic enzymes necessary for fermentation (171), rather than 
the direct dissipation of the ΔpH. Consistently, the internal pH was higher in PBT2 and 
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PBT2+zinc-treated GAS cells than untreated (P = 0.084 and P = 0.1556, respectively), 
supporting a comparatively lower production of acidic metabolites. For VRE, PBT2+zinc had 
no effect on either component of the PMF or on the internal pH (Fig S3.4A, S3.4B, S3.4C and 
S3.4D). Together, this suggests that MRSA, in comparison to the other Gram-positive 
pathogens investigated, is more susceptible to the dissipation of the ΔpH by zinc ionophoric 





Figure 3.4. PBT2-zinc perturbs pH homeostasis in MRSA USA300. (A) Membrane 
potential (ΔΨ) (mV), (B) transmembrane pH gradient (ZΔpH) (mV), (C) total proton motive 
force (PMF) and (D) internal and external pH of MRSA USA300 cells following treatment with 
PBT2 (2 µM) and zinc (50 µM), individually or in combination, for 1 hr in CAMHB. The ΔΨ 
was calculated from [14C]TPP+ uptake according to the Nernst relationship, while the ΔpH was 
calculated from [7-14C]benzoate accumulation using the Henderson-Hasselbalch equation and 
multiplied by 61 mV to convert to ZΔpH. Internal pH was determined from the ΔpH. Total 
PMF was calculated as the sum of the ΔΨ and ZΔpH. Error bars represent the standard deviation 
of the means from a biological triplicate. ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001 
by one-way analysis of variance (ANOVA). 
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3.4.5 PBT2-zinc induces a cell-wall stress response and represses the virulence regulator 
SaeRS  
To investigate if zinc ionophores interfere with the expression of β-lactam resistance 
determinants, qPCR was undertaken on MRSA USA300 treated with oxacillin, PBT2+zinc, or 
PBT2+zinc+oxacillin. While the β-lactam resistance determinant mecA was upregulated 1.5 
log2-fold in response to oxacillin, combining PBT2+zinc with oxacillin caused mecA expression 
to decrease by 1.1 log2-fold (Fig. 3.5A). PBT2+zinc treatment alone had no effect on mecA 
expression, indicating that excess zinc does not directly act on mecA transcription but rather 
interferes with the normal transcriptional response initiated by oxacillin.  
Expression of mecA is regulated by the homologous mecR1-mecI and blaR1-blaI 
systems that consist of a membrane-bound β-lactam-sensor (MecR1/BlaRI) and a 
transcriptional repressor (MecI/BlaI) (322). MRSA USA300, among other SCCmec type I, IV 
and VI strains, however, lacks a functional mecR1-mecI regulatory system (346). For these 
SCCmec types, the blaR1-blaI system is believed to predominantly regulate mecA expression 
(347). Both blaR1 and blaI were upregulated in response to oxacillin (2.2 and 1.3 log2-fold, 
respectively), and to a similar degree in response to PBT2+zinc alone (blaR1, 1.5 log2-fold; 
blaI, 0.9 log2-fold) (Fig. 3.5A). Despite the observed downregulation of mecA, expression of 
blaR1-blaI increased when cells were exposed to PBT2+zinc and oxacillin in combination, with 
blaR1 and blaI transcripts increasing 4.8 log2-fold and 1.9 log2-fold, respectively (Fig. 3.5A).  
Aside from mecR1-mecI and blaR1-blaI systems, various other genetic elements have 
been identified as auxiliary factors necessary for β-lactam resistance. Continued peptidoglycan 
biosynthesis and growth in the presence of β-lactam antibiotics requires the transpeptidase 
domain of PBP2a as well as the penicillin-insensitive transglycosylase domain of the native 
PBP2 (28). The pbp2 and mecA genes also cooperate at the level of transcription, as changes in 
pbp2 expression induces parallel changes in the transcription of mecA (348). We examined if 
the observed decrease in mecA expression by PBT2+zinc+oxacillin might be explained by a 
parallel decrease in the transcription of pbp2. Expression of pbp2 was upregulated following 
oxacillin treatment (1.1 log2-fold), consistent with the increased transcription of mecA in 
response to oxacillin (Fig. 3.5A). Unexpectedly, PBT2+zinc was an even stronger inducer of 
pbp2 expression (3.4 log2-fold), and the addition of oxacillin amplified expression further (4.9 
log2-fold) (Fig. 3.5A). Similar trends in expression were observed for pbp4 (Fig. 3.5A), another 
essential PBP for β-lactam resistance in CA-MRSA (349).  
Genes involved in the biosynthesis of peptidoglycan precursors, including murE and 
femA, are also required for β-lactam resistance in MRSA (322). MurE catalyses the addition of 
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the third amino acid residue, L-lysine, to the peptide stem of the UDP-N-acetylmuramyl 
pentapeptide precursor (350), and FemA (together with FemX and FemB) synthesises the 
pentaglycine bridges between murein monomers in S. aureus peptidoglycan (351). Expression 
of murE also appears to directly or indirectly coordinate mecA and pbp2 transcription (350). 
Consistent with this, we found oxacillin-treated cells had a 1.3 log2-fold increase in murE 
expression (Fig. 3.5A). Expression of femA was additionally upregulated in response to 
oxacillin (1.1 log2-fold). Further, the transcriptional changes in murE and femA in response to 
PBT2+zinc or PBT2+zinc+oxacillin mirrored those seen for pbp2 and pbp4 (Fig. 3.5A). 
PBT2+zinc caused 2.9 log2-fold and 3.2 log2-fold increases in the expression of murE and femA 
respectively, while the combination of PBT2+zinc and oxacillin appeared to have an additive 
effect on the upregulation of both genes (murE, 4.3 log2-fold; femA, 4.6 log2-fold) (Fig. 3.5A).  
The functioning of VraSR (for vancomycin-resistance-associated sensor/regulator), a 
two-component system that mediates the response to cell-wall synthesis inhibitors in S. aureus, 
is necessary for β-lactam resistance in MRSA (352, 353). VraSR senses perturbations in cell 
wall peptidoglycan (354-356), and once activated, VraSR induces expression of a cell-wall 
stress stimulon that includes, among others, various genes involved in peptidoglycan 
biosynthesis (e.g. pbp2 and murZ) as well as its own operon (352). Oxacillin and PBT2+zinc 
individually upregulated vraSR operon genes (vraS, vraR and vraT), and again, mirroring the 
trends in expression of peptidoglycan biosynthesis genes, a clear additive effect on vraSR 
upregulation occurred in response to the combination of PBT2+zinc+oxacillin (Fig. 3.5A). The 
activation of VraSR and the cell wall stress response suggests PBT2+zinc inhibits a key step in 
peptidoglycan biosynthesis, an effect that is exacerbated in the presence of oxacillin.  
PBT2+zinc and PBT2+zinc+oxacillin both downregulated SaeRS operon genes (saeS, 
saeR, saeQ), whereas expression was upregulated in response to oxacillin (Fig. 3.5B). The 
SaeRS two-component system is a major regulator of numerous virulence factors including 
hemolysins, leukocidins, coagulase and fibrinogen-binding proteins, and is critical for S. aureus 
survival and pathogenesis during infection (357). Deletion of saeRS severely attenuates 
USA300 in murine models of sepsis, peritonitis, skin infection and necrotizing pneumonia 
(357-359). As zinc represses the SaeRS system by inhibiting the autophosphorylation of the 
SaeS sensor kinase (360), we propose that cellular zinc accumulation by PBT2 may promote 
the mismetallation and inactivation of SaeS. This suggests PBT2 could serve a dual role in vivo 
as both an anti-virulence compound and β-lactam antibiotic adjuvant.   
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Figure 3.5. PBT2-zinc alters the expression of genes involved in β-lactam resistance and 
virulence. Relative expression of selected genes involved in (A) β-lactam resistance expression 
and the (B) SaeRS operon in mid-log-phase MRSA USA300 cells (OD600 0.5) after 4 hrs of 
treatment with or without oxacillin (8 µg/mL) and PBT2+zinc (9 µM PBT2 + 50 µM zinc), 
individually or in combination. Relative expression (expressed as log2-fold change) was 
calculated relative to an untreated control and normalized to the reference gene (gyrB) using 




3.4.6 Effect of PBT2+zinc and oxacillin on MRSA autolysis 
Peptidoglycan biosynthesis requires the concerted action of cell wall synthases and hydrolases 
(autolysins) that build and break peptidoglycan covalent bonds, respectively (361). To provide 
further insight into the physiological effect of PBT2+zinc on the cell wall of MRSA, we 
examined the rates of autolysis induced by the non-ionic detergent Triton X-100. Cells from 
cultures that were actively growing in the presence of oxacillin showed the highest rate of Triton 
X-100-induced autolysis compared to all other treatment groups (Fig. 3.6). This is consistent 
with an increased autolysin expression to balance active cell wall biosynthesis, as well as the 
heightened susceptibility of oxacillin-treated cell walls to autolysin degradation due to their 
hypo-cross-linked peptidoglycans (361). PBT2+zinc treatment also increased the autolytic rate 
compared to untreated cells, despite its comparatively lower growth rate (Fig. 3.6 and S3.1A). 
Based on these data, we propose that PBT2-zinc stimulates autolysis. Furthermore, cells treated 
with a combination of PBT2+zinc+oxacillin were more susceptible to autolysis than cells 
treated with PBT2+zinc alone (Fig. 3.6). As PBT2+zinc+oxacillin treatment inhibits growth of 
MRSA, we propose that zinc ionophoric activity dysregulates the normal expression and/or 




Figure 3.6. PBT2-zinc stimulates autolysis. Triton-X-100 (0.1% w/v)-stimulated autolysis of 
MRSA USA300 cells following 4 hr treatment with either oxacillin (8 µg/mL), PBT2 (9 µM), 
zinc (50 µM), PBT2+zinc, or PBT2+zinc+oxacillin. Error bars represent the standard 
deviations of the means from biological triplicates.  
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3.4.7 PBT2 upregulates membrane phospholipid biosynthesis and interacts with lipids 
PBT2 has recently been shown to remodel the lipid profile of the Gram-negative pathogen 
Klebsiella pneumoniae, with mass spectrometry analysis revealing decreases in the abundance 
of ions corresponding to cardiolipin (CL) species and increases in those corresponding to the 
related monolysocardiolipin (MLCL) (De Oliveira et al; unpublished data). CL, 
phosphatidylglycerol (PG) and lysylphoshatidylglycerol (LPG) are abundant phospholipids in 
staphylococcal membranes (362). Phospholipids serve crucial structural and metabolic roles in 
cell wall biosynthesis. The glycerolphosphate head group of PG is incorporated into cell wall 
lipoteichoic acid (LTA), and several studies have implicated CL in the biosynthesis and 
translocation of the precursor building block for peptidoglycan: lipid II (363-365). It is therefore 
unsurprising that membrane lipid composition is implicated in bacterial resistance to cell wall-
acting antibiotics (366). Based on these observations, we hypothesised that PBT2-mediated 
remodelling of the lipid profile in MRSA might contribute to its synergy with β-lactams. Both 
oxacillin and PBT2+zinc treatments individually upregulated genes involved in membrane 
phospholipid biosynthesis, although PBT2+zinc caused a stronger upregulation in the genes 
responsible for PG and CL biosynthesis, pgsA and cls1, respectively (Fig 3.7A and 3.7B). 
Expression of pgsA and cls1 was further amplified in the response to combination treatment 
with PBT2+zinc and oxacillin (Fig 3.7B). These data are consistent with previous reports that 
cell-wall acting antibiotics stimulate an increase in the cardiolipin content of S. aureus 
membranes (367), and that excess zinc influences glycerophospholipid metabolism at a 
transcriptional level (368). 
Zinc pyrithione (ZPT), another antimicrobial zinc ionophore, has been described to 
interact with the head group structure of the bacterial membrane phospholipid 
phosphatidylethanolamine (PE) (369). This interaction appears to occur via the chelated zinc 
atom of ZPT and suggests that PBT2-zinc complexes may directly interact with PG and CL 
phospholipid head groups by a similar mechanism. As mixtures of molecules and lipids that 
interact tend to precipitate, as seen with telomycin and CL (329), we employed a previously 
described turbidity assay to assess PBT2 and phospholipid interactions (329). No turbidity was 
observed with either oxacillin, zinc or DMSO in the presence of CL or PG in ultrapure water 
(Fig 3.7C). Mixtures of PBT2 and zinc rapidly became turbid in the presence of an increasing 
concentration of CL, but not with the tested concentrations of PG (Fig. 3.7C). Precipitation 
between PBT2 and CL was markedly reduced in the absence of zinc (Fig. 3.7C), suggesting 
that zinc enhances PBT2-CL interactions but is not necessary.  
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Furthering our investigations into the potential interaction between PBT2 and 
membrane phospholipids, we undertook time-dependent cell-killing assays to determine 
whether exogenous CL or PG could neutralize the potentiation of oxacillin by PBT2+zinc. 
Exogenous CL alleviated the bactericidal action of PBT2+zinc+oxacillin against MRSA in a 
dose-dependent manner, with the addition of 100 µM CL restoring growth at a faster rate than 
25 µM CL (Fig 3.7D). PG similarly attenuated PBT2+zinc+oxacillin killing, but complete 
restoration of growth required a higher concentration of PG (100 µM) compared to CL (25 µM) 
(Fig 3.7D). This stronger preference for CL over PG might be explained by the fact that the 
headgroup of CL is more negatively charged than that of PG (363), and thus may be more 
interactive with positively-charged zinc or PBT2-zinc complexes. Taken together, these data 
suggest PBT2 and PBT2-zinc complexes are chemically interactive with membrane 
phospholipids and that this may contribute to its mechanism of β-lactam antibiotic re-




Figure 3.7. PBT2 upregulates membrane phospholipid biosynthesis genes and interacts 
with lipids in MRSA. (A) Diagram of the phospholipid biosynthesis pathway in MRSA 
USA300 (derived from the KEGG pathway database). (B) Relative expression of genes 
involved in membrane phospholipid biosynthesis in MRSA USA300 cells after 4 hrs treatment 
with oxacillin (8 µg/mL) and/or PBT2+zinc (9 µM + 50 µM). Relative expression (expressed 
as log2-fold change) was calculated relative to an untreated control and normalized to the 
reference gene (gyrB) using the ΔΔCT method. Error bars represent the standard deviations of 
the means from biological triplicates. (C) Turbidity (OD490) of mixtures of PBT2 (1 mM) and/or 
zinc (0.1 mM), or oxacillin (16 µg/mL) with cardiolipin (CL) or phosphatidylglycerol (PG) 
after a 10 min incubation. Data are representative of three independent experiments. (D) Growth 
of MRSA following treatment with oxacillin (16 µg/mL) and/or PBT2+zinc (3 µM PBT2 + 50 
µM zinc) in the presence or absence of CL or PG (25 µM or 100 µM) at OD600 0.05. Dashed 
lines indicate the limit of detection (1 × 102 CFU/mL). Error bars represent the standard 
deviations of the means from biological triplicates. 
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3.4.8 Effect of PBT2-zinc and oxacillin on cell morphology 
To investigate if PBT2-zinc causes any morphological changes in MRSA, we examined 
USA300 cells exposed to PBT2, zinc or oxacillin, either alone or in combination, alongside 
untreated control cells, by TEM. MRSA cells exposed to either PBT2 or zinc appeared virtually 
identical to the untreated control group, with defined, intact cell walls and membranes (Fig. 
3.8A). Those grown in the presence of oxacillin exhibited some abnormalities in cell wall 
structure and septum formation (Fig. 3.8A). By contrast, the cell walls of MRSA treated with 
PBT2+zinc, either alone or in combination with oxacillin, showed distinct bulges and 
separation from the cell membrane, producing a wavy cell wall-membrane interface with 
inconsistent cell wall thickness (Fig 3.8A). In some cells exposed to PBT2+zinc, abnormal 
septum formation was evident (Fig 3.8A). Moreover, PBT2+zinc exposure appeared to promote 
the degradation of the cell wall, as evidence of apparent cell wall material was observed in both 
PBT2+zinc and PBT2+zinc+oxacillin sample groups (Fig 3.8B). These results clearly 







Figure 3.8. PBT2-zinc alters cell morphology in MRSA. (A) Transmission electron 
microscopy of MRSA USA300 cells following 4 hrs exposure to the following conditions: 
antibiotic-free control (untreated), oxacillin (8 µg/mL), zinc (50 µM), PBT2 (9 µM), 
PBT2+zinc, or PBT2+zinc+oxacillin. (B) Cell wall or membrane shedding (black arrows) in 
MRSA USA300 cells treated with PBT2+zinc or PBT2+zinc+oxacillin.  
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3.4.9 PBT2 synergises with oxacillin in a mouse model of invasive MRSA infection 
To test the efficacy of PBT2 as an antibacterial adjuvant for the treatment of invasive MRSA 
infections, we investigated whether PBT2 could synergise with oxacillin against MRSA 
USA300 in a murine peritoneal infection model. For these experiments, PBT2 was administered 
in the absence of additional zinc to examine if bioavailable zinc within the body would be 
sufficient for ionophoric activity. A lethal dose of 5 × 108 CFU of USA300 for this infection 
model was determined, with all deaths at this dose occurring within the first 12 hrs of challenge 
(Fig. S3.5). Mice treated with intraperitoneal injections of either saline, PBT2 (1.5 mg/kg) or 
oxacillin (15 mg/kg) at various time-points post-infection all had a 40% survival rate (Fig. 
3.9A). The combination treatment of PBT2 and oxacillin significantly improved the survival 
rate of infected mice to 80% (P = 0.0226) (Fig. 3.9A).  
Following intraperitoneal infection, staphylococci disseminate into the bloodstream and 
within the peritoneal cavity, forming surface abscesses on abdominal organs such as the kidneys 
(370). To examine if PBT2+oxacillin treatment enhances MRSA clearance in mice, the kidneys 
of mice were extracted and homogenized 24 hrs following infection with a sub-lethal dose of 
MRSA (1 × 108 CFU) and treatment with either saline, PBT2 (1.5 mg/kg), oxacillin (15 mg/kg) 
or PBT2+oxacillin in combination. PBT2+oxacillin treatment significantly reduced the 
bacterial burden in the kidneys after 24 hrs infection compared to saline (P = 0.0116) or 
oxacillin treatments (P = 0.0031) (Fig. 3.9B). Although the bacterial burden in the blood was 
noticeably lower for PBT2+oxacillin than other treatment groups at 6 hrs post-infection, this 
was not statistically significant (Fig. 3.9C), and staphylococci in blood were cleared to a 





Figure 3.9. PBT2 synergises with oxacillin in an invasive murine model of MRSA USA300 
peritoneal infection. (A) Survival analysis of BALB/c mice treated with PBT2 and/or oxacillin 
in an intraperitoneal model of MRSA USA300 infection (n = 20/group). Mice were infected 
with USA300 (5 × 108 CFU) and treated at 0.5, 6, 24, 30 and 48 hrs post-infection by 
intraperitoneal injection of saline, PBT2 (1.5 mg/kg) and/or oxacillin (15 mg/kg). (*, P < 0.05 
by log-rank test). (B – D) Recovered viable bacteria in kidneys (B) and blood at 6 hrs (C) and 
24 hrs (D) post-infection. Mice were infected with USA300 (1 × 108 CFU) and treated at 0.5 
and 5 hrs post-infection with saline, PBT2 (1.5 mg/kg) and/or oxacillin (15 mg/kg) by 
intraperitoneal injection. Values for individual mice are plotted, and black lines represent the 
group geometric means (n = 10/group). ns, P > 0.05; *, P < 0.05; **, P < 0.005 by one-way 




Here, we demonstrate that the zinc ionophoric activity of PBT2 and the related 8-
sulfonamidoquinoline compounds restores the bactericidal activity of β-lactam antibiotics 
against both HA- and CA-MRSA. Importantly, PBT2 synergised with oxacillin in vivo in a 
murine model of invasive MRSA infection to improve animal survival and pathogen clearance 
from the kidneys. We have shown that zinc accumulation by PBT2 and the 8-
sulfonamidoquinoline ZDR090 disrupts cellular manganese homeostasis, and manganese 
supplementation abolishes the potentiating effect of PBT2-zinc with oxacillin. Using PBT2 as 
a model zinc ionophore, this study examined the underlying biological mechanism of β-lactam 
(oxacillin) resensitization in the epidemic CA-MRSA USA300 strain to reveal clear targeting 
of the cell wall and cell membrane, as well as the regulation of methicillin resistance and energy 
generation. 
The intersection between cell wall biosynthesis, antibiotic resistance and bacterial 
metallostasis – particularly zinc and manganese homeostasis – is becoming increasingly more 
evident. Transcriptomic and proteomic analyses indicate that bacteria modulate cell wall 
biosynthesis in accordance with zinc and manganese availability (334, 368). This is likely a 
physiological response to circumvent the hyperactivation or inactivation of metalloproteins 
involved in cell wall metabolism under conditions of metal limitation or excess (337). As can 
therefore be expected, perturbing the normal balance of zinc and manganese through either 
metal starvation or toxicity substantially alters cell wall metabolism and increases β-lactam 
sensitivity in several pathogens (334-337). In line with this, our study revealed that manganese 
levels significantly increase during the expression of oxacillin resistance in MRSA. We propose 
that PBT2 and ZDR090-mediated zinc accumulation and accompanying manganese depletion 
consequently disrupts the cell wall metabolic activity necessary for the expression of β-lactam 
resistance in MRSA. In support of this mechanism, PBT2-zinc stimulated autolysis in MRSA. 
We hypothesise this might occur through the hyperactivation of the major zinc-dependent 
autolysin AmiA (371), or the release of autolysins from LTA anionic sites upon competitive 
zinc binding (372). 
The phosphodiester linkages of wall teichoic acid (WTA) and LTA, together with 
peptidoglycan carboxyl groups, provide anionic binding sites for extracellular metal cations 
(372). Metal binding to the cell wall provides structural stability and serves as a reservoir of 
metals required for intracellular and cell wall biochemistry (373). Early work with B. subtilis 
revealed manganese is a major cation in the cell wall (374), thus, given the capacity of zinc to 
outcompete manganese for ligand binding (102), it is plausible that ionophore-mediated zinc 
 122
accumulation in the cell wall facilitates the displacement of manganese from anionic binding 
sites. In addition, excess exogenous zinc is known to cause cellular manganese starvation in  
S. pneumoniae by competitively and irreversibly binding to the manganese importer PsaABC 
(178). Recently we demonstrated that PBT2-mediated intracellular zinc accumulation 
dysregulates the expression of the MtuABC manganese importer in S. uberis and causes cellular 
manganese limitation (320)(Chapter II). Zinc accumulated in the cytoplasm and cell wall of 
MRSA by zinc ionophores may therefore additionally impede the expression or activity of 
manganese transporters.  
Supplementation of manganese restored growth of MRSA in the presence of an 
otherwise lethal concentration of PBT2-zinc and oxacillin. Several manganese-dependent β-
lactam resistance determinants have been described in MRSA, such as the WTA β-
glycosyltransferase TarS and the eukaryotic-type serine/threonine kinase and phosphatase 
system, Skt1/Stp1 (375, 376). TarS attaches β-O-N-acetyl-D-glucosamine (β-O-GlcNac) 
residues to WTA in S. aureus, and this modification has been proposed to scaffold cell surface 
factors necessary for β-lactam resistance (377). Inhibition of TarS by mismetallation with zinc 
could explain the resensitization to β-lactam antibiotics; however, in contrast to MRSA cells 
treated with PBT2-zinc, ΔtarS mutants lack detectable morphological defects (377) thereby 
indicating this is not the sole target of resensitization by zinc ionophores.  
The manganese-dependent Stk1/Stp1 system functions as the master regulator of genes 
involved in cell wall metabolism, autolysis and β-lactam resistance in MRSA (376, 378). 
Through their opposing kinase and phosphatase activities, respectively, the balance of Stk1 and 
Stp1 signalling regulates the activity of several two-component systems (TCS), including the 
VraR response regulator (379). Phosphorylation of VraR by Stk1 negatively affects its DNA 
binding properties, resulting in decreased expression of the VraSR regulon (380, 381). While 
VraSR is essential for β-lactam resistance in MRSA (353), overexpression of the VraSR 
regulon paradoxically increases β-lactam susceptibility (382). Consistently, MRSA Δstk1 and 
Δstk1Δstp1 mutants are more susceptible to β-lactams whereas Δstp1 mutants are more resistant 
(376, 379). It is therefore plausible that upon exposure to PBT2-zinc, zinc binding inactivates 
Stk1 and Stp1 and is responsible for the amplified expression of vraSR and cell wall 
biosynthetic genes.  
Recent evidence suggests BlaZ-BlaI mediated expression of mecA in S. aureus is 
dependent on Stk1/Stp1 signalling, although a detailed mechanism of this pathway is currently 
lacking (383). Dysregulation of Stk1/Stp1 signalling by excess zinc may explain the induction 
of blaR1-blaI by PBT2-zinc in the absence of oxacillin, and the repression of mecA by 
PBT2+zinc in combination with oxacillin. In support of this model, Δstk1Δstp1 mutants have 
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similarly wavy, abnormal cell membranes as PBT2-zinc treated cells and similarly exhibit cell 
wall/membrane shedding (376). With that being said, however, there are clear differences in 
cellular morphology, including the lack of widespread abnormalities in septum formation in 
cells treated with PBT2-zinc+oxacillin compared to Δstk1Δstp1 mutants (376). This supports 
our hypothesis that our observed phenotype is a product of multiple, interconnected 
determinants of cell wall and membrane morphology that are differentially affected by cellular 
zinc accumulation.  
Overexpression of vraSR by PBT2-zinc is also consistent with the proposition that 
dysregulated zinc and manganese status causes alterations in peptidoglycan biosynthesis or 
hydrolysis, known stimuli for VraSR activation (352, 353, 384), and that its induction is further 
amplified by β-lactam-mediated cell wall damage. Reorganization of the membrane 
phospholipid structure in MRSA upon daptomycin treatment has additionally been proposed to 
activate VraSR signalling (382). The proposed interaction of PBT2-zinc complexes with 
anionic membrane phospholipids may additionally contribute to VraSR activation via a similar 
mechanism. At present, we cannot clearly define the exact mechanism(s) responsible for VraSR 
activation by PBT2-zinc and its potential role in contributing to the associated cell wall 
morphology and β-lactam sensitivity.  
An interaction between PBT2-zinc complexes and membrane phospholipids is 
supported by the abnormalities in cell membrane morphology visualised under TEM, in which 
obvious gaps between the cell wall and membrane suggest a weaker membrane integrity of 
PBT2-zinc treated cells. This is in disagreement with our previous study that found no 
disruption in membrane integrity for PBT2-zinc-treated MRSA cells based on the relative 
fluorescent signals of SYTO9 and propidium iodide (PI) (243) (Appendix). It should be noted, 
however, that these earlier experiments were undertaken on MRSA cells treated with a lower 
concentration of PBT2-zinc for a shorter time period compared to the current study. In B. 
subtilis, daptomycin-phospholipid interactions facilitate the delocalization of the lipid II 
synthase MurG and the resulting inhibition of peptidoglycan biosynthesis (385). It is tempting 
to speculate that PBT2-zinc-phospholipid interactions similarly disrupt the lipid 
microenvironment of membrane-interacting enzymes involved in peptidoglycan biosynthesis 
in MRSA.  
Although we previously established that PBT2 exchanges extracellular zinc ions for 
intracellular protons and causes the internal alkalization of liposomes (320), here PBT2-zinc 
dissipated the ΔpH component of the PMF and acidified the cytosol in MRSA. The loss of 
intracellular protons from zinc ionophoric activity is thus overwhelmingly countered by a 
physiological effect of excess zinc that equilibrates the internal and external pH. Zinc is a 
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known inhibitor of respiratory enzymes including succinate dehydrogenase and cytochrome aa3 
terminal oxidase (165, 175), and strongly inhibits the activity of the proton-translocating F1Fo-
ATPase in Vibrio parahaemolyticus (386). PBT2-zinc may thereby inhibit proton extrusion 
across the cytoplasmic membrane by respiration or ATP hydrolysis, leading to the accumulation 
of cytoplasmic protons and dissipation of the ΔpH. As MRSA is able to maintain the ΔΨ, this 
suggests that compensatory cations are extruded from the cell. This may explain the lower 
levels of cellular magnesium and potassium observed following PBT2-zinc treatment.  
In M. tuberculosis, inhibition of the PMF by 2-AI compounds only partially contributes 
to its β-lactam potentiation, as evident by the observation that β-lactam potentiation by CCCP, 
which principally acts as an uncoupler, is comparatively mild (343). Similar observations have 
been made in S. aureus (342, 387), raising the possibility that ΔpH dissipation by PBT2-zinc 
similarly has a partial effect on β-lactam activity. Dysregulating respiration and the PMF by 
zinc inhibition could ultimately alter the cellular redox state and generate ROS, the production 
of which is described as a common mechanism of antibiotic lethality (388). We suggest that the 
mechanism of zinc ionophore and β-lactam synergy might involve both breaking the MRSA 
resistance mechanism, as well as amplifying the cidality of the antibiotic through increased 
ROS production. Our work in S. uberis indicates that PBT2-zinc generates ROS independently 
of changes to the PMF, notably via the impairment of manganese-dependent ROS 
detoxification strategies (320). Manganese acquisition in S. aureus likewise plays an important 
role in the defence against oxidative stress (389). The possibility that zinc ionophores increase 
ROS production via multiple mechanisms in MRSA, along with its implications for the cidality 
of β-lactam antibiotics, warrants future investigation. 
Based on these findings, we propose that zinc ionophore-mediated zinc accumulation 
and manganese depletion in MRSA causes the widespread perturbation of multiple, 
interdependent pathways that coordinate β-lactam resistance, reflecting the global effect of 
metal ion homeostasis on cellular physiology. This study provides evidence that PBT2-zinc 
treatment alters cell wall and membrane morphology, activates the cell wall stress response, 
represses mecA and saeRS expression, stimulates autolysis, and dissipates the ΔpH. Combined 
with a β-lactam antibiotic, these physiological alterations become lethal for MRSA in vitro and 
in vivo during a severe and invasive infection. The finding that 8-sulfonamidoquinolines 
similarly function as zinc ionophores, perturb bacterial metal homeostasis and display synergy 
with β-lactams, is encouraging for the potential development of a series of effective and safe 
antibiotic adjuvants based on the 8-HQ structure. To drive this, however, future investigations 





 Supplementary Information 
Table S3.1. Bacterial strains used in this study 
Strain Description Reference 
S. aureus   
USA300 MetR, EryR 
SCCmec type IV 
(243) 
EMRSA-15 MetR 
SCCmec type IV 
(331) 
NCTC10442 MetR 
SCCmec type I 
(330) 
RA120 MetR 
BB255 transformed with 
SCCmec type I  
(332) 
Group A Streptococcus 
(GAS) 
  
HKU16 EryR, CldR, TetR (243) 
E. faecium   
RBWH1 MetR, EryR, CldR, VanR, TetR (243) 




Table S3.2. Chemical structures of PBT2 and 8-sulfonamidoquinoline compounds 
ZDR090 and ZDR115. 





























































































































































































































































































































































































































































































































































































































































Table S3.4. Minimum inhibitory concentrations (MIC) of PBT2, ZDR090 and ZDR115 in 
combination with zinc against MRSA strains grown in TSB.  
 MRSA strain 
 USA300 NCTC10442 EMRSA-15 RA120 
 Zinc MIC (mM) 
 6 12 3 1.5 
Zinc (µM) PBT2 MIC (µM) 
0 32 16 32 32 
10 16 16 16 16 
50 8 8 8 8 
100 4 8 4 4 
200 4 4 4 2 
Zinc (µM) ZDR090 MIC (µM) 
0 64 64 64 32 
50 32 64 16 16 
100 32 32 8 8 
200 16 32 8 4 
500 16 16 2 2 
1000 8 16 0.5 0.5 
Zinc (µM) ZDR115 MIC (µM) 
0 32 16 16 16 
50 32 16 8 8 
100 32 16 8 8 
200 16 16 8 8 
500 16 16 4 8 
1000 16 16 2 2 
a MIC values were determined by broth microdilution in Tryptic Soy broth (TSB) (n=3) 
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Table S3.5. Minimum inhibitory concentration (MIC) of β-lactam antibiotics in the 
presence of PBT2 and zinc, ZDR090 or ZDR115 against MRSA strains grown in TSB. 
 Strain    
 USA300 NCTC10442 EMRSA-15 RA120 
Antibiotic Oxacillin MICa (µg/ml) 
Oxacillin alone 32 4 16 32 
+PBT2+Znb 0.25 1 0.5 0.5 
+ZDR090c 2 0.5 0.5 0.25 
+ZDR115d 1 0.5-1 2 1 
 Ampicillin MIC (µg/ml) 
Ampicillin alone 256 256 128 32 
+PBT2+Znb 0.5 16 16 2 
+ZDR090c 32 16 16 1 
+ZDR115d 32 64 32 4 
a MIC values were determined by broth microdilution in Tryptic Soy broth (TSB) (n=3).  
b 4 µM PBT2 + 50 µM Zn (USA300), 3 µM PBT2 + 50 µM Zn (NCTC10442), 2 µM PBT2 + 
50 µM Zn (EMRSA-15 and RA120); c 24 µM ZDR090; d 16 µM ZDR115.  
PBT2 MICs (+50 µM supplementary zinc): 8 µM (all strains).  
ZDR090 MICs (+0 µM supplementary zinc): 64 µM (USA300, NCTC10442, EMRSA-15);  
32 µM (RA120).  
ZDR115 MICs (+0 µM supplementary zinc): 32 µM (USA300); 16 µM (NCTC10442, 





Figure S3.1. Growth of MRSA USA300 following treatment with oxacillin and/or 
PBT2+zinc/ZDR090 at mid-log phase.  
MRSA USA300 cells at mid-log phase (OD600 0.5) were treated with 8 µg/mL oxacillin and/or 
(A) 9 µM PBT2 + 50 µM zinc or (B) 72 µM ZDR090. Error bars represent the standard 










Figure S3.2. Sub-inhibitory ZDR090 and a lethal ZDR090+oxacillin combination cause 
immediate increases in cellular zinc and decreases in cellular manganese. Cellular zinc and 
manganese concentrations as determined by ICP-MS of mid-log-phase MRSA USA300 cells 
treated with ZDR090 (72 µM) and/or oxacillin (8 µg/mL) for 1 hr. Error bars represent the 
standard deviations of the means from a biological triplicate. ns, P > 0.05; *, P < 0.05; **, P < 




Figure S3.3. Oxacillin, PBT2-zinc, and ZDR090 treatments are associated with changes 
in cellular metal ion abundances. Cellular sodium, magnesium and potassium concentrations 
as determined by ICP-MS of mid-log-phase MRSA USA300 cells treated for 4 hrs with (A) 
oxacillin (8 µg/mL) and PBT2+zinc (9 µM PBT2 + 50 µM zinc), alone and in combination, or 
(B) oxacillin and ZDR090 (72 µM), alone and in combination. Error bars represent the standard 
deviations of the means from a biological triplicate. ns, P > 0.05; *, P < 0.05; **, P < 0.005; 




Figure S3.4. Effects of PBT2 and zinc on components of the proton motive force (PMF) in 
GAS HKU16 and VRE RBWH1. Measurements of the (A) ΔΨ, (B) ZΔpH, (C) total PMF and 
(D) internal and external pH of GAS HKU16 and VRE RBWH1 cells following treatment with 
PBT2 (4.75 µM for GAS and 1.75 µM for VRE) and/or zinc (128 µM). Strains were grown to 
mid-log phase (OD600 0.6) in CAMHB and treated for 1 hr with compounds prior to 
bioenergetic measurements. The ΔΨ was calculated from [14C]TPP+ uptake according to the 
Nernst relationship, while the ΔpH was calculated from [7-14C]benzoate accumulation using 
the Henderson-Hasselbalch equation and multiplied by 61 mV to convert to ZΔpH. Internal pH 
was determined from the ΔpH. Total PMF was calculated as the sum of the ΔΨ and ZΔpH. 
Error bars represent the standard deviations of the means from three biological replicates. ns, P 
> 0.05; *, P < 0.05; **, P < 0.01 by one-way analysis of variance (ANOVA).  
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Figure S3.5. Survival analysis of mice in a peritonitis model of MRSA USA300 infection. 
Six-week-old BALB/c mice were infected by intraperitoneal injection with the indicated doses 





Chapter IV.  
Final discussion and future directions 
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 Novel bactericidal mechanisms of dysregulating metal homeostasis  
For millennia the antimicrobial properties of metal ions have been exploited for medical and 
agricultural applications by humanity. Metals such as zinc, copper and silver were used to 
prevent and treat infections in ancient civilizations before the existence of microorganisms was 
even recognised (390, 391). For far longer than human history, mammalian immune systems 
have exploited the vulnerability of microbial pathogens to metal toxicity and starvation (94). In 
the face of rising AMR and a dwindling supply of effective antibiotics, there has been a 
resurgence of interest in exploiting metals such as zinc for novel metal-based antibacterials in 
both human and agricultural settings. Although bacterial metal homeostasis and resistance has 
been studied for decades, little progress has been made in defining the biochemical mechanisms 
by which metals exert toxicity in bacteria. Difficulties in experimentally defining these 
mechanisms relates to the innate tendency of metals to target multiple cellular ligands 
simultaneously. Recent advancements in genetic, chemical and biochemical tools, as well as a 
constantly growing understanding of bacterial metal homeostasis, now offer new insights into 
this field of study (96). 
This work has revealed that intracellular zinc toxicity inflicted by the zinc ionophore 
PBT2 disrupts the delicate balance of metal ion homeostasis within the bovine mastitis-causing 
pathogen S. uberis, causing a global effect on cellular physiology (Chapter II). As has been 
proposed for 8-HQ and the copper ionophore disulfiram (227, 392), PBT2 effectively resembles 
a molecular Trojan horse that allows zinc to overcome the cell membrane barrier and interact 
with sensitive target sites. Zinc toxicity results when PBT2-mediated cellular zinc accumulation 
exceeds normal detoxification and buffering mechanisms, leading to the mismetallation of 
essential cellular pathways. Our study indicates novel intracellular mechanisms of zinc toxicity: 
the generation of ROS, the dysregulation of manganese uptake, the consequent impairment of 
manganese-dependent antioxidant activity, and the direct inactivation of the manganese-
dependent SodA by zinc mismetallation.  
The relationship between zinc toxicity and manganese starvation in streptococci has 
previously been described (178, 297, 313), although this has solely focused on the effects of 
elevated extracellular zinc on manganese homeostasis. Heightened exogenous zinc 
mismetallates the membrane-associated manganese importer SBP, PsaA, thereby preventing 
manganese uptake and causing its cytoplasmic depletion (178). The effects of extracellular zinc 
on manganese homeostasis were reproduced in our study, although notably, manganese levels 
were not depleted to the same extent as cells treated with PBT2 and zinc in combination, 
suggesting the existence of an alternative mechanism of zinc-mediated manganese starvation. 
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Importantly, whereas our study and others demonstrate extracellular zinc toxicity induces 
mtuA/psaA expression in an appropriate response to manganese starvation (Figure 2.4) (297, 
313), PBT2-mediated intracellular zinc toxicity downregulates mtuA expression.   
Given that PBT2-zinc complexes appear to affect the cell membrane in MRSA 
(Chapter III), we propose that zinc could accumulate within the lipid bilayer in addition to the 
cytoplasm, either bound to PBT2 or cellular ligands. Manganese starvation in S. uberis by 
PBT2-zinc complexes therefore likely occurs by a dual mechanism: 1) the mismetallation of 
MtuA in a manner analogous to that described for PsaA and 2) the mismetallation of an as-yet 
undefined metalloregulator of mtuA that, under normal conditions, would never encounter zinc 
due to tightly-controlled zinc homeostatic mechanisms (Chapter I).  
 Through mass spectrometric measurements of intracellular manganese, and 
biochemical assays of SodA activity and H2O2 generation, the work herein supports a model 
where PBT2 impairs manganese-dependent ROS detoxification strategies and promotes ROS 
accumulation through both limiting manganese cofactor availability and elevating intracellular 
zinc. Thus, similar to the dual mechanism hypothesised for manganese starvation by PBT2-
zinc, intracellular zinc toxicity appears to act on cellular redox status through multiple 
mechanisms. Because zinc is able to exert its toxicity via multiple pathways, this provides an 
explanation as to why efforts to generate resistance to PBT2 in S. uberis, as well as MRSA, 
GAS and VRE (243), have so far been unsuccessful.  
Whether or not these bactericidal mechanisms are specific to S. uberis or shared between 
other important animal and human pathogens remains to be explored. The observation that both 
PBT2 and derivative 8-sulfonamidoquinoline zinc ionophores cause zinc accumulation and 
manganese depletion in MRSA (Chapter III), however, supports the view that metal 
homeostasis dysregulation is a broad underlying mechanism of zinc ionophore action. The exact 
bactericidal mechanism(s) within different organisms likely depend upon species-specific 
metal requirements and the unique pathways affected under conditions of intracellular zinc 
toxicity.  
 
 An overlap between zinc and manganese homeostasis, cell wall metabolism, and  
β-lactam resistance in MRSA 
Bohlmann et al (2018) established zinc ionophoric activity by PBT2 causes the lethal 
accumulation of zinc within the multi-drug resistant pathogens MRSA, GAS and VRE, while 
sub-inhibitory PBT2 and zinc could resensitize these strains to various classes of antibiotics 
(243). This led to the idea that a window between intracellular zinc homeostasis and toxicity 
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exists in which antibiotic resistance pathways, but not essential cellular pathways, are disrupted. 
The identity of affected pathways has so far only been explored for polymyxin sensitization by 
PBT2 in N. gonorrhoeae (280). The work herein investigated the mechanism of β-lactam 
resensitization in MRSA by zinc ionophores (Chapter III).  
This study expanded on the existing knowledge that PBT2 reverses β-lactam resistance 
in the CA-MRSA strain USA300. Here, we showed that PBT2 restores the cidality of β-lactam 
antibiotics in various MRSA strains with unique genetic backgrounds (CA-MRSA, HA-MRSA 
and a laboratory MRSA strain). β-lactam resistance in these strains could also be broken by 
ZDR090 and ZDR115, related 8-sulfonamidoquinoline-based bioisosteres of PBT2. Mass 
spectrometry experiments in CA-MRSA USA300 revealed the resensitizing concentrations of 
PBT2 and ZDR090 were both associated with zinc accumulation and manganese depletion, as 
well as similar changes in cellular sodium, magnesium and potassium. Together, this supports 
a shared mechanism of action between PBT2 and 8-sulfonamidoquinolines. Given that 
exogenous manganese supplementation abolished PBT2 and oxacillin synergy, our data support 
a model whereby zinc ionophoric dysregulation of zinc and manganese homeostasis impairs 
PBP2a-mediated β-lactam resistance pathways. This is in agreement with previous studies in 
other pathogens demonstrating a link between zinc and manganese homeostasis, cell wall 
metabolism and susceptibility to cell-wall acting antibiotics (334-337). Importantly, using a 
murine model of MRSA peritonitis, this present work demonstrated the synergy between PBT2 
and oxacillin can be replicated in vivo, significantly improving animal survival and pathogen 
clearance.  
Using PBT2 as a tool zinc ionophore compound, this study explored the specific 
physiological effects of zinc ionophore and oxacillin treatment against CA-MRSA USA300. 
Our findings that PBT2 disrupts MRSA cell wall and membrane integrity, the PMF, and the 
expression of key β-lactam resistance and virulence determinants, are consistent with the multi-
faceted disruption to cellular physiology that can be expected from dysregulating metal 
homeostasis. In addition, biochemical and growth assays suggest a chemical interaction 
between zinc ionophore complexes and membrane phospholipids which may affect membrane 
permeability and protein localization. A summary of the proposed pathways targeted by zinc 
ionophore adjuvant activity and potential mechanisms of resensitization are shown in Figure 
4.1. As discussed in the following section (4.3.3), further investigations of these phenotypes are 
required to dissect the precise mechanism(s) responsible for the reversal of β-lactam resistance 
in MRSA. Taken together, our study and others suggest an intimate relationship between zinc 
and manganese homeostasis, cell wall and membrane metabolism, and β-lactam resistance in 




Figure 4.1. Proposed pathways affected by zinc ionophore activity and mechanisms of β-
lactam resensitization in MRSA. Ionophore-mediated zinc accumulation (as depicted by 
PBT2) leads to manganese depletion and dysregulated metal homeostasis. β-lactam 
resensitization may result from multiple mechanisms: 1) repressed mecA expression and 
decreased PBP2a production, 2) impaired peptidoglycan biosynthesis via 
inhibition/hyperactivation of peptidoglycan biosynthetic enzymes, 3) cell membrane disruption 
due to zinc ionophore-phospholipid interactions and disrupted localization of membrane-
interacting resistance proteins, and 4) abnormal cell wall metabolism due to VraSR 
overactivation. Zinc-mediated targeting of peptidoglycan biosynthesis, the cell membrane, or 
manganese-dependent Stk1/Stp1 signalling all could result in VraSR activation. Inhibited 
Stk1/Stp1 signalling may additionally influence BlaR1 activation and blaR1-blaI and mecA 
expression. β-lactam-mediated mecA induction may alternatively be impaired through an 
undefined metal-dependent mechanism. Zinc ionophoric activity dissipates the ΔpH, 
potentially through inhibition of the proton-translocating respiratory chain or alternative proton 
transporters. β-lactam lethality may be enhanced by increased ROS generation as a result of 
inhibited respiration or impaired manganese-dependent antioxidant activity. Finally, zinc-
mediated inhibition of the key virulence regulator SaeSR may reduce MRSA pathogenicity.  
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 Future directions and considerations 
4.3.1 Considerations for developing zinc ionophores as novel antibacterials 
Although oral administration of PBT2 at 250 mg/day for 12 months had no associated adverse 
side-effects in patients during a Phase II clinical trial for Alzheimer’s (241), antibacterial 
chemotherapy may require higher doses of PBT2 at more frequent intervals, necessitating 
further pharmacological investigations of tolerability. As metal requirements vary between cell 
types (312), zinc ionophores may exert differential toxicity during treatment depending on the 
route of administration and drug distribution within host tissues. The potential for these 
compounds to negatively affect metal homeostasis in host cells is therefore a significant safety 
concern. Furthermore, although they exhibit similar biological activity to PBT2, the 
cytotoxicity and tolerability of derivative 8-sulfonamidoquinoline compounds requires 
examination. These, among various other pharmacological factors, are important to consider in 
terms of developing PBT2 and derivative zinc ionophores as novel antibacterials. 
Given the requirement of exogenous zinc for ionophoric activity, zinc bioavailability at 
the site of infection is an important factor influencing the efficacy and therapeutic potential of 
zinc ionophores. Underlying mechanisms of nutritional immunity that restrict serum zinc 
(hypozincaemia) during infection (180) could theoretically antagonize zinc ionophore 
bactericidal or adjuvant activity. Under zinc limited conditions, zinc ionophore complexes may 
even assist pathogen growth by providing a means for bacterial zinc acquisition without energy 
expenditure. Considering this, the application of zinc ionophores for topical or local infections 
is advantageous in that exogenous zinc and the ionophore can easily be co-administered at the 
site of infection. In addition, local antimicrobial administration tends to have a lower risk of 
systemic toxicity and gut microbiome exposure compared with systemic administration routes 
(393, 394). Systemic infection models will be important for establishing the utility of zinc 
ionophores for different complications, particularly in regards to its application as an adjuvant 
for MRSA where novel therapeutic strategies for invasive infections are most needed (39). Our 
finding that PBT2 and oxacillin combination therapy has in vivo efficacy in treating MRSA 
peritonitis suggests bioavailable zinc is sufficient within the peritoneal fluid and abdominal 
organs of mice to enable ionophoric activity and β-lactam synergy. As such, there are grounds 
for optimism in regards to the potential of zinc ionophores as therapeutics for systemic disease.  
Members of our laboratory have demonstrated the antiseptic efficacy of several 8-
sulfonamidoquinolines, including ZDR090 and ZDR115, against the bovine mastitis-causing 
pathogens S. uberis, S. aureus and E. coli (245, 246). Examination of antiseptic efficacy was 
performed under the strict requirements of a standardised test with bovine skim milk as an 
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interfering agent (BS EN 1656, European Committee for Standardization, 2009), and provides 
validation of the potential for 8-HQ-based zinc ionophores as preventative teat disinfectants for 
the control of bovine mastitis. Although the bactericidal mechanisms of ZDR090 and ZDR115 
against S. uberis were not investigated in this present study, our mass spectrometry experiments 
of these compounds in MRSA (Chapter III) support a similar mode of action to PBT2 in 
dysregulating zinc and manganese homeostasis.  
Whether or not zinc ionophores display any potential as antibiotics within the bovine 
mammary gland remains an active area of investigation. In order to effectively treat 
intramammary infection, the ionophore would need to evenly distribute through the mammary 
gland and exert activity despite the interfering proteins and lipids present within serum and 
milk. In addition, the ionophore should be rapidly eliminated from the lactating cow to avoid 
residues in milk (395). The essentiality of the high-affinity manganese importer MtuABC in S. 
uberis for intramammary invasion, however, suggests that manganese sequestration is an 
important mechanism of host defence within the bovine mammary gland (303). Taking this into 
consideration, nutritional immunity strategies during bovine mastitis may therefore 
complement the bactericidal mechanism of manganese starvation by zinc ionophores.  
 
4.3.2 Zinc ionophore resistance and its potential for antibiotic cross-resistance 
Based on our model of action, PBT2 resistance is more likely to emerge via mechanisms that 
either limit ionophore entry into the cell or restrict zinc accumulation rather than by the 
modification of multiple targets. In the case of zinc restriction, to prevent cytoplasmic zinc 
rising above a tolerable threshold, zinc efflux or intracellular sequestration must become more 
efficient than the membrane translocation of PBT2-zinc complexes. Studies investigating 
polyether ionophore resistance suggest resistance mechanisms involving ion movement are 
extremely unlikely (396), and in fact, any form of resistance to ionophores is rare (214). Instead, 
resistance to polyethers appears primarily mediated by strategies that restrict ionophore 
translocation. Reversible physiological adaptations that modify bacterial cell membrane 
permeability or cell wall thickness have been implicated in reduced susceptibility to certain 
ionophores (397, 398), as have certain ABC-type transporter genes that presumably efflux 
ionophores from the lipid bilayer before the complexed ions can be released at the cytoplasmic 
face of the membrane (399, 400).  
The non-specific biochemical nature of ionophores such as PBT2 and 8-
sulfonamidoquinolines is consistent with the view that resistance mechanisms are inherently 
challenging and slow to develop. Thus, further investigations of ionophore resistance and its 
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potential for antibiotic cross-resistance are called for (42, 401). As discussed in Chapter I, 
several studies link zinc resistance to antibiotic resistance mechanisms (141, 260, 263), and 
there is mounting evidence that zinc can positively or negatively affect antibiotic susceptibility 
(250-257, 268-271). It therefore stands to reason that intracellular zinc accumulation by 
ionophores may decrease the efficacy of certain antibiotics. While synergy between zinc 
ionophores and antibiotics have been reported (243, 252, 276, 278-280), the potential for 
antibiotic antagonism is less explored and warrants further investigation. In addition, efforts to 
generate zinc ionophore resistance in the laboratory should be undertaken via long-term serial-
passaging studies or mutagenesis experiments, given that short-term serial passaging studies 
have so far been unsuccessful. This will be important to investigate the potential of cross-
resistance between zinc ionophores and medically important antibiotics. Given that ionophore 
restriction via cell wall and membrane modifications is important for polyether resistance, we 
hypothesise that zinc ionophores may select for similar modifications and potentially drive 
cross-resistance to cell wall-acting antibiotics.  
  
4.3.3 Defining the molecular mechanism of zinc ionophore and β-lactam synergy in 
MRSA 
The work herein supports a model whereby zinc ionophores enhance β-lactam activity in 
MRSA through the disruption of multiple cellular elements involved in resistance, as depicted 
in Figure 4.1. Further experimentation is necessary, however, to define the precise molecular 
mechanism(s) involved in resensitization. In addition, the present study has focused solely on 
the resensitization of MRSA to penicillins (penicillin G, oxacillin and ampicillin), with a 
particular focus on oxacillin as a model β-lactam for mechanistic investigations. Whether PBT2 
and derivative 8-sulfonamidoquinolines restore the sensitivity of MRSA to other β-lactam sub-
classes, such as the cephalosporins, remains to be explored. Discussed below are suggested 
experiments for further exploration into the mechanism of zinc ionophore and β-lactam synergy 
in MRSA. 
 Our study and others indicate an intersection between zinc and manganese homeostasis 
and β-lactam susceptibility, although further investigations are needed to establish the 
molecular consequences of dysregulating these metals for the expression of resistance. Based 
on our current data, if β-lactam resensitization occurs through an imbalance in manganese 
homeostasis, the protective effect of exogenous manganese supplementation against zinc 
ionophore adjuvant activity in MRSA should be visualised by mass spectrometry analysis as an 
associated increase in cellular manganese to normal levels. As 8-HQ binds manganese, albeit 
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with much lower affinity (402), it is plausible that high concentrations of manganese encourage 
the formation of PBT2-manganese complexes and drive ionophoric manganese delivery at the 
expense of zinc. Further mass spectrometry experiments will be necessary to examine if this 
protective effect is simply due to a reduction in zinc accumulation, or the restoration of 
manganese homeostasis.  
Given that combination treatment with PBT2-zinc and oxacillin downregulates mecA, 
it stands to reason that the mechanism of β-lactam resensitization in MRSA is through zinc-
mediated inhibition of PBP2a expression. Western blot analyses to compare PBP2a protein 
expression and localization within the cell membrane between β-lactam- and β-lactam+zinc 
ionophore-treated cells should be undertaken to expand upon this finding. This study serves as 
the basis for further dissection into the molecular mechanism of how zinc interrupts mecA 
expression. Building upon the observed protective effects of re-establishing manganese 
homeostasis on β-lactam resistance, it would be of value to investigate whether supplemental 
manganese restores mecA expression in the presence of PBT2-zinc and oxacillin. Likewise, 
investigations into the effects of supplemental manganese on the other associated 
transcriptional (e.g. blaR1-blaZ and the VraSR regulon) and morphological changes should 
provide valuable insight into the role of the cellular manganese:zinc ratio in MRSA resistance 
pathways.  
Bacterial eukaryotic-like serine/threonine kinases (eSTKs) and their cognate 
phosphatases have been implicated in β-lactam resistance in numerous pathogens, consistent 
with their deep involvement as regulators of cell division (403). Cellular manganese and zinc 
status influences the activity of the manganese-dependent serine/threonine phosphatase PhpP 
in S. pneumoniae, whereby excess cellular manganese leads to PhpP hyperactivation while 
excess cellular zinc causes PhpP inhibition. Both situations negatively affect cell division (337), 
and consistently, S. pneumoniae mutants in the cognate kinase (StkP) of this system exhibit 
increased sensitivity to β-lactams (404). The equivalent mutant in S. aureus (Δstk1) is likewise 
sensitive to β-lactams (376, 379), and intriguingly, recent evidence implicates Stk1/Stp1 
signalling in BlaZ-BlaI mediated regulation of mecA (383). Given that both S. aureus Stk1 and 
Stp1 mediated-phosphorylation favour manganese as a cofactor (376, 405), we hypothesise that 
zinc ionophoric activity inactivates this system through 1) deprivation of the manganese 
cofactor and/or 2) zinc mismetallation of the metal-binding sites. We propose this causes the 
observed broad changes in cell wall homeostasis and dysregulation of BlaZ-BlaI mediated 
mecA expression. Mass spectrometry analysis of purified Stk1 and Stp1 from zinc ionophore 
exposed cells could provide insight into the metallation status of these regulators under 
intracellular zinc stress.  
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Given that VraR is regulated by Stk1 and Stp1 signalling, inactivation of Stk1/Stp1 by 
zinc ionophoric activity is consistent with the amplified expression of the VraSR regulon 
observed in this study (379). Alternatively, as VraSR is activated by disruptions in 
peptidoglycan metabolism and cell membrane integrity (352, 353, 382, 384), these pathways 
may be affected by excess zinc or zinc ionophore complexes. We are currently undertaking an 
HPLC analysis of the peptidoglycan content of MRSA cells exposed to PBT2-zinc and oxacillin 
to determine whether PBT2 acts on peptidoglycan biosynthesis. Upon comparison to the 
peptidoglycans of untreated and oxacillin-treated MRSA, this analysis will reveal if certain 
muropeptides accumulate or are depleted upon exposure to PBT2-zinc complexes and may 
indicate a specific enzyme target. Our data suggesting that PBT2-zinc complexes may interact 
with membrane phospholipids, along with the apparent abnormalities in the cell wall and 
membrane visualised through TEM, support the idea that PBT2-zinc disrupts membrane 
integrity. Future investigations into the effect of PBT2-zinc and derivative zinc ionophores on 
MRSA membrane permeability should complement these studies.  
In our proposed model, we hypothesise that the dissipation of the ΔpH by PBT2-zinc 
reflects the zinc-mediated inhibition of proton-translocating enzymes within the respiratory 
chain (165, 175, 386). This dysregulation of respiration might lead to increased production of 
ROS in MRSA, and as previous studies have suggested, increased ROS may amplify the 
lethality of β-lactams. Confirming this requires further examination and raises the question of 
whether supplemental H2O2 or antioxidants (e.g. glutathione) amplify or impede the cidality of 
β-lactams, respectively, in zinc ionophore-resensitized MRSA. Likewise, an investigation into 
the possible impairment of manganese-dependent antioxidant strategies in MRSA by zinc 
ionophore adjuvant activity, as shown by reduced SodA activity in S. uberis, would provide 
further insight into this potential role for ROS.  
 
 Conclusions 
In conclusion, this body of work provides new insights into the mechanisms of zinc ionophores 
as standalone bactericidal agents and β-lactam antibiotic adjuvants. Collectively, this thesis 
contributes and adds to the current knowledge in the field of bacterial metal ion homeostasis 
and exemplifies how it can be exploited for antibacterial potential. We show the bactericidal 
mechanism of the zinc ionophore PBT2 in the agricultural pathogen S. uberis occurs via a lethal 
destabilisation of cellular zinc and manganese homeostasis and redox balance. Further, we 
demonstrate sub-inhibitory concentrations of PBT2 and 8-sulfonamidoquinoline compounds 
similarly destabilise cellular zinc and manganese ratios in the multi-drug resistant pathogen 
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MRSA, breaking β-lactam antibiotic resistance in vitro and in vivo through multiple potential 
mechanisms. Understanding the underlying causative mechanisms of zinc ionophore-mediated 
β-lactam resensitization in MRSA, along with investigations into the practicality and efficacy 
of zinc ionophores as antibacterials or antiseptics for veterinary or human medicine, are the 
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ABSTRACT Streptococcus uberis forms part of the native microbiota of cattle and is
able to opportunistically infect the mammary gland; as such, it is a leading cause of
bovine mastitis globally. Here, we report the complete genome sequence of S. uberis
NZ01, isolated in New Zealand from a cow with a clinical case of bovine mastitis.
Streptococcus uberis is a Gram-positive bacterium with a global distribution, beingcommonly found as part of the native microflora in cattle (1, 2). Opportunistic
infection of the bovine mammary gland by S. uberis can lead to the bacterium acting
as a major pathogen, causing the inflammatory disease mastitis (3). Economic losses
associated with bovine mastitis have been estimated at $35 billion per year globally,
with S. uberis being the leading cause of bovine mastitis in New Zealand (4) and the
United Kingdom (5) and a major cause in the Unites States (6), Canada (7), and Chile (8),
among other countries.
As of this writing, there has been one complete genome of S. uberis assembled,
which originated from the United Kingdom (2). Here, we report a second complete
genome, that of New Zealand strain NZ01, which was isolated from a cow with a clinical
case of bovine mastitis in Palmerston North, New Zealand. This complete genome will
support efforts to manage bovine mastitis and further our understanding of the
evolutionary responses of S. uberis to antimicrobial use.
DNA extraction and next-generation sequencing were performed at the Microbio-
logical Diagnostic Unit Public Health Laboratory of the University of Melbourne.
Genomic DNA was prepared from a culture grown from a single colony using a JANUS
Chemagic workstation and Chemagic DNA/RNA kit (PerkinElmer, USA). DNA libraries
were created using the Nextera XT DNA preparation kit (Illumina, USA). Next-generation
sequencing was performed using the Illumina NextSeq platform.
The assembly involved a preliminary assembly in Geneious version 10.1.3 (9),
followed by repeat spanning and gap closure with Sanger sequencing of PCR products.
The complete genome was compared to that of S. uberis 0104J (GenBank accession
number AM946015) by progressiveMauve alignment (10). Genomic features and coding
DNA sequences (CDSs) were predicted with the NCBI Prokaryote Genome Annotation
Pipeline (PGAP) (11).
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The complete NZ01 genome comprises a single chromosome of 1,863,842 bp, with
1,808 CDSs and 1,886 predicted genes. Approximately 146 CDSs found in the NZ01
genome are novel, compared to those of strain 1040J from the United Kingdom.
Conversely, approximately 163 CDSs found in the UK strain do not appear in NZ01,
further illustrating the genomic flexibility of this species (12). Estimates of the S. uberis
pangenome have been made on a geographically limited set of strains (13), with many
of the above-described novel genes identified in NZ01 being found in this pangenome.
An identified prophage in NZ01 (1,520,084 to 1,560,140 bp) has been shown as
active, with a subset of next-generation sequencing reads highlighting the presence of
a circular phage particle. This could be of interest for the control of bovine mastitis, as
the phage encodes multiple holin and lysin genes and may be able to actively lyse S.
uberis (14).
As further efforts to control S. uberis are made, it will be increasingly useful to track
the emergence of resistance to these measures, with complete genomes such as that
presented here providing a resource for such investigations. A detailed phylogenetic
study of this and other New Zealand S. uberis isolates will follow, with analysis of both
horizontally acquired elements and antimicrobial resistance determinants.
Accession number(s). This complete genome sequence has been deposited at
GenBank under the accession number CP022435.
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ABSTRACT The World Health Organization reports that antibiotic-resistant patho-
gens represent an imminent global health disaster for the 21st century. Gram-
positive superbugs threaten to breach last-line antibiotic treatment, and the phar-
maceutical industry antibiotic development pipeline is waning. Here we report the
synergy between ionophore-induced physiological stress in Gram-positive bacteria
and antibiotic treatment. PBT2 is a safe-for-human-use zinc ionophore that has pro-
gressed to phase 2 clinical trials for Alzheimer’s and Huntington’s disease treatment.
In combination with zinc, PBT2 exhibits antibacterial activity and disrupts cellular ho-
meostasis in erythromycin-resistant group A Streptococcus (GAS), methicillin-resistant
Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE). We were
unable to select for mutants resistant to PBT2-zinc treatment. While ineffective alone
against resistant bacteria, several clinically relevant antibiotics act synergistically with
PBT2-zinc to enhance killing of these Gram-positive pathogens. These data represent a
new paradigm whereby disruption of bacterial metal homeostasis reverses antibiotic-
resistant phenotypes in a number of priority human bacterial pathogens.
IMPORTANCE The rise of bacterial antibiotic resistance coupled with a reduction in
new antibiotic development has placed significant burdens on global health care.
Resistant bacterial pathogens such as methicillin-resistant Staphylococcus aureus and
vancomycin-resistant Enterococcus are leading causes of community- and hospital-
acquired infection and present a significant clinical challenge. These pathogens have
acquired resistance to broad classes of antimicrobials. Furthermore, Streptococcus
pyogenes, a significant disease agent among Indigenous Australians, has now ac-
quired resistance to several antibiotic classes. With a rise in antibiotic resistance and
reduction in new antibiotic discovery, it is imperative to investigate alternative ther-
apeutic regimens that complement the use of current antibiotic treatment strategies.
As stated by the WHO Director-General, “On current trends, common diseases may
become untreatable. Doctors facing patients will have to say, Sorry, there is nothing
I can do for you.”
KEYWORDS Enterococcus faecium, Staphylococcus aureus, Streptococcus pyogenes,
antibiotic resistance
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Combating antibiotic resistance remains a critical global health priority (1). Over thepast decade, the overall trend of bacterial pathogens exhibiting drug resistance has
steadily increased (1–3). In high-income settings such as the United States, reports
estimate that more than 2 million antibiotic-resistant infections occur per annum with
a death toll of 23,000 at a direct cost of $20 billion (3). In low-income settings,
communicable diseases remain the leading cause of death, now heightened by emerg-
ing and reemerging infectious diseases (4). Largely driven by the excessive and
inappropriate use of antibiotics, the threat of antibiotic resistance has recently been
amplified by a substantial decline in new antimicrobial discovery. From 2011 to 2016,
only 8 new antibiotics were approved by the U.S. FDA (5). This significant decline in
novel antibiotic discovery and commercialization has paralleled an escalation in anti-
biotic resistance, highlighting the urgent need for new antibiotic development and
complementary therapy. Today, several strategies are being investigated to combat
bacterial resistance to existing antibiotics (5–7), including the repurposing of existing
drugs, originally developed as therapeutics for noninfectious disease.
The hydroxyquinoline PBT2 has been developed as a potential treatment for Alz-
heimer’s and Huntington’s disease and has progressed to phase 2 human clinical trials,
with a daily dose of 250 mg over 6 months being safe and well tolerated (8–10). PBT2
is an ionophore that facilitates the transport of first-row transition metal ions, such as
zinc, across biological membranes, thereby altering intracellular metal homeostasis.
Bacterial pathogens encounter significant fluctuations in metal ion abundance during
host colonization and have been shown to be highly susceptible to phagocytic cell
induction of zinc toxicity (11). Although metals such as zinc are critical nutrients for
bacterial cell survival, metal-transporting ionophores can facilitate accumulation of
high levels of zinc in the bacterial cytosol, leading to bacterial cell toxicity (11, 12). Here,
we report that in combination with zinc, the ionophore PBT2 destabilizes key cellular
homeostasis pathways involved in bacterial antibiotic resistance mechanisms. Further-
more, the combination of PBT2 and zinc is able to resensitize erythromycin-resistant
group A Streptococcus (GAS), methicillin-resistant Staphylococcus aureus (MRSA), and
vancomycin-resistant Enterococcus (VRE) to previously resistant classes of antibiotic in
vivo. These data highlight a new and encouraging alternative therapeutic regimen
which complements the use of current antibiotic strategies.
RESULTS AND DISCUSSION
PBT2 was originally developed as a potential therapeutic for Alzheimer’s and
Huntington’s disease. Here, we sought to examine the therapeutic potential of PBT2 as
an antibacterial agent, which has not been previously tested. Following chemical synthesis
of PBT2 (13) (see Materials and Methods and Fig. S1 in the supplemental material), the
purity of the final product was determined to be !95% by 1H and 13C NMR.
Erythromycin-resistant GAS, MRSA, and VRE are categorized by the U.S. Centers for
Disease Control and Prevention as concerning or serious threats to human health (3).
Using Clinical and Laboratory Standards Institute guidelines for antimicrobial sensitivity
testing (14), we investigated the potential of PBT2 to act as an antibacterial agent
against GAS strain HKU16 (15), MRSA strain USA300 (16), and VRE clinical isolate RBWH1
(Fig. S2). At the concentrations used, neither PBT2 nor zinc displayed significant
antibacterial activity. However, the combination of PBT2 and zinc (PBT2-zinc) exhibited
antibacterial activity against each pathogen (Fig. 1a and Table S1). Bactericidal activity
is defined as a !3-log reduction in bacterial CFU relative to the initial inoculum.
Measured to the effects of vancomycin (bactericidal) and tetracycline (bacteriostatic) on
MRSA, the mode of action of PBT2-zinc was found to be bactericidal (Fig. 1b). We next
investigated the capacity of each pathogen to develop resistance to the combination
of PBT2-zinc. We were unable to isolate resistant mutants for any of the strains
following serial passage for a period of 30 days in the presence of subinhibitory
concentrations of PBT2-zinc (Fig. 1c). To explore the safety of PBT2-zinc in human cells,
we investigated the survival of human primary tonsil epithelial cells in the presence of
this combination. After 24 h, cell viability was unaffected by PBT2-zinc treatment
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FIG 1 Synergistic antimicrobial activity of PBT2 and zinc. (a) Growth of GAS, MRSA, and VRE serially diluted on THY agar
in the presence or absence of PBT2 (1.5 "M) and/or zinc (400 "M) or vancomycin (20 "g/ml). Dilution values are indicated
on the left of each figure panel. (b) Time-kill curves of GAS, MRSA, and VRE in THY broth with or without PBT2 (2 "M for
GAS or 6 "M for MRSA and VRE) and/or ZnSO4 (400 "M for GAS and 600 "M for MRSA and VRE) or vancomycin
(Continued on next page)
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(Fig. S3). We next investigated the efficacy of PBT2-zinc treatment using a murine
wound infection model (17). The application of PBT2-zinc (zinc in the form of either
ZnCl2 or ZnSO4) resulted in a significant reduction in the bacterial burden at the site of
infection upon topical treatment (Fig. 1d).
Next, we determined the intracellular zinc content of each pathogen in response to
subinhibitory concentrations of PBT2-zinc. As assessed by inductively coupled plasma
mass spectrometry (ICP-MS), increased cellular levels of zinc were observed in GAS,
MRSA, and VRE upon treatment (Fig. 2a). PBT2 and zinc combinations were also shown
to affect intracellular iron, manganese, and copper content, suggesting a mechanism
involving disruption of heavy metal homeostasis (Fig. S4A to C). To further explore the
mechanism of action of PBT2-zinc treatment, we analyzed the transcriptome of each
pathogen in response to subinhibitory concentrations of PBT2-zinc. Significant changes
in the transcription of heavy metal homeostasis genes were observed and confirmed by
quantitative real-time PCR (Fig. 2b and c; Table S2). Consistent with metal ion intoxi-
cation, the transcriptional responses to PBT2-zinc treatment in the Gram-positive
pathogens included the induction of zinc efflux systems (GAS, czcD; MRSA, czcD and
zntA), copper efflux systems (GAS, copA; MRSA, copZ; VRE, copA), and manganese
transport systems (VRE, mntA). In addition, the transcription of several essential viru-
lence, oxidative stress, and metabolic systems was also perturbed by subinhibitory
concentrations of PBT2-zinc (Fig. 2b and c; Table S2). Despite these changes in the
transcriptional profile, PBT2-zinc did not alter cell membrane permeability of GAS,
MRSA, and VRE compared to the pore-forming antibiotic nisin (Fig. S5A). PBT2-zinc did
not visibly disrupt the bacterial cell wall of GAS and MRSA (Fig. S5B and C); however,
visible depressions in the VRE cell wall were observed after 3 h of treatment and VRE
cells became enlarged after 24 h (Fig. S5D).
Building on the observed significant transcriptional and physiological impacts in-
duced by the combination of PBT2-zinc upon these bacterial strains (Table 1), we then
assessed whether these disruptions enhanced antibiotic sensitivity in otherwise resis-
tant bacterial pathogens. To achieve this, the tetracycline- and macrolide-resistant GAS
strain HKU16 and the multidrug-resistant strains MRSA USA300 and VRE RBWH1 were
further investigated. In the presence of antibacterial only, HKU16, USA300, and RBWH1
were resistant to several antibiotic classes (Table 1). Addition of either PBT2 or zinc
alone did not affect their susceptibility profile. However, in the presence of subinhibi-
tory concentrations of PBT2-zinc, GAS strain HKU16 became susceptible to tetracycline,
azithromycin, and clindamycin; MRSA strain USA300 became susceptible to oxacillin,
erythromycin, and ampicillin; and VRE strain RBWH1 became susceptible to vancomy-
cin, tetracycline, azithromycin, and clindamycin (Table 1). While resistance to erythro-
mycin was overcome in MRSA USA300, erythromycin resistance was maintained in GAS
HKU16 and VRE RBWH1. This difference may relate to the inducible erythromycin
resistance mechanism in MRSA USA300 (clindamycin sensitive) compared to the alter-
native constitutive erythromycin resistance mechanism (clindamycin resistant) (15,
18–20) operating in GAS HKU16 and VRE RBWH1 (Table 1). Bactericidal activity of
PBT2-zinc and antibiotic combinations was partially rescued with the addition of the
antioxidant glutathione (Fig. S6), suggesting the involvement of reactive active oxygen
species in the mechanism of cell killing (21).
To investigate the efficacy of PBT2-zinc in combination with antibiotics on infection,
we again employed the murine wound infection model. Neither antibiotic nor subin-
FIG 1 Legend (Continued)
(bactericidal; 4 "g/ml for MRSA) or tetracycline (bacteriostatic; 1 "g/ml for MRSA). Error bars indicate standard deviations
from 2 biological replicates. (c) Development of resistance during serial passage in the presence of subinhibitory
concentrations of antimicrobial compounds in CAMHB. Data represent means for 3 biological replicates. (d) CFU recovered
from a murine wound infection model 4 days after challenge with GAS (1.1 " 107 CFU), MRSA (6 " 105 CFU), or VRE
(8.8 " 105 CFU). Mice were treated twice daily with carrier ointment only or ointment with 5 mM PBT2 and/or 50 mM Zn
(ZnSO4 for MRSA or ZnCl2 for GAS) or 2.75 mM PBT2 and/or 75 mM ZnSO4 for VRE. Values for individual mice are plotted,
and black lines are representative of group geometric mean (*, P # 0.05; **, P # 0.005; ***, P # 0.001; ****, P # 0.0001,
one-way ANOVA).
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FIG 2 PBT2 and zinc affect heavy metal homeostasis, metabolism and virulence. (a) Intracellular zinc concentrations as determined by
ICP-MS for GAS, MRSA, and VRE grown in THY with or without PBT2 and zinc (GAS, 0.3 "M PBT2 $ 50 "M ZnSO4; MRSA, 1 "M PBT2 $ 200
"M ZnSO4; and VRE, 1 "M PBT2 $ 150 "M ZnSO4) (error bars indicate standard error of the mean from at least 3 biological replicates; *,
P # 0.05; **, P # 0.005; ***, P # 0.001; ****, P # 0.0001, one-way ANOVA). (b) RNASeq transcriptome analysis of bacteria treated with PBT2
and ZnSO4 for GAS (4.75 "M PBT2 $ 128 "M ZnSO4), MRSA (2 "M PBT2 $ 50 "M ZnSO4), and VRE (1.75 "M PBT2 $ 128 "M ZnSO4) in
CAMHB. Genes with log2 fold changes of !1/#1 and P # 0.05 are shown in blue, and selected genes of interest are shown in red. Data were
collected from 3 biological replicates. (c) Transcript levels for selected genes measured by real-time PCR. Log2 fold changes were calculated
relative to untreated controls and normalized to a reference gene using the ∆∆CT method (reference genes were proS for GAS, rrsA for MRSA,
and 23S for VRE). Error bars represent standard deviations from 3 biological replicates.
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hibitory concentrations of PBT2-zinc alone significantly reduced bacterial burden at the
site of infection (Fig. 3). However, the combination of PBT2-zinc and tetracycline
significantly reduced GAS infection; PBT2-zinc and erythromycin significantly reduced
MRSA infection; and PBT2-zinc and vancomycin significantly reduced VRE infection
(Fig. 3). Amounts of zinc and PBT2 utilized in each respective treatment were well below
concentrations typically employed for the treatment of actinic keratosis (ZnSO4, 25%
[wt/vol]) (22) and are significantly below the regimens tested in phase I and II clinical
trials of PBT2 (8–10). Thus, concentrations of both PBT2 and zinc used in this study are
likely to be well tolerated via topical delivery over a prolonged period of time. Overall,
these data demonstrate the novel therapeutic synergy of PBT2-zinc in combination
with antibiotics to topically treat otherwise resistant infections.
The steady and unrelenting rise in antibiotic resistance is one of the greatest global
challenges confronting medicine and global heath. Strategies that are being explored
to address the problem of bacterial resistance to existing antibiotics include the
development of new antibiotics, blocking of resistance mechanisms against existing
antibiotics, bacteriophage therapy, targeting of virulence mechanisms that weaken
bacterial defense against host immunity, stimulating host immunity to improve bac-
terial clearance, destabilization of the Gram-negative cell envelope, vaccine develop-
ment, and repurposing existing drugs used for noninfectious disease indications (6,
23–28). The Gram-positive bacterial pathogens GAS, MRSA, and VRE cause a wide range
of hospital-acquired and community-acquired infections, place significant pressure and
economic burden on health care systems, and are a major contributor to global human
morbidity and mortality (29). Here we reveal that the safe-for-human-use ionophore
PBT2, in combination with zinc, possesses antibacterial activity and at subinhibitory
concentrations reverses Gram-positive bacterial resistance against a number of impor-
tant antibiotics. The mechanism of action underlying this effect appears to be associ-
ated with dysregulation of transition metal ion homeostasis and profound disruption of
essential virulence and metabolic systems, all of which may weaken the capacity of
these bacterial pathogens to cause infection. Effects on antibiotic resistance were not
universal. For instance, erythromycin resistance was reversed in MRSA but not in GAS.
PBT2 is a safe-for-human-use ionophore that has progressed to phase 2 human clinical
FIG 3 PBT2 and zinc reverse antibiotic resistance in a murine wound infection model. CFU recovered 4 days after wound infection
with GAS (3.8 " 106 CFU), MRSA (5.3 " 105 CFU), or VRE (9.4 " 105 CFU). Mice were treated twice daily with ointment only or ointment
containing PBT2, Zn, and/or antibiotic (2 mM PBT2, 25 mM ZnSO4, and/or 15 "g/ml tetracycline for GAS; 3 mM PBT2, 30 mM ZnSO4,
and/or 4 "g/ml erythromycin for MRSA; and 2 mM PBT2, 30 mM ZnSO4, and/or 20 "g/ml vancomycin for VRE). Values for individual
mice are plotted, and black lines are representative of group geometric mean (*, P # 0.05; ***, P # 0.001; ****, P # 0.0001, one-way
ANOVA). Abbreviations: Tet, tetracycline; Erm, erythromycin; Van, vancomycin.
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trials (9, 10). Zinc is used as a nutritional supplement and homeopathic remedy, and
here we show that the delivery of zinc using the ionophore PBT2 can reduce the
concentration of zinc required for efficacy to levels that are tolerated physiologically
(30). Taken together, these data demonstrate a new paradigm whereby destabilizing
bacterial physiology may circumvent the antibiotic resistance problem, by rescuing the
function of antibiotics to which bacteria have become resistant.
MATERIALS AND METHODS
PBT2 synthesis. PBT2 (compound 3) was synthesized following the reaction conditions shown below
(13). Initially, oxidation of the methyl side chain of 5,7-dichloro-2-methylquinolin-8-ol (compound 1) was
achieved by heating compound 1 with selenium dioxide in 1,4-dioxane to provide the required aldehyde
(compound 2), in quantitative yield. The resultant crude product was then further reacted with
dimethylamine-hydrochloride in 1,2-dichloroethane and triethylamine to yield a product that was reduced in
situ, by treatment with sodium triacetoxyborohydride to provide the free amine of PBT2 as an oil. Upon
acidification of the free amine with HCl, PBT2 hydrochloride-salt (compound 3) was obtained in 81% yield.
(i) General synthetic methods. Reagents and dry solvents purchased from commercial sources were
used without further purification. Anhydrous reactions were carried out under an atmosphere of argon,
using oven-dried glassware. Reactions were monitored using thin-layer chromatography (TLC) on
aluminum plates precoated with Silica Gel 60 F254 (E. Merck). Developed plates were observed under UV
light at 254 nm and then visualized after application of a solution of H2SO4 in EtOH (5% [vol/vol]) and
heating. Flash chromatography was performed on Silica Gel 60 (0.040 to 0.063 mm) using distilled
solvents. 1H and 13C NMR spectra were recorded at 400 and 100 MHz, respectively, on a Bruker Avance
400-MHz spectrometer. Chemical shifts (#) are reported in parts per million, relative to the residual
solvent peak as internal reference (CDCl3, 7.26 [s] for 1H, 77.0 [t] for 13C). Low-resolution mass spectra
(LRMS) were recorded, in electrospray ionization mode, on a Bruker Daltonics Esquire 3000 ESI spec-
trometer, using positive ionization mode. The purity of the final product (compound 3) was determined
to be !95% by 1H and 13C NMR. The synthetic work followed the procedures reported in the patent
describing PBT2 preparation (13). The details of synthetic methods used and full characterization data of
the final product are reported below.
(ii) 5,7-Dichloro-8-hydroxy-2-quinolinecarboxaldehyde (compound 2).
To a stirred suspension of selenium dioxide (1.75 g, 15.80 mmol) in 1,4-dioxane (80 ml) at 55°C was added a
solution of 5,7-dichloro-2-methyl-quinolin-8-ol (2.0 g, 8.77 mmol) in 1,4-dioxane (20 ml) in a dropwise manner
over a period of 3 h. After complete addition, the heating temperature was raised to 80°C, and heating was
maintained overnight. The reaction mixture was then allowed to cool down to room temperature, and the
insoluble solids were filtered off on a Celite bed. The filtrate was concentrated under vacuum, and the residue
was washed with diethyl ether (10 ml " 3) to yield 2.10 g (quantitative yield) of the aldehyde 2 as a yellow
powder, which was used in the following step without further purification.
(iii) 5,7-Dichloro-2-((N,N-dimethylamino)methyl)quinolin-8-ol HCl salt (compound 3, PBT2 HCl).
To a stirred solution of the crude aldehyde 2 (2.0 g, 8.26 mmol) and dimethylamine hydrochloride
(730 mg, 8.96 mmol) in 1,2-dichloroethane (100 ml) was added triethylamine (1.25 ml, 8.96 mmol) in a
dropwise manner. The mixture was stirred at room temperature (RT) for 5 min, and then sodium
triacetoxyborohydride (2.4 g, 11.32 mmol) was added portionwise over a period of 5 min. The mixture
was then stirred at RT overnight. Upon reaction completion, the reaction mixture was diluted with
dichloromethane (200 ml) and washed with saturated sodium bicarbonate (100 ml " 3). The organic
layer was then dried over anhydrous Na2SO4 and concentrated under vacuum to yield an oily product
of the free amine base of PBT2. The oily product was triturated with water (100 ml) and extracted with
diethyl ether (100 ml " 4). The ethereal extracts were combined, washed with brine, dried over Na2SO4,
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and concentrated under vacuum. To the obtained residue was added 10 ml of concentrated HCl, and the
mixture was concentrated in vacuo. The resulting residue was washed with dichloromethane (50 ml " 3)
to yield 2.30 g of PBT-HCl salt (compound 3) as pale yellow powder (81% yield). 1H NMR (400 MHz, CDCl3):
# 2.32 (s, 6H, 2NCH3), 3.78 (s, 2H, CH2), 7.51 (s, 1H, H-6), 7.61 (d, J % 8.7 Hz, 1H, H-4), 8.39 (d, J % 8.6 Hz,
1H, H-3); 13C NMR (101 MHz, CDCl3): # 45.64 (NCH3 " 2), 65.46 (CH2), 115.51 (C-7), 120.35 (C-5), 122.26
(C-3), 124.07 (q carbon), 127.76 (C-6), 133.83 (C-4), 138.16 (q carbon), 147.98 (C-8), 158.93 (C-2); LRMS
[C12H12Cl2N2O] (m/z): (positive ion mode) 272.0 [M$H]$.
Bacterial strains, media, and growth conditions. GAS HKU16, MRSA USA300, and VRE RBWH1 were
grown in Todd-Hewitt broth (THB) or agar with 1% yeast extract (THY) (31) or in cation-adjusted
Mueller-Hinton broth (CAMHB) (32) or agar (supplemented with 2.5% lysed horse blood [LHB] for GAS
HKU16). Bacteria were routinely grown at 37°C under static conditions in ambient air.
Sequencing of VRE. To determine the complete genome sequence of RBWH1, long-read, single-
molecule real-time (SMRT) sequencing was performed using the Pacific Biosciences RS II platform.
Genomic DNA was manually sheared through a 26-gauge syringe, and a library was prepared using the
SMRTbell DNA Template Prep kit 1.0 (Pacific Biosciences). Sequencing was performed on a single SMRT
cell using polymerase P6 and V4 chemistry (Pacific Biosciences). Filtering of the long reads identified
147,593 reads with an average polymerase read length of 4.8 kb. To aid in genome assembly validation,
RBWH1 was also sequenced on an Illumina Next-Seq 500 to produce paired-end reads with a read length
of 150 bases. De novo genome assembly was performed using SMRT analysis v2.3.0 (Pacific Biosciences)
and HGAP v3 and polished using Quiver. The chromosome and plasmids were circularized either
manually or using Circlator (33), and the resulting genome assembly was validated using the Illumina
short-read sequence data using Pilon v1.22 (34). Putative plasmid sequences were trimmed and
orientated to published E. faecium plasmids. The final genome comprised a single circular chromosome
of 2,876,110 bp and six plasmid sequences larger than 2,000 bp in length: pRBWH1.1, 167,502 bp;
pRBWH1.2, 55,808 bp; pRBWH1.3, 39,621 bp; pRBWH1.4, 11,916 bp; pRBWH1.5, 4,453 bp; pRBWH1.6,
3,008 bp. Genome annotation was performed using Prokka (35).
Drop test assay. Bacteria were diluted from overnight cultures to obtain a starting OD600 of 0.01 in
THY. Once the bacteria grew to an OD600 of 0.6, the cultures were serially diluted in PBS and 5 "l of each
dilution (undiluted, 10&1, 10&2, 10&3, 10&4, 10&5) was plated on THY agar plates with or without zinc
(400 "M) and/or PBT2 (1.5 "M) or vancomycin (20 "g/ml). Plates were incubated at 37°C overnight. Drop
tests were undertaken in biological triplicates.
Inductively coupled plasma mass spectrometry (ICP-MS). Overnight cultures of bacteria were
diluted to an OD600 of 0.05 in THY (GAS, 45 ml; MRSA and VRE, 20 ml) with or without PBT2 and zinc (GAS,
0.3 "M PBT2 $ 50 "M ZnSO4; MRSA, 1 "M PBT2 $ 200 "M ZnSO4; and VRE, 1 "M PBT2 $ 150 "M ZnSO4)
and grown to mid-log phase (GAS, OD600 % 0.5; MRSA and VRE, OD600 % 1.0). Cells were harvested at
7,000 " g for 7 min at 8°C. The pellet was resuspended in 20 ml PBS containing 5 mM EDTA and pelleted
again at 7,000 " g for 7 min at 8°C. The wash was repeated two more times, and then the pellet was
resuspended in 20 ml PBS without EDTA. The cells were harvested again at 7,000 " g for 7 min at 8°C, and
then the pellet was washed with PBS. After centrifugation, the pellet was resuspended in 1 ml PBS and
transferred into a microcentrifuge tube. The cells were pelleted at 18,000 " g for 7 min at 8°C, the
supernatant was removed, and the pellet was dried at 96°C overnight. The dry pellet was weighed to
determine the dry cell weight, resuspended in 1 ml of 35% HNO3, and carefully heated to 96°C for 60 min.
After vortexing, the sample was centrifuged at 18,000 " g for 25 min to pellet cell debris. For ICP-MS
analysis, 200 "l of the supernatant was diluted into 1.8 ml of double-distilled H2O. Samples were
analyzed on an Agilent 8900 ICP-QQQ (Adelaide Microscopy, University of Adelaide). At least three
biological replicates were analyzed.
MIC determination. MICs were determined by broth microdilution in accordance with CLSI guidelines
(14). MIC assays were undertaken in 96-well plates in a total volume of 100 "l per well. For MRSA and VRE,
the assays were performed in MHB, and for GAS, MHB plus 2.5% lysed horse blood (LHB) was used. The
bacterial inoculum was prepared by direct colony suspension aiming for 2 " 105 to 8 " 105 CFU/ml bacteria
per well. Antibiotics/compounds were serially diluted 2-fold across the 96-well plate; the last column
contained no antibiotics/compounds. The inoculum was added to the plate containing antibiotic/compound
and incubated for 16 to 24 h at 35 '2°C. The MIC was determined as the lowest concentration of
antibiotic/compound that showed no visible growth. MIC assays were carried out in biological triplicates.
Resistance development studies. The development of resistance to antibiotics/compounds was
undertaken essentially as previously described (6). To investigate resistance development for GAS, MRSA,
and VRE in the presence of subinhibitory concentrations of PBT2 and zinc, bacteria were sequentially
passaged over 30 days in CAMHB. As a control, the antibiotic ciprofloxacin was used for GAS and MRSA,
and chloramphenicol was used for VRE. Initially, the MIC for PBT2-zinc or antibiotic was determined by
broth microdilution according to CLSI guidelines in a microtiter plate. The highest antibiotic or PBT2-zinc
concentration that still showed growth after overnight incubation was diluted 1/250 into a new
microtiter plate containing 2-fold dilutions of antibiotic or PBT2-zinc. This procedure was repeated for
30 days. The assays were undertaken in biological triplicates.
Bacterial time-kill assays. Bacteria were grown to mid-log phase in THY and then diluted to a
starting OD600 of 0.05 in THY only, THY containing PBT2 (2 "M for GAS or 6 "M for MRSA and VRE) and/or
ZnSO4 (400 "M for GAS and 600 "M for MRSA and VRE), or THY containing vancomycin (4 "g/ml for
MRSA; 2" MIC) or tetracycline (1 "g/ml for MRSA; 2" MIC). To determine surviving numbers of bacteria,
aliquots were removed at 0, 1, 2, 4, 6, and 24 h; serially diluted in PBS; and plated onto THY agar plates.
Viable bacteria were counted after overnight incubation at 37°C. Time-kill assays were performed in
biological duplicates.
Chemical Synergy between PBT2, Zinc, and Antibiotics ®
November/December 2018 Volume 9 Issue 6 e02391-18 mbio.asm.org 9
 on Septem









Cytotoxicity assay. TEpi cells were incubated with increasing concentrations of PBT2-zinc (3 "M
PBT2 $ 300 "M ZnSO4 or 6 "M PBT2 $ 600 "M ZnSO4) at 37°C, 5% CO2, for 24 h. Cell death was
quantified at 4 h and 24 h posttreatment by measuring lactate dehydrogenase (LDH) release from cell
supernatants as previously described (36). A two-way ANOVA with Sidak’s posttest was performed to
detect statistical significance.
Ethics. Animal experiments were performed according to the Australian code of practice for the care
and use of animals for scientific purposes. Permission was obtained from the University of Queensland
ethics committee (SCMB/140/16/NHMRC).
Murine wound infection model. For wound infection (17), 4- to 7-week-old female BALB/c mice
were used and housed in individual cages. The neck area of the mice was shaved, and residual hair was
removed using Nair (Church & Dwight) prior to the experiment. On the day of infection, mice were
anesthetized by inhalation of methoxyflurane, and a small superficial scarification was made on the
shaved skin using a metal file. For infection, bacteria were cultured to mid-log phase in THY medium and
5 " 106 to 2 " 107 CFU GAS or 5 " 105 to 2 " 106 CFU MRSA/VRE was applied onto the scarified skin
(exact inoculum is specified in figure legends). After the inoculum had been absorbed by the skin
(approximately 10 min), the mice were treated with carrier ointment only (Pharmacy Choice aqueous
cream) or ointment containing PBT2 and/or zinc and/or antibiotic (tetracycline for GAS, erythromycin for
MRSA, vancomycin for VRE). Mice were treated with ointment twice daily, and a total of 9 treatments
were applied. Each treatment consisted of around 25 to 30 mg ointment and contained 5 mM PBT2
and/or 50 mM Zn (as ZnSO4 for MRSA and ZnCl2 for GAS) and 2.75 mM PBT2 and/or 75 mM ZnSO4 for
VRE. For experiments including antibiotics, the ointment contained 2 mM PBT2 and/or 25 mM ZnSO4
and/or 1.5% tetracycline for GAS, 3 mM PBT2 and/or 30 mM ZnSO4 and/or 0.4% erythromycin for MRSA,
and 2 mM PBT2 and/or 30 mM ZnSO4 and/or 2% vancomycin for VRE. After 4 days of treatment, the mice
were euthanized, and the scarified skin was excised and washed twice in PBS by vortexing for 30 s. The
skin was then homogenized in lysing matrix F tubes using a FastPrep instrument (MP Biomedicals) and
plated out on antibiotic selective THY plates to determine viable bacteria (for GAS, homogenates were
plated out on THY with 10 "g/ml neomycin; for MRSA and VRE, on THY with 10 "g/ml ampicillin). Each
treatment group contained five to eight mice, and statistical significance was calculated with one-way
ANOVA using log-transformed values.
RNA isolation. RNA was isolated using the FastRNA Pro Blue kit (MP Biomedicals) and the SV total
RNA isolation system (Promega). Briefly, bacteria were grown to mid-log phase (OD600 of 0.4 to 0.5) in
MHB ($2.5% LHB for GAS) in the presence or absence of PBT2 and/or ZnSO4. Two volumes of RNAprotect
(Qiagen) was added to the cultures, and the samples were then centrifuged at 5,000 " g for 25 min at
4°C to pellet cells. The dry pellet was stored at &80°C overnight and then resuspended in 1 ml RNA Pro
solution (FastRNA Pro Blue kit). The sample was transferred to lysing matrix B and processed in a FastPrep
instrument (MP Biomedicals). After centrifugation at 13,000 " g for 15 min at 4°C, the supernatant was
transferred into a fresh tube and incubated at room temperature for 5 min. Three hundred microliters of
chloroform was added, and the mixture was vortexed for 10 s. After 5 min incubation at room temper-
ature, the upper phase was moved to a fresh tube containing 200 "l cold 95% EtOH. The sample was
placed on ice for at least 5 min and then transferred into an SV total RNA isolation system spin column.
The sample was processed according to the manufacturer’s instructions and eluted in 110 "l of
nuclease-free water. To ensure complete removal of DNA, the RNA was then further purified using the
TURBO DNA-free kit (Thermo Fisher Scientific) according to the manufacturer’s instructions.
RNASeq analysis. RNASeq analysis was performed at the Australian Genome Research Facility. The
library was prepared using a Ribo Zero stranded protocol. In brief, rRNA was depleted with Ribo Zero,
RNA was fragmented (heat and divalent cations), and first-strand cDNA synthesis was done with
SuperScript II reverse transcriptase (Invitrogen). For the second-strand cDNA synthesis, the strand was
“marked” with dUTP. A 3= adenylation of DNA fragments was performed followed by sequencing adapter
ligation (utilizing T-A pairing of adapter and DNA fragments). The library was amplified by PCR
(amplification of “unmarked” first strand only). Libraries were assessed using either Agilent’s Bioanalyzer
DNA 1000 chip or the TapeStation D1K TapeScreen system. qPCR was used to quantify individual libraries
before normalizing (2 nM) and pooling. Libraries were pooled and clustered through the Illumina cBot
system using TruSeq PE Cluster kit v3 reagents followed by sequencing on the Illumina HiSeq 2500
system with TruSeq SBS kit v3 reagents with 110 (101 read 1, 9 cycles index read). Libraries were
sequenced with a HiSeq 2500 ultrahigh-throughput sequencing system (Illumina) to produce 100-base-
paired-end reads. An average of 45 million reads per sample were generated and mapped to the
reference genome (Sscrofa10.2) using the 2-pass method of the STAR aligner with default parameters.
Eighty percent of these reads uniquely hit to the reference genome. Duplicate reads were denoted with
the MarkDuplicates tool of Picard (http://broadinstitute.github.io/picard). Differential gene expression
was analyzed using Degust (http://victorian-bioinformatics-consortium.github.io/degust/), and figures
were generated using RStudio (37).
Real-time PCR. Only selected genes associated with heavy metal homeostasis, virulence systems,
and metabolic processes were selected for real-time PCR analysis. Briefly, 1 "g of isolated RNA was
transformed into cDNA using the SuperScript III first-strand synthesis kit (Invitrogen). Real-time PCR was
undertaken with the SYBR Green master mix (Applied Biosystems) following the manufacturer’s instruc-
tions. Measurements were performed using the ViiA7 real-time PCR system (Life Technologies), using the
following conditions: 95°C for 10 min, 40 cycles of 95°C for 15 s, and 60°C for 1 min, and a final
dissociation cycle of 95°C for 2 min, 60°C for 15 s, and 95°C for 15 s. Relative gene expression was
calculated by the ∆∆CT method using proS (GAS), rrsA (MRSA), and 23S (VRE) as the reference genes. All
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experiments were done in biological triplicates and measured in technical triplicates. Primers used for
real-time PCR are given in Table S3.
Glutathione supplementation assay. Bacteria were grown to mid-log phase in THY and then
diluted to a starting OD600 of 0.05 in THY only or THY containing PBT2 (2 "M for GAS or 6 "M for MRSA
and VRE), ZnSO4 (400 "M for GAS and 600 "M for MRSA and VRE), antibiotic at 4 "g/ml (tetracycline for
GAS, erythromycin for MRSA, and vancomycin for VRE), and reduced glutathione (1 mM, 5 mM, and
10 mM). To determine surviving numbers of bacteria, aliquots were removed at 0, 1, 2, 4, 6, and 24 h;
serially diluted in PBS; and plated on THY agar plates. Viable bacteria were counted after overnight
incubation at 37°C. Glutathione supplementation assays were performed in biological duplicates.
Cell membrane permeability assays. Membrane permeability of bacterial strains was measured
using the Live/Dead BacLight bacterial viability kit (L7007) (ThermoFisher Scientific) according to the
manufacturer’s instructions. Strains were grown as previously described (in CAMHB [$2.5% LHB for GAS])
with the exception of MRSA USA300, which was grown in tryptic soy broth (TSB). Mid-exponential-phase
cells were harvested (4,000 " g, 10 min, 4°C), washed, and resuspended to an OD600 of 0.6 in potassium
phosphate buffer (100 mM, pH 7.5), containing MgCl2 (2 mM) with the addition of 10 mM NaCl for MRSA
USA300. A 0.4 ml volume of the cell suspension was removed and maintained on ice as the t % 0 sample.
The cell suspension was energized by a 10-min incubation with glucose (20 mM). Aliquots (5 ml) were
either untreated or treated with relevant concentrations of PBT2 and zinc (alone or in combination),
nigericin (10 "M), or nisin (25 "g/ml) for 1 h under the same conditions in which they were grown.
Aliquots (100 "l) of the t % 0 and 60-min samples were resuspended with 2" Live/Dead BacLight
staining reagent (100 "l) in a 96-well, flat-bottom microtiter plate. Following incubation in the dark
(15 min, RT), the fluorescence emission was measured using a Varioskan Flash plate reader (ThermoFisher
Scientific). Membrane permeability was measured as a relative fluorescence emission ratio (530/630 nm)
of the fluorescent dyes SYTO9 (which stains cells with intact or damaged membranes) and propidium
iodide (which stains only cells with damaged membranes) and expressed as the relative change in
membrane integrity after 1-h treatment with compounds. All experiments were done in biological
triplicates and measured in technical triplicates.
Scanning electron microscopy (SEM). SEM studies were undertaken at the Centre for Microscopy and
Microanalysis at the University of Queensland. Bacterial strains were cultured in THY medium to mid-
exponential phase and treated with PBT2 (6 "M) and ZnSO4 (500 "M) for up to 24 h at 37°C. Bacteria were
washed twice preceding glutaraldehyde fixation followed by secondary fixation in 1% osmium tetroxide.
Samples were then dehydrated via a series of ethanol treatments and were applied to coverslips coated with
poly-L-lysine (1 mg/ml) before being dried in a critical point dryer (Tousimis) according to the manufacturer’s
instructions. Coverslips were attached to stubs with double-sided carbon tabs and coated with gold using a
sputter coater (SPI) following manufacturer’s instructions. Samples were imaged in a JEOl JSM 7001F or JEOl
JSM 7100F field emission SEM at an accelerating voltage of 1 kV.
Accession number(s). The genome of RBWH1 is publicly available under the BioProject identifier
PRJNA497960 (accession numbers CP033206 to CP033212). RNASeq data are available at the GEO
repository (GSE121555).
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ABSTRACT Globally, more antimicrobials are used in food-producing animals than in
humans, and the extensive use of medically important human antimicrobials poses a
significant public health threat in the face of rising antimicrobial resistance (AMR). The
development of novel ionophores, a class of antimicrobials used exclusively in animals,
holds promise as a strategy to replace or reduce essential human antimicrobials in veter-
inary practice. PBT2 is a zinc ionophore with recently demonstrated antibacterial activity
against several Gram-positive pathogens, although the underlying mechanism of action
is unknown. Here, we investigated the bactericidal mechanism of PBT2 in the bovine
mastitis-causing pathogen, Streptococcus uberis. In this work, we show that PBT2 func-
tions as a Zn2!/H! ionophore, exchanging extracellular zinc for intracellular protons in
an electroneutral process that leads to cellular zinc accumulation. Zinc accumulation
occurs concomitantly with manganese depletion and the production of reactive oxy-
gen species (ROS). PBT2 inhibits the activity of the manganese-dependent super-
oxide dismutase, SodA, thereby impairing oxidative stress protection. We pro-
pose that PBT2-mediated intracellular zinc toxicity in S. uberis leads to lethality
through multiple bactericidal mechanisms: the production of toxic ROS and the impair-
ment of manganese-dependent antioxidant functions. Collectively, these data show that
PBT2 represents a new class of antibacterial ionophores capable of targeting bacterial
metal ion homeostasis and cellular redox balance. We propose that this novel and multi-
target mechanism of PBT2 makes the development of cross-resistance to medically im-
portant antimicrobials unlikely.
IMPORTANCE More antimicrobials are used in food-producing animals than in hu-
mans, and the extensive use of medically important human antimicrobials poses a sig-
nificant public health threat in the face of rising antimicrobial resistance. Therefore, the
elimination of antimicrobial crossover between human and veterinary medicine is of
great interest. Unfortunately, the development of new antimicrobials is an expensive
high-risk process fraught with difficulties. The repurposing of chemical agents provides a
solution to this problem, and while many have not been originally developed as antimi-
crobials, they have been proven safe in clinical trials. PBT2, a zinc ionophore, is an exper-
imental therapeutic that met safety criteria but failed efficacy checkpoints against both
Alzheimer’s and Huntington’s diseases. It was recently found that PBT2 possessed potent
antimicrobial activity, although the mechanism of bacterial cell death is unresolved. In
this body of work, we show that PBT2 has multiple mechanisms of antimicrobial action,
making the development of PBT2 resistance unlikely.
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homeostasis, oxidative stress
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The widespread emergence of antimicrobial resistance (AMR) threatens the securityof modern medicine. Antimicrobial use in food-producing animals is recognized as
an important driver of AMR, raising concerns in light of the considerable overlap of
antimicrobials used in both humans and animals (1). With food consumption rising to
meet the demands of a growing global population, antimicrobial use in food-producing
animals is consequently set to increase (2). This intensification of antimicrobial use
comes with a greater risk of resistance emerging (3, 4) and warrants the elimination of
antimicrobial crossover between human and veterinary medicine.
Bovine mastitis, an inflammatory disease of the bovine mammary gland, is the
leading cause for antimicrobial use in the dairy industry worldwide (5, 6). The Gram-
positive pathogen Streptococcus uberis is a common environmental cause of bovine
mastitis (7). Due to the ubiquity of environmental pathogens such as S. uberis in the
dairy environment, prevention of environmental mastitis is particularly challenging and
relies heavily on antimicrobial sanitizers (8, 9). Chlorhexidine and iodine, which the
World Health Organization (WHO) recognizes as essential antiseptics for human med-
icine (10), are among the most common antiseptics used in teat disinfectants (11).
Increased tolerance to chlorhexidine has been reported in both Gram-positive and
Gram-negative hospital-associated pathogens (12–14), illustrating the pressing need to
discover novel animal-only antimicrobials for mastitis prevention and treatment.
Ionophores represent a class of molecules capable of binding and transporting
protons or other cations across biological membranes (15). With the exception of the
mycobactericidal drug bedaquiline, with recently demonstrated H!/K! ionophoric
activity (16), ionophoric drugs (e.g., monensin, lasalocid, salinomycin, and narasin) are
exclusively used in agriculture (17). Despite the routine use of ionophores in agriculture
for more than 35 years, there is little indication of increasing resistance to these drugs
or of cross-resistance to medically important classes of antimicrobials (17). Developing
novel antimicrobials with ionophoric mechanisms of action for veterinary-only medi-
cine satisfies the requirement for antimicrobials in food-producing animals without
risking crossover with human medicine.
PBT2, a derivative of the 8-hydroxyquinoline (8-HQ) scaffold, has been demonstrated
to act as a zinc and copper ionophore in mammalian cells (18). PBT2 facilitates the
intracellular accumulation of these metals and showed promise as a therapeutic for
targeting the abnormal metallochemistry in Alzheimer’s and Huntington’s diseases (18,
19). In phase II clinical trials, however, efficacy endpoint criteria were not met in
PBT2-treated patients with these neurodegenerative diseases (20–22). Despite this,
extensive preclinical and clinical data demonstrate PBT2 is safe and well tolerated in
humans and in animal (mouse) models (20–22).
In bacterial cells, zinc is an essential micronutrient for normal physiology yet can
mediate significant toxicity in excess (23, 24). The essentiality and toxicity of zinc in
bacterial pathogens has been exploited by host defense mechanisms that starve cells
of zinc, in a concept termed “nutritional immunity” (25, 26), or deliver the metal in
excess toxic quantities (27, 28). Given the vulnerability of bacterial cells to zinc stress
and the safety profile of PBT2 in mammalian hosts, the antimicrobial potential of this
zinc ionophore was recently investigated. Indeed, PBT2 in combination with zinc
(PBT2-zinc) has potent antibacterial activity against multiple Gram-positive pathogens
(29). Antibacterial activity was observed in vitro and in vivo in a murine wound infection
model, highlighting the potential of PBT2 to be repurposed as a topical antimicrobial
in veterinary medicine (29).
While PBT2 was shown to increase cytosolic zinc and disrupt metal ion homeostasis
in bacteria (29), a defined molecular mechanism of killing remained unresolved and is
key to the development of effective next-generation derivatives. In this study, we show
that PBT2 is a Zn2!/H! ionophore and exerts bactericidal activity in S. uberis through
intracellular zinc toxicity, which leads to the accumulation of toxic reactive oxygen
species (ROS) and dysregulates manganese homeostasis, causing cells to become
hypersensitive to oxidative stress. Our work builds on the current knowledge of the
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coordinated relationship between zinc and manganese in bacteria and illustrates how
it can be exploited for antimicrobial potential.
RESULTS
PBT2 and zinc exhibit antibacterial synergy. We examined if the reported anti-
bacterial activity of PBT2 extended to the bovine pathogen S. uberis. A checkerboard
assay was undertaken to determine the MIC and combined inhibitory concentrations
(CICs) of PBT2 and zinc. Both PBT2 and zinc individually displayed antibacterial activity
against S. uberis, with MICs of 5.0 mg/liter (14.5 !M) and 800 !M, respectively (Table S1;
see also Fig. S1 in the supplemental material). Combining PBT2 and zinc dramatically
increased the antibacterial effectiveness of both compounds, with a CIC of 0.5 mg/liter
PBT2 (1.45 !M) in the presence of 10 !M zinc or 0.05 mg/liter PBT2 (0.145 !M) with
100 !M zinc. The fractional inhibitory concentration indexes (FICIs) of 0.113 and 0.135
indicate PBT2 and zinc interact synergistically (FICI " 0.5). A time-dependent cell-killing
assay revealed "3-log10 reductions in CFU/ml of initial inocula following treatment
with the MIC of either PBT2 or zinc, indicating a bactericidal mechanism of action
(Fig. 1A). The observed bactericidal activity of PBT2 alone may be attributable to the
concentration of 23 !M zinc in the growth medium, Todd-Hewitt broth (THB), which
was determined by inductively coupled plasma mass spectrometry (ICP-MS). However,
the extent to which PBT2 mobilizes the bioavailable proportion of medium zinc was not
determined. Remarkably, treatment with the CIC of PBT2 and zinc (PBT2!Zn) was
bactericidal, even at 10-fold and 80-fold lower concentrations of PBT2 and zinc MICs,
respectively (Fig. 1A).
We next sought to compare the ability of S. uberis to develop resistance to PBT2!Zn
and two medically important antibiotics, rifampin and the fluoroquinolone antibiotic
ciprofloxacin, by serial passaging through progressively increasing drug concentrations
over a course of 30 days. While the ciprofloxacin and rifampin MICs increased by 72-fold
and 4,608-fold, respectively, the PBT2!Zn MIC increased by only 4-fold (Fig. 1B).
Because antimicrobial activity can be negatively affected by proteins and lipids
present in milk (30), assessing the antimicrobial efficacy in bovine milk is important for
the development of potential new therapeutics for mastitis prevention or treatment.
We tested the bactericidal efficacy of PBT2!Zn in whole cow’s milk and observed that
PBT2 remained bactericidal against S. uberis (MBCs of 32 mg/liter for PBT2 ! 0 !M Zn,
16 mg/liter for PBT2 ! 200 !M Zn, and 8 mg/liter for PBT2 ! 400 !M Zn).
PBT2-zinc disrupts metal ion homeostasis. ICP-MS analysis was used to determine
the metal ion content of S. uberis cells in response to PBT2 treatment. Consistent with
the ionophore activity of PBT2, a concentration-dependent increase in whole-cell zinc
accumulation was observed in response to increasing concentrations of PBT2 (Fig. 2A).
FIG 1 Bactericidal action and resistance development of PBT2 and zinc against S. uberis. (A) Time-
dependent cell killing of S. uberis in response to MICs of PBT2 and zinc, alone (5.0 mg/liter PBT2, 800 !M
zinc) and in combination (0.5 mg/liter PBT2 ! 10 !M zinc). THB contains a background concentration of
23 !M zinc. Error bars represent the standard deviations of the means from biological triplicates. (B)
Development of resistance to PBT2!Zn compared to that for rifampin and ciprofloxacin. S. uberis was
serially passaged for 30 days in the presence of subinhibitory concentrations of PBT2 (!100 !M Zn),
rifampin, or ciprofloxacin in THB. Data represent the means from two biological replicates.
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While 0.25 mg/liter PBT2 alone had no effect on cellular zinc abundance, in the
presence of zinc (100 !M), cells treated with 0.25 mg/liter PBT2 accumulated "3-fold
more zinc than untreated cells (P # 0.006) (Fig. 2A). Additional PBT2 did not increase
cellular zinc further, with zinc plateauing at a similar level to that in cells treated with
the highest tested concentration of PBT2 alone (1.0 mg/liter) (Fig. 2A). This suggests
zinc accumulated by higher concentrations of PBT2 may exceed tolerated cellular levels
and either induces mechanisms to maintain zinc homeostasis or causes cell death.
Previous evidence in mammalian cell models indicates that PBT2 acts as both a zinc and
copper ionophore (18). However, there were no observable changes in S. uberis copper
levels in response to PBT2 treatment (Fig. 2B). This is likely attributable to the low
concentration of copper (1 !M) in the growth medium relative to that of zinc (23 !M).
We speculate that under our experimental conditions, zinc outcompetes copper for
chelation to PBT2.
Treatment with PBT2 and zinc altered the cellular abundances of manganese and
iron (Fig. 2C and D). Manganese levels decreased by up to 7.5-fold in response to
PBT2-zinc challenge (P # 0.0001) compared to those in untreated cells (Fig. 2C).
Decreased manganese levels were also observed in cells treated with either PBT2 or
zinc alone (Fig. 2C). Exogenous zinc was previously reported to deplete cellular man-
ganese in Streptococcus pneumoniae, causing cells to become hypersensitive to oxida-
tive stress (27, 31). In response to oxidative stress, streptococci restrict cellular iron
levels as a strategy to limit the generation of ROS through iron-mediated Fenton
chemistry (32–34). Similarly, S. uberis treated with either PBT2 (0.5 and 1.0 mg/liter) or
zinc had significantly lower cellular iron than untreated cells (P # 0.0387, 0.0335, and
0.0498, respectively) (Fig. 2D). Collectively, these data suggest that PBT2-mediated zinc
FIG 2 PBT2-zinc alters intracellular metal ion homeostasis. Intracellular zinc (A), copper (B), manganese
(C), and iron (D) concentrations as determined by ICP-MS of mid-log-phase S. uberis NZ01 cells (OD600 of
0.3) treated with various concentrations of PBT2 with or without additional zinc (100 !M) or untreated.
Error bars represent the standard deviations of the means from biological triplicates. *, P $ 0.05; **, P $
0.005; ***, P $ 0.001; ****, P $ 0.0001 by one-way analysis of variance (ANOVA).
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accumulation perturbs normal metal ion homeostasis and may sensitize cells to oxi-
dative stress.
PBT2 exchanges zinc ions for protons. Ionophores are compounds with the ability
to translocate cations, protons, or both and are therefore capable of dissipating either
the membrane potential (∆#) (e.g., valinomycin) or transmembrane pH gradient (∆pH)
(e.g., nigericin) components of the proton motive force (PMF) (15). To examine if the
bactericidal mechanism of PBT2 is explained by dissipation of the PMF, we measured
the ∆# and ∆pH of S. uberis cells in response to PBT2-zinc by using the radioisotopes
[14C]methyltriphenyl phosphonium iodide ([14C]TPP!) and [7-14C]benzoate, respec-
tively. No observable differences in either component of the PMF occurred in response
to treatment with PBT2-zinc at either 1% or 10% the CIC (0.5 mg/liter PBT2 ! 10 !M
zinc) (see Fig. S2).
As we observed an increase in cellular zinc, but no effect on the membrane potential
of whole cells (Fig. S2C), we hypothesized that a counterion (either protons or other
cations) might be moved to make the process electroneutral. To test this, we assessed
the ability of PBT2 to move protons in phosphatidylcholine liposomes loaded with the
non-membrane-permeable and pH-sensitive probe, pyranine (Fig. 3). Pyranine-
containing liposomes have previously been used as a controlled system for measuring
internal pH changes in response to protonophoric or ionophoric drugs (16, 35) where
finite, (electro)chemical gradients are artificially established and used to assess proton
movement across artificial lipid bilayers. Changes in the liposome luminal pH (internal
pH) are detected by measuring the fluorescence of the acidic and basic forms of
pyranine, the ratio of which is dependent on pH (Fig. 3A).
In response to external zinc addition, PBT2 was able to cause a concomitant increase
(alkalization) of the liposome internal pH (Fig. 3B and C and Fig. S3). As PBT2-zinc does
not alter the cell membrane permeability of group A Streptococcus (GAS), vancomycin-
resistant Enterococcus (VRE), or methicillin-resistant Staphylococcus aureus (MRSA) (29),
we attribute this effect to a direct interaction of PBT2 with protons rather than proton
leakage through damaged liposomal membranes. This effect was not observed in the
absence of zinc (see Fig. S4), suggesting it is dependent on the formation of a PBT2-zinc
complex. Using isothermal titration calorimetry (ITC), we confirmed the formation of 2:1
PBT2-Zn complexes, as previously observed (see Fig. S5) (36). Collectively this suggests
PBT2 exchanges zinc for protons in an antiport-like process. Inverting the gradient, by
incorporating zinc inside the liposome during preparation, resulted in a concomitant
internal acidification upon PBT2 addition (Fig. 3C and Fig. S6). This suggests the process
is not direction specific and is driven purely by the Zn2! concentration gradient.
Notably, acidification of the assay buffer to pH 6.5 enhanced this antiport activity up to
7.5-fold, compared to that at pH 8.5 (Fig. 3B and C and Fig. S3). Given the apparent
absence of a biological effect from PBT2-mediated proton translocation, we continued
this work with a focus on the consequences of zinc delivery into cells by PBT2.
PBT2-zinc induces transcriptional changes to metal ion transporter genes. To
further understand the effect of PBT2 and zinc on metal ion homeostasis, changes in
the expression of genes involved in metal ion transport were investigated. Consistent
with the observed changes in metal ion levels, several metal ion transporters were
differentially expressed in response to PBT2-zinc challenge (Fig. 4). S. uberis contains the
ATP-binding cassette (ABC) permease AdcABC, a conserved zinc acquisition system
among streptococci (37). We observed that the zinc-specific solute binding protein
(SBP), adcA (CGZ53_03345), was downregulated 4.5 log2-fold in response to PBT2-
zinc (Fig. 4). Consistent with previous work on cadA homologs demonstrating
function in zinc export, S. uberis cadA (CGZ53_06375) was upregulated 3.7 log2-fold
in response to PBT2-zinc (Fig. 4). In another demonstration of increased zinc export
in response to PBT2-zinc, expression of a putative homolog of the czcD zinc efflux
pump (CGZ53_05790) increased 1.8 log2-fold (Fig. 4).
S. uberis contains a homolog of the S. pneumoniae PsaABC manganese importer,
termed MtuABC, with an established role in manganese uptake (38). Consistent with
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the observed depletion in manganese upon PBT2-zinc treatment (Fig. 2C), transcrip-
tional profiling revealed that mtuA (CGZ53_02610) was strongly downregulated (3.5
log2-fold) in response to PBT2-zinc treatment (Fig. 4). The upregulation of fetB, a
putative iron export ABC transporter permease, following PBT2-zinc treatment, to-
gether with our previous finding of decreased cellular iron in PBT2-zinc treated wild-
type cells (Fig. 4 and 2D), supports the inference that cells must tightly regulate iron to
avoid iron toxicity under conditions where antioxidative mechanisms are compromised.
PBT2-mediated zinc toxicity sensitizes cells to killing by ROS. If excess zinc in S.
uberis exerts toxicity through manganese starvation, as previously observed in S.
pneumoniae (27), then supplementing cells with manganese should rescue the ob-
served lethality associated with PBT2-zinc treatment. We found cultures pretreated with
manganese (800 !M) were completely protected against cell killing by PBT2, zinc, and




































































FIG 3 PBT2 is a Zn2!/H! ionophore. (A) Schematic for measuring internal pH using pyranine-containing
liposomes: pyranine is a non-membrane-permeable pH indicator where the ratio of the acidic to basic
forms of pyranine is pH dependent. Excitation of acidic ($ex 405 nm) and basic ($ex 455 nm) pyranine
generates detectable fluorescence ($em 510 nm). The internal pH of liposomes equilibrates over time with
the external pH, and internal pH can be determined using a standard curve of pH to pyranine
fluorescence ratios. In these experiments, pyranine fluorescence was measured and internal pH was
determined after addition of PBT2 and/or zinc to liposomes from a 15-min endpoint. Changes to internal
pH by PBT2-zinc were normalized for the effect of external zinc (10&3 M) alone. (B) Changes in internal
pH of pyranine-containing liposomes with matching internal and external pH values following addition
of PBT2 (10&6 M) in combination with zinc (10&3 M). (C) Relative changes in internal pHs of liposomes
suspended in Mes-Mops-Tris buffer (pH indicated) containing PBT2 (10&6, 10&7, or 10&8 M), where zinc
(10&3 M) is either external to liposomes (plain bars) or internal (striped bars). Error bars represent the
standard deviations from triplicate measurements.
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Manganese has prominent roles in oxidative stress protection in biological systems,
from serving as a cofactor for manganese-dependent superoxide dismutase to forming
ROS-scavenging Mn-organic acid complexes (39–41). As in related streptococcal species
(31, 33), S. uberis relies solely on a manganese-dependent superoxide dismutase (SodA)
for the conversion of accumulated O2·& to H2O2 and O2. To determine if oxidative stress
contributes to the lethality of PBT2 and zinc, we tested whether an antioxidant could
FIG 4 PBT2-zinc alters the expression of metal ion transport genes. Relative expression of selected genes
in mid-log-phase S. uberis cells (OD600 of 0.3) after 1 h of treatment with or without PBT2 (1.0 mg/liter)
and zinc (100 !M), individually or in combination. Relative expression (expressed as log2-fold change)
was calculated relative to the untreated control and normalized to the reference gene (pflC) using the
''CT method. Error bars represent the standard deviations of the means from biological triplicates.
FIG 5 Manganese and reduced glutathione (GSH) protect against PBT2-zinc killing. Pretreatment of S. uberis cells (OD600 of
0.05) with manganese or GSH before the addition of PBT2 (A), zinc (B), or PBT2!Zn (C) at respective MICs and CICs prevents
cell killing. Error bars represent the standard deviations of the mean from biological triplicates.
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prevent cell killing. Pretreatment with reduced glutathione (GSH) (50 mM) added
extracellularly, an antioxidant capable of neutralizing ROS in bacteria (42), provided
protection against the bactericidal action of PBT2 and zinc (Fig. 5A to C). Because zinc
is able to bind to the sulfhydryl group of the GSH cysteine moiety and form GSH-Zn
complexes (43), which may explain the observed protective effect of GSH, we under-
took further experimentation to clarify the role of oxidative stress in the PBT2-zinc
bactericidal mechanism.
We hypothesized that by depleting intracellular manganese, PBT2-zinc would inhibit
SodA enzyme activity. As anticipated, cultures treated with PBT2-zinc showed a 2.7-fold
reduction in SodA activity compared to that in untreated cells (P # 0.0156) (Fig. 6A).
Treatment with PBT2 alone reduced SodA activity by 2.6-fold (P # 0.0179), but zinc
alone had no effect (Fig. 6A). Transcriptional profiling of sodA revealed no changes in
expression following PBT2, zinc, or PBT2-zinc treatment, suggesting PBT2 does not
interfere with normal sodA regulation (see Fig. S7). Provision of excess exogenous
manganese significantly increased the SodA activity (P # 0.0041), and when in com-
bination with PBT2-zinc, manganese partially restored SodA function (P # 0.0345)
(Fig. 6A).
To examine if ROS accumulate as a consequence of PBT2-mediated zinc toxicity and
manganese starvation, we specifically measured the production of H2O2. We found that
PBT2 or zinc alone had no effect on H2O2 levels compared to that in untreated cells
(Fig. 6B). However, cells treated with PBT2-zinc showed increased H2O2 (P # 0.0380)
(Fig. 6B). S. uberis harbors an alkyl hydroperoxidase (ahpC and ahpF) for the detoxifi-
cation of H2O2, yet no changes in expression of either ahpC or ahpF were observed in
response to PBT2-zinc (Fig. S7). As a critical test of the hypothesis that manganese
abolishes PBT2-zinc lethality by restoring antioxidant function, we examined the effect
of manganese on H2O2 production. The addition of exogenous manganese to PBT2-
zinc-treated cells dramatically increased detectable H2O2 (P # 0.0001) (Fig. 6B). This
finding supports the notion that providing excess manganese enables the sole super-
oxide dismutase, the manganese-dependent SodA, to convert accumulated O2·& to
H2O2 and O2, ultimately increasing detectable H2O2. Treatment with manganese alone
also demonstrated an increase in H2O2, although this was not statistically significant
(P # 0.4742) (Fig. 6B). This supports an increased rate of O2·& turnover through SodA
by provision of excess amounts of the manganese cofactor.
FIG 6 PBT2-zinc impairs SodA activity and generates ROS. (A) Superoxide dismutase (SOD) activity
of mid-log-phase S. uberis cells (OD600 of 0.3) treated with PBT2 (1.0 mg/liter), zinc (100 !M), or
manganese (800 !M), individually or in combination. Cell lysates were analyzed for SOD activity and
normalized for total protein. (B) H2O2 generation of mid-log-phase S. uberis cells (OD600 of 0.3)
treated with PBT2 (1.0 mg/liter), zinc (100 !M), or manganese (800 !M), individually or in combina-
tion, as detected by Amplex Red fluorescence (560 $ex, 590 $em). Untreated and H2O2-treated
controls are included for comparison. Error bars represent the standard deviations of the means from
biological triplicates. ns, P " 0.05; *, P $ 0.05; **, P $ 0.005; ***, P $ 0.001; ****, P $ 0.0001 by
one-way ANOVA.
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In this work, we show that the bactericidal mechanism of PBT2 is mediated by
intracellular zinc toxicity, which disrupts manganese homeostasis and leads to the
accumulation of toxic ROS. In this global bactericidal mechanism of action, S. uberis was
unable to generate significant resistance to PBT2!Zn in comparison to the single-
target antibiotics ciprofloxacin (44) and rifampin (45). In addition, this work provides a
molecular mechanism for PBT2 ionophoric activity in bacterial cells, whereby PBT2
translocates across the bacterial cell membrane acting as a Zn2!/H! ionophore. The
absence of an effect on the membrane potential indicates PBT2 functions as an
electroneutral ionophore, in support of an exchange of one Zn2! ion for two H! ions.
While there was a pronounced alkalization of pyranine-containing liposomes from
PBT2-mediated proton translocation, no changes in internal pH were found in whole
cells. Bacterial cells employ multiple homeostatic mechanisms to maintain intracellular
pH in a narrow tolerable range (46), and such regulatory mechanisms likely protect cells
from intracellular pH alterations by PBT2.
We observed an enhancement of PBT2 ionophoric activity at lower pH, suggesting
that protonation of PBT2 is required for efficient zinc transport. A detailed structural
analysis by Nguyen et al. (36) has revealed zinc chelation by PBT2 occurs through the
pyridine nitrogen and deprotonated phenoxide. Protonation of the PBT2-zinc complex
at low pH may therefore promote the release of zinc according to the membrane
potential and zinc concentration gradient. Given that cytosolic “free” zinc in bacterial
cells is in the picomolar to nanomolar range (47) and PBT2 binds zinc with an affinity
of (2 !M, it is unlikely PBT2 is capable of moving zinc ions out of bacterial cells.
Collectively, these data, along with the finding of PBT2-mediated zinc accumulation,
provide a novel molecular model for PBT2 ionophoric activity in which PBT2 exchanges
extracellular zinc for intracellular protons in an electroneutral process (Fig. 7).
Similar to previous work investigating zinc toxicity in S. pneumoniae (27, 31, 48), we
show exogenous zinc significantly depletes cellular manganese in S. uberis. Consis-
tently, addition of manganese (800 !M) protects against zinc toxicity. In these previous
studies, the proposed mechanism of zinc-mediated manganese starvation is through
zinc competitively binding to the extracellular PsaA, the manganese SBP of the PsaABC
manganese importer, thereby limiting manganese uptake. Given the identical compo-
sitions of the metal-binding sites in the S. uberis PsaA homolog (MtuA) and S. pneu-
moniae PsaA (38), zinc may similarly impede manganese import in S. uberis by mis-
metallation of MtuA. While this may be the case under conditions of excess exogenous
zinc, manganese depletion occurred concomitantly with PBT2-mediated intracellular
zinc accumulation. This indicates the existence of an alternative mechanism whereby
intracellular zinc intoxication interferes with normal manganese homeostasis. The
depletion of mtuA transcripts following PBT2-zinc treatment indicates excess intracel-
lular zinc dysregulates mtuA expression, thereby preventing manganese import. Con-
sistently, Bohlmann et al. (29) found that expression of the GAS mtuA homolog (mtsA)
is reduced 2.3 log2-fold in response to PBT2-zinc. The molecular target of this zinc
mismetallation was not identified in our study; however, mismetallation of metallo-
regulators, which sense specific metal ions and modulate transcription of regulated
genes in accordance with physiological needs, was previously observed under condi-
tions of cytosolic metal intoxication (49). In Bacillus subtilis, intracellular zinc intoxication
leads to mismetallation of the peroxide response regulator PerR, which, when bound to
zinc, cannot repress heme biosynthesis and consequently leads to toxic heme accu-
mulation (50). Similarly, under conditions of manganese intoxication, the ferric uptake
regulator Fur is mismetallated with manganese and inappropriately represses iron
uptake (51).
Given that exogenous zinc (100 !M) does not affect intracellular zinc content nor
SodA activity yet depletes manganese to similar levels as PBT2 alone, PBT2-mediated
zinc accumulation may inhibit SodA function through zinc mismetallation. Reduced
SodA activity as a result of the zinc ionophoric activity of PBT2 may therefore result
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from a combination of depletion of the essential manganese cofactor and mismetal-
lation of SodA with zinc. Mismetallation of the GAS SodA with iron reduces the enzyme
activity (33); however, investigations into the functionality of the Zn-SodA enzyme are
lacking.
The accumulation of H2O2 in PBT2-zinc-treated cells indicates a bactericidal mech-
anism whereby intracellular zinc intoxication leads to the generation of ROS, in addition
to impairing the ability to manage oxidative stress. Zinc lacks biological redox activity
but may perturb the intracellular redox status indirectly through protein mismetallation
and inactivation. Indeed, heme accumulation following zinc mismetallation of PerR
causes toxic superoxide generation as a result of redox cycling between heme and
menaquinone (50). Because the provision of manganese to PBT2-zinc-treated cells
increased cellular H2O2, we infer that intracellular zinc intoxication accumulates O2·& in
addition to H2O2. In addition to providing protection against O2·&, manganese can
catalytically scavenge H2O2 and replace iron in the active sites of iron-containing
enzymes, thereby preventing iron oxidation by H2O2 and subsequent protein inactiva-
tion (52, 53). Our data suggest that providing sufficient manganese restores the activity
of Mn-SodA and nonenzymatic manganese-based antioxidants that scavenge ROS,
thereby reestablishing redox balance under conditions of zinc toxicity.
We propose a model for the bactericidal mechanism of action of the zinc ionophore
PBT2 (Fig. 7): PBT2 binds extracellular zinc as a complex and dissociates in the
cytoplasm, releasing zinc in exchange for intracellular protons in an electroneutral
process that leads to cellular zinc accumulation. Excess intracellular zinc perturbs
normal metal ion homeostasis and dysregulates the expression of mtuABC, causing
manganese depletion. Zinc intoxication additionally disrupts the intracellular redox
FIG 7 Proposed bactericidal model of action of PBT2. PBT2 has Zn2!/H! ionophore activity and
mediates intracellular zinc accumulation by exchanging extracellular Zn2! for intracellular 2H! in an
electroneutral process. Excess zinc leads to ROS accumulation and additionally dysregulates manganese
homeostasis by inappropriately downregulating expression of the MtuABC manganese import system.
The resulting cellular manganese depletion predisposes cells to oxidative stress by limiting manganese-
dependent antioxidant activity. The manganese-dependent SodA may be inhibited by two mechanisms:
depletion of the essential manganese cofactor and zinc mismetallation. Cell death results when ROS
accumulate beyond a tolerable threshold and induce excessive oxidative damage to essential cellular
proteins and genomic DNA.
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balance and ROS accumulate. Antioxidant activity is compromised under these
manganese-starved conditions, leaving the cell vulnerable to toxic O2·& and H2O2.
Ferrous iron (Fe2!) may potentiate this oxidative stress by reacting with H2O2 in the
Fenton reaction, generating damaging hydroxyl radicals (·OH). Extensive oxidative
damage to DNA by ·OH and to cellular proteins by O2·& and H2O2 (54) ultimately proves
lethal to the bacterial cell.
Here, we have demonstrated the original intended ability of PBT2 in altering the
metallochemistry in Alzheimer’s and Huntington’s diseases can be used to destabilize
metal ion and redox homeostasis in S. uberis, sensitizing cells to oxidative stress in a
global bactericidal mechanism. Given the essentiality of manganese acquisition for S.
uberis to infect the bovine mammary gland (38) and the observed bactericidal activity
of PBT2 in bovine milk, the therapeutic potential of PBT2 as an antimicrobial for mastitis
prevention or treatment is promising. Indeed, the importance of manganese for
virulence extends to other pathogens, including S. pneumoniae, GAS, Staphylococcus
aureus, and Bacillus anthracis (27, 55–57). PBT2 represents a new class of antibacterial
capable of targeting bacterial metal ion homeostasis, and through understanding the
molecular basis of zinc ionophoric toxicity, this work serves as a platform for designing
future lead compounds with potential for veterinary-only medicine.
MATERIALS AND METHODS
Bacterial strain and growth conditions. Streptococcus uberis strain NZ01 (58) was isolated from a
clinical bovine mastitis case in the Manawatu-Wanganui region of New Zealand. S. uberis NZ01 was
grown in Todd-Hewitt broth (THB) (Sigma-Aldrich) or on THB agar (THA) containing 1.5% (wt/vol) agar
for all experiments. Bacteria were routinely grown at 37°C with agitation (200 rpm). All inoculations were
performed from overnight cultures (16 h) to a final optical density at 600 nm (OD600) of 0.05.
Chemical and radiochemical reagents. PBT2 was synthesized as described previously (29). All
stocks of PBT2 (2 mg/ml) were prepared in 100% dimethyl sulfoxide (DMSO) unless otherwise stated.
ZnSO4·7H2O (zinc) and MnSO4·H2O (manganese) stocks were prepared in filter-sterilized distilled water
(dH2O). The following radiochemicals were obtained from Moravek Inc.: [7-14C]benzoate (54.1 mCi/
mmol), [14C]methyltriphenyl phosphonium iodide (TPP!) (57 mCi/mmol), [14C]polyethylene glycol 4000
(PEG), and [3H]water (1 mCi/g).
Determination of cell growth inhibition. The antibacterial activities of PBT2 and zinc, both alone
and in combination, were assessed with a checkerboard broth microdilution assay. Various concentration
combinations of PBT2 (0 to 10 mg/liter [0 to 29 !M]) and zinc (0 to 800 !M) were arrayed in a 96-well
flat-bottom microtiter plate and resuspended in THB inoculated with S. uberis NZ01 (OD600 of 0.05) at a
final volume of 200 !l. After 24 h of incubation, cell growth (OD600) was determined by a Varioskan Flash
microplate reader (Thermo Scientific). The PBT2 and zinc MIC and CIC were determined as the lowest
concentrations that showed no visible growth. The interaction effects were derived from calculation of
the FICI, the sum of the FIC for each compound, which is in turn defined as the quotient of the MIC of
the inhibitor in combination (CIC) and the MIC of the inhibitor alone, as follows (59):
FICI % FICPBT2 & FICZn % ! CICPBT2MICPBT2" & ! CICZnMICZn" .
FICI analysis was interpreted according to threshold values described previously (60), whereby
synergism between two inhibitors is regarded at an FICI of " 0.5, antagonism at an FICI of ' 4.0, and no
interaction at an FICI between 0.5 and 4.0. Checkerboard assays were undertaken in biological triplicates.
For susceptibility testing of PBT2 in bovine milk, overnight cultures of S. uberis NZ01 were harvested
by centrifugation and washed twice in phosphate-buffered saline (PBS) (3,220 % g for 10 min at 4°C)
before inoculation into pasteurized whole-fat (3.8%) cow milk at an OD600 of 0.1. S. uberis cells were then
inoculated 1:2 into milk containing 2-fold serial dilutions of PBT2 with various concentrations of Zn in a
96-well flat-bottom microtiter plate. After a 24-h incubation at 37°C, 10-!l aliquots were spot plated on
THA plates according to the Miles-Misra drop plate method (61). Bactericidal activity was examined after
24 h of incubation at 37°C, in which a "3-log10 reduction in CFU/ml was determined as bactericidal. As
a measure of sterility, the absence of CFU in uninoculated milk was verified by plating on THA.
Bacterial time-dependent cell killing assays. S. uberis NZ01 was inoculated at an OD600 of 0.05 in
THB only, THB containing the MIC of PBT2 (5.0 mg/liter) or zinc (800 !M), or THB containing a CIC of PBT2
and zinc (0.5 mg/liter PBT2 and 10 !M zinc) in biological triplicates. Aliquots of cultures were taken at 0,
2, 4, 6, and 24 h postchallenge, serially diluted in 1% phosphate-buffered saline (PBS), and spot plated
on THA plates. The surviving CFU/ml of cultures was determined after a 24-h incubation at 37°C.
Examination of resistance development. Serial passaging experiments to generate resistance to
PBT2!Zn/antibiotics were undertaken as described in Bohlmann et al. (29). Broth (THB) 2-fold microdi-
lution assays of PBT2 in the presence of 100 !M Zn, ciprofloxacin, and rifampin were first set up in a
96-well flat-bottom microtiter plate with an initial inoculum of S. uberis NZ01 at an OD600 of 0.05. Cells
from the highest PBT2!Zn or antibiotic concentrations that showed growth after 24 h of incubation
were subcultured in a new microtiter plate with 2-fold dilutions of PBT2!Zn or antibiotics. Serial
passaging was repeated for 30 days in biological duplicates.
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Inductively coupled plasma mass spectrometry. Overnight cultures of S. uberis were diluted to an
OD600 of 0.05 in THB and grown to mid-log phase (OD600 of 0.3). Aliquots (45 ml) of mid-log-phase cells
were separated into individual flasks and challenged for 1 h with PBT2 (0.25, 0.5, or 1.0 mg/liter) with or
without zinc (100 !M) or untreated. Samples were prepared for ICP-MS analysis according to the protocol
used by Bohlmann et al. (29). The metal contents of samples were determined using an Agilent 7500ce
ICP-MS (Centre for Trace Element Analysis, Department of Chemistry, University of Otago). Three
biological replicates were analyzed. For analysis of THB, a 2-ml aliquot of the medium was sent for
analysis.
Metal ion concentrations (milligrams/liter) of samples were converted to molar units, whereby the
intracellular metal ion concentrations of bacterial samples were calculated from the S. uberis NZ01
protein content (111 mg protein/OD600/liter) and internal cell volume (3.76 ) 0.78 !l/mg protein).
Protein content was determined by a bicinchoninic acid (BCA) assay, and the internal cell volume was
estimated from the difference between the intracellular and extracellular partitioning of 3H2O and the
nonmetabolizable [14C]PEG, as in a previously described method (62).
Transmembrane pH and membrane potential measurements. Overnight cultures of S. uberis were
diluted to an OD600 of 0.1 in THB (50 ml) at pH 7.5 and grown to an OD600 between 0.5 and 1.0. For ∆pH
experiments, cells were harvested by centrifugation (3,220 % g for 20 min at 4°C), washed twice in THB
(pH 5.0), and resuspended to an OD600 of 1.0. For ∆* experiments, cells were harvested under the same
centrifugation conditions and then resuspended to an OD600 of 1.0 in THB (pH 7.5). In both experiments,
cultures were then energized by incubating with glucose (20 mM) for 1 h at 37°C and 200 rpm. Aliquots
of energized cells were either untreated or treated with membrane-permeabilizing toluene (0.4%
[vol/vol]) or PBT2!Zn at 1% or 10% the CIC (0.5 mg/liter PBT2 ! 10 !M zinc) for a further 20 min (37°C,
200 rpm). Following this, 1-ml aliquots were incubated in glass tubes with either [7-14C]benzoate (11 !M
final concentration) or [14C]TPP! (5 nM final concentration) for 5 min at 37°C. Radioisotope measure-
ments and calculations of the ∆pH and ∆* were performed as previously described (62). Assays were
undertaken in biological triplicates.
Preparation of pyranine-containing liposomes. Pyranine-containing liposomes were prepared
according to the previously described method by Hards et al. (16). Liposomes were prepared in an
incorporation buffer (5 mM MES [morpholineethanesulfonic acid]-MOPS [morpholinepropanesulfonic
acid]-Tris in required proportions for desired pH) with or without zinc sulfate (1 mM).
Quantification of internal pH by pyranine fluorescence. The internal pH of liposomes was
measured as previously described (16). A standard curve of the pyranine fluorescence ratio to pH was
determined for each incorporation buffer, in the presence of 0.5 !M pyranine, at known pH values.
Kinetic traces were measured on a Varioskan Flash plate reader (Thermo Scientific), and data were
presented from the 15-min endpoint measurements. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP;
1 !M) equilibrated the internal pH of liposome preparations with the external pH (Fig. S8), confirming the
responsiveness of our preparations to pH gradients.
Isothermal titration calorimetry. ITC (isothermal titration calorimetry) experiments were performed
at 30°C with continuous stirring using a VP-ITC (GE Healthcare). ZnSO4·7H2O (zinc) and PBT2 were
dissolved in 100 mM MOPS-Tris buffer (pH 7.7, 1% DMSO). The zinc sample (0.3 mM) was injected
(30 % 10 !l) into PBT2 (0.035 mM), and the data were analyzed using Origin 7 software and fitted to a
single site-binding model.
RNA extraction and real-time PCR. Biological triplicates of S. uberis NZ01 cells were grown to
mid-log phase (OD600 of 0.3) in THB (45 ml) and treated for 1 h with either PBT2 (1.0 mg/liter), zinc
(100 !M), PBT2 and zinc combined, or untreated. Total RNA was isolated using TRIzol-chloroform
extraction as described previously (63) and purified using the RNA clean and concentrator-5 extraction
kit (ZYMO research). Following elution of RNA into DNase/RNase-free H2O, RNA was DNase treated using
the TURBO DNA-free kit (Invitrogen) according to the manufacturer’s instructions, and RNA was quan-
tified on a NanoDrop instrument (Thermo Scientific).
cDNA for each sample was synthesized using a SuperScript III reverse transcriptase kit (Invitrogen).
Primers used for quantitative PCR (qPCR) were designed on Primer-BLAST and are detailed in Table S2
in the supplemental material. Primer optimization and efficiency assays were performed, and qPCR
experiments were conducted in a ViiA7 real-time PCR system (Applied Biosystems) using the PowerUp
SYBR green master mix (Applied Biosystems) according to the manufacturer’s instructions. Results were
normalized to the gene pflC using the threshold cycle (∆∆CT) method (64).
SOD activity assays. Overnight cultures were inoculated to an OD600 of 0.05 in THB and grown to
an OD600 of 0.3. Cultures were split into 50-ml aliquots and treated for 1 h with PBT2 (1.0 mg/liter), zinc
(100 !M), or manganese (800 !M), individually or in combination, or were untreated. Cultures were then
harvested by centrifugation (3,220 % g for 10 min at 4°C), washed with HEPES buffer (50 mM, pH 7.4),
resuspended in 1 ml of HEPES buffer, and lysed mechanically by bead beating three times (48,000 rpm,
30 s). Lysates were centrifuged (17,000 % g, 2 min, 4°C) and assayed for SOD activity using a SOD assay
kit (Invitrogen) according to the manufacturer’s instructions. Protein concentrations in the lysates were
determined by a BCA assay, and SOD activity was normalized for total protein content.
H2O2 measurement. H2O2 was measured using the Amplex Red hydrogen peroxide/peroxidase
assay kit (Invitrogen) according to the manufacturer’s instructions. An overnight culture of S. uberis cells
was diluted to an OD600 of 0.05 in THB and grown to mid-log phase (OD600 of 0.3). Mid-log-phase cells
were separated into aliquots (10 ml) and were treated for 1 h with PBT2 (1.0 mg/liter), zinc (100 !M), or
manganese (800 !M), individually or in combination, H2O2 (1 mM), or untreated. Cells were then
harvested by centrifugation (3,220 % g for 7 min at 4°C). Cell pellets were washed twice in PBS under the
same centrifugation conditions and resuspended in 1% reaction buffer at an OD600 of (3.5. For analysis,
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samples were diluted to an OD600 of (0.4 in 1% reaction buffer and Amplex Red reagent/horseradish
peroxidase (HRP) working solution in a black-walled, clear-bottomed 96-well microplate. Amplex Red
fluorescence was then measured using a Varioskan Flash microplate reader at excitation and emission
wavelengths ($ex and $em) of 560 and 590 nm, respectively.
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A B S T R A C T
A series of substituted sulfonamide bioisosteres of 8-hydroxyquinoline were evaluated for their antibacterial
activity against the common mastitis causative pathogens Streptococcus uberis, Staphylococcus aureus and
Escherichia coli, both in the presence and absence of supplementary zinc. Compounds 9a-e, 10a-c, 11a-e, 12 and
13 were demonstrated to have MICs of 0.0625 µg/mL against S. uberis in the presence of 50 µM ZnSO4. Against S.
aureus compounds 9g (MIC 4 µg/mL) and 11d (MIC 8 µg/mL) showed the greatest activity, whereas all com-
pounds were found to be inactive against E. coli (MIC > 256 µg/mL); again in the presence of 50 µM ZnSO4. All
compounds were demonstrated to be significantly less active in the absence of supplementary zinc. Compound
9g was subsequently confirmed to be bactericidal, with an MBC (≥3log10 cfu/mL reduction) of 0.125 µg/mL
against S. uberis in the presence of 50 µM ZnSO4. To validate the sanitising activity of compound 9g in the
presence of supplementary zinc, a quantitative suspension disinfection (sanitizer) test was performed. In this
preliminary test, sanitizing activity (> 5log10 reduction of CFU/mL in 5 min) was observed against S. uberis for
compound 9g at concentrations as low as 1 mg/mL, validating the potential of this compound to function as a
topical sanitizer against the major environmental mastitis-causing microorganism S. uberis.
Despite the discovery and evolution of several classes of antibiotics
over the last 100 years, bacterial resistance remains a globally re-
cognized problem to which there are presently few solutions.1 Though
bacterial resistance can be considered a natural process, the widespread
use, and in many instances misuse, of antibiotics in livestock farming
has artificially driven a rise in resistant strains, heightening the like-
lihood of antibiotic-resistant bacteria of animal origin ultimately in-
fecting humans.2 Bovine mastitis, an inflammatory response to a bac-
terial infection of the udder, is the most significant production limiting
disease for dairying worldwide. Not only is it a disease of vast economic
importance, but also one with conceivable implications for public
health. Bovine mastitis is recognized as the single most common reason
for antibiotic use within the dairy industry. Preventative teat sprays
containing sanitizers such as chlorhexidine and iodine are considered
important tools in the management of bovine mastitis. However, both
chlorhexidine and iodine are considered equally valuable in the control
of infectious diseases in humans, and as such are listed on the World
Health Organization’s model list of essential medicines.
8-Hydroxyquinoline3–5 (8-HQ, 1, Fig. 1) has been utilized as a
scaffold in the design of a number of drug candidates with wide-ranging
applications such as neuroprotection,6–9 anticancer,10,11 antiviral,12
antimalarial,13 antifungal14 and antibacterial.15–17 It is known that 8-
HQ and its derivatives can act as both mono and bidentate metal che-
lators (coordination involves participation of both the endocyclic qui-
noline nitrogen and the exocyclic phenolate oxygen as donor
atoms).18,19 8-HQs have been reported to form metal–ligand complexes
with most of the divalent transition metal ions including Mn2+, Co2+,
Ni2+, Cu2+ and Zn2+, with a known preference for copper(II) and zinc
(II).20,21 The biological mode of action of 8-HQ has been studied ex-
tensively and it has been shown that the participation of a metal is
https://doi.org/10.1016/j.bmcl.2020.127110
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essential for effective antibacterial activity.22 Examples of halogenated
8-HQs include 5-chloro-7-iodo-8-quinolinol (clioquinol, CQ, 2, Fig. 1),
5,7-diiodo-8-quinolinol, 5,7-dibromo-8-quinolinol, 5,7-dichloro-2-me-
thyl-8-quinolinol and 5-chloro-8-quinolinol, many of which have been
developed as topical antiseptics.23 More recently CQ, along with later-
generation halogenated 8-HQs such as PBT2 (3, Fig. 1), have been
utilized in the treatment of non-infectious pathologies such as Alzhei-
mer's disease,7 Parkinson's disease,24 Huntington's disease8 and
cancer.10,11 More pertinent to this study, it has recently been shown
that PBT2 can reverse antibiotic resistance in the presence of zinc.25
While the precise mode(s) of action of CQ and PBT2 have yet to be fully
clarified, postulated mechanisms to date suggest that these molecules
could be functioning as metal ionophores,26–28 As lipid-soluble che-
mical entities with the capacity to reversibly bind and transport metal
ions across cell membranes, metal ionophores have been used as growth
promotants in livestock farming for decades (e.g. monensin, an animal
feed additive used to improve weight gain in beef cattle).29,30 Current
evidence suggests that the use of metal ionophores as antibacterials
would be unlikely to contribute towards the spread of antibiotic re-
sistance in humans on the basis that they exploit a distinct mode of
action not currently utilized in human medicine. Zinc homeostasis is
recognized as being critical for bacterial survival, with excessive cel-
lular zinc accumulation leading to zinc intoxication.31,32 As such, zinc-
based therapies could offer an attractive means of controlling bovine
mastitis. In the search for antibacterials designed to be used exclusively
as animal therapeutics, we herein report a series of zinc-dependent 8-
sulfonamidoquinoline derivatives as bioisosteric structural analogues of
8-hydroxyquinoline (i.e. the phenol group of the 8-HQ motif has been
interchanged for a sulfonamide moiety).
Compounds 9–4533 were accessed through the reaction of 8-ami-
noquinoline 8 with the corresponding sulfonyl chloride (Scheme 1). 8-
Aminoquinoline 8 was prepared over four steps from commercially
available 2-methyl-8-aminoquinoline (4) via sequential protection (to
give tert-butyl carbamate 5), oxidation (using selenium dioxide to give
aldehyde 6), reductive amination (using dimethylamine hydrochloride
and sodium triacetoxyborohydride in the presence of N,N-diisopropy-
lethylamine to give protected 8-aminoquinoline 7) and lastly, depro-
tection (using trifluoroacetic acid) (Scheme 1). Phenols 9x and 10l were
prepared through the O-demethylation of methyl ethers 9m and 10g,
respectively (using boron tribromide) (Scheme 2). Compounds 9y and
45 were prepared through the deprotection of tert-butyl carbamates 9j
and 45a (see supplementary material for compound 45a), respectively
(again using trifluoroacetic acid) (Scheme 2). Finally, nitro-substituted
benzenesulfonamide 10h was reduced (catalytic hydrogenation) to af-
ford aniline 10n (Scheme 2).
Numerous experimental methods exist to measure the lipophilicity
of molecules. The classical shake-flask procedure34 is a long-established
technique used to determine the partition (log P) or distribution (log D)
coefficients of prospective drug candidates, yet it can be both time and
labor intensive when working with larger numbers of compounds. More
recently, modern day techniques such as HPLC have been developed as
alternative, high-throughput, indirect methods of determining lipo-
philicity.35 Within this study compound lipophilicity was experimen-
tally determined using two protocols (Tables 1–4). For ionizable mo-
lecules such as 8-sulfonamidoquinolines, where a compound is likely to
exist as a variety of species at a given pH, log D is generally perceived as
the better descriptor for lipophilicity; since it is a measure of the pH-
dependent differential solubility of all species present. Accordingly, a
shake-flask method (using 1-octanol/aqueous phosphate buffer, pH 7.8)
was employed to determine the distribution coefficient (log D7.8) for a
select number of compounds (experiments were carried out at pH 7.8
on account of this being the pH of the Todd Hewitt broth in which
antibacterial activity against S. aureus was originally determined).
Secondly, to measure the contribution of the sulfonamide substituent
on overall compound lipophilicity, independent of its influence on
sulfonamide ionization, a series of HPLC experiments were commis-
sioned to generate accompanying retention factor data (k′); such ex-
periments were conducted at low pH to ensure that all ionizable moi-
eties within the molecule were ‘standardized’. Acid-dissociation
constants (pKa(NH)) for the sulfonamide group were experimentally
determined for a select number of compounds in an endeavour to ‘va-
lidate’ in silico derived pKa(NH) values (Table 1). In silico derived log P/D
and pKa(NH) values were generated using ACD labs version 12 (Tables
1–4).
Despite over 100 different microorganisms having been identified as
potential causative agents of bovine mastitis, only a few species are
considered to be of economic or epidemiological importance.36 Of
these, the most significant include contagious Gram-positive pathogens
such as Staphylococcus aureus (S. aureus), and environmental Gram-
Fig. 1. Known examples of 8-hydroxyquinolines exhibiting antibacterial ac-
tivity.
Scheme 1. Reagents and conditions: (a) Boc2O, 1,4-dioxane, 90 °C, 48 h, 76%; (b) SeO2, 1,4-dioxane, 85 °C, 18 h, 74%; (c) Me2NH.HCl, NaBH(OAc)3, DIPEA, 1,2-
DCE, RT, 18 h, 86%; (d) TFA, DCM, RT, 3 h, 47%; (e) RSO2Cl, Et3N, DCM, RT, 18 h (see Tables 1–4 for yields).
Scheme 2. Reagents and conditions: (a) BBr3, DCM, RT, 2 h; or (b) TFA, DCM,
RT, 3 h; or (c) H2, Pd-C, MeOH, RT, 18 h.
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positive and Gram-negative pathogens such as Streptococcus uberis (S.
uberis) and Escherichia coli (E. coli), respectively.37 Environmental pa-
thogens can be found in soil, animal housing, feedstuffs and standing
water, and as such cannot be eliminated from the herd as they form part
of the natural surroundings in which dairy cattle live. These pathogens
are able to survive outside the udder, and can often be found on the
skin. Contagious pathogens generally live within the udder or teat skin,
and can be transmitted from cow to cow, particularly at milking. Major
regional variations in the prevalence and distribution of mastitis cau-
sative pathogens exists. In New Zealand, the most common mastitis
causative pathogens are S. uberis and S. aureus.
The antibacterial activities of compounds 9–45 were subsequently
evaluated against S. uberis, S. aureus and E. coli, in both the presence
and absence of supplementary zinc salts; independently, all three
mastitis-causative pathogens were previously shown to be highly tol-
erant to supplementary zinc salts (ZnSO4), with the minimum in-
hibitory concentrations (MIC) ranging from 800 to 1600 μM for S.
uberis, through to 6400 μM for E. coli. The antibacterial activities
(MIC)38 of compounds 9–45 against S. uberis strain ATCC 19436 in the
presence of 50 µM ZnSO4 are reported in Tables 1–4; a concentration of
50 µM ZnSO4 (a level at which zinc will be present in significant excess
to compound) was adopted on the basis that it has no observed effect on
the growth of any of the target pathogens. Within the 4-substituted
benzenesulfonamide series (Table 1), compounds 9a (R = Cl), 9b (Br),
9c (tBu), 9d (OCF3) and 9e (SMe) were revealed to be among the most
active (MIC 0.0625 µg/mL). These were closely followed by 9f (F), 9g
(CF3), 9h (OCHF2), 9i (SCF3) and 9j (NHCO2tBu), with MICs a single
dilution higher at 0.125 µg/mL. Conversely, 9t (SO2Me), 9u (CONH2),
9v (SO2NH2), 9w (NHCOMe), 9x (OH) and 9y (NH2) were demon-
strated to be significantly less active, with MICs of 4, 8, 16, 32, ≥256
and ≥256 µg/mL, respectively. Within the 3-substituted benzene-
sulfonamide series (Table 2) similar trends were observed, with com-
pounds 10a (R = Cl), 10b (CF3) and 10c (OCF3) being found to be
among the most active, with MICs of 0.0625 µg/mL, followed by 10d
(F) and 10e (Br), with MICs a single dilution higher at 0.125 µg/mL.
Akin to their 4-substituted benzenesulfonamide counterparts, com-
pounds 10k (SO2Me), 10l (OH), 10m (NHCOMe), 10n (NH2), 10o
(CONH2) and 10p (SO2NH2) were again revealed to exhibit inferior
activity, with MICs of 4, 8, 8, 16, 16 and 16 µg/mL, respectively. Within
the 2-substituted benzenesulfonamide series (Table 3) compounds 11a
(R = F), 11f (Cl), 11g (Br), 11h (CF3) and 11i (OCF3) were found to be
largely comparable to their 3- and 4-substituted counterparts, with
MICs ≤ 0.125 µg/mL, whereas derivative 11j (R = CN) was shown to
be less active (MIC 1 µg/mL). Polyhalogenated benzenesulfonamides
11b, 11c, 11d and 11e all displayed good activity (MIC 0.0625 µg/mL)
(Table 3). In the absence of 50 µM ZnSO4 compounds 9–11 were de-
monstrated to be significantly less active against S. uberis
(MIC ≥ 64 µg/mL). Against S. uberis, zinc alone (as ZnSO4 in the ab-
sence of compound) was shown to have an MIC in excess of 800 µg/mL.
Over a century ago, Overton39 and Meyer40 demonstrated that the
lipophilicity of a compound (or in this particular instance a metal–li-
gand complex) could be related quantitatively to its biological activity.
Table 1
Antibacterial activity of compounds 9a-y against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4.
Compound R Yield (%) pKa(NH)a Log P calc.a Retention factor (k′)b Log D7.8a MIC (µg/mL)c,d
9a Cl 56 6.69 3.25 11.4 2.72 (2.08 ± 0.07)f 0.0625
9b Br 80 6.69 4.03 12.8 3.50 0.0625
9c tBu 92 7.18 4.92 39.5 4.61 0.0625
9d OCF3 50 6.60 3.37 23.3 2.80 0.0625
9e SMe 81 6.95 3.03 12.0 2.63 0.0625
9f F 61 6.73 2.84 6.0 2.34 0.125
9g CF3 74 6.59 3.52 18.6 2.95 (2.03 ± 0.09)f 0.125
9h OCHF2 92 6.74 3.44 11.2 2.94 0.125
9i SCF3 76 6.59 4.06 36.5 3.49 0.125
9j NHCO2 tBu 82 7.83 3.75 27.7 3.49 0.125
9k H 68 7.08 (6.99)e 2.61 5.1 2.24 (1.99 ± 0.09)f 0.25
9l Me 63 7.17 3.11 8.5 2.78 0.25
9m OMe 45 7.05 2.32 6.8 1.97 0.25
9n NO2 45 6.30 (6.10)e 2.54 7.2 1.79 0.25
9o CO2Me 50 6.67 2.84 7.7 2.33 0.25
9p COMe 38 6.65 2.24 5.2 1.71 0.5
9q CN 65 6.42 2.36 5.1 1.68 (1.57 ± 0.04)f 1
9r CHO 40 6.71 2.17 3.8 1.67 1
9s NHCO2Me 88 7.83 2.47 4.7 2.22 2
9t SO2Me 43 6.38 1.88 3.0 1.18 4
9u CONH2 40 6.73 1.57 1.9 1.05 (0.94 ± 0.04)f 8
9v SO2NH2 25 6.53 1.32 2.1 0.72 16
9w NHCOMe 34 7.80 2.23 2.9 1.97 32
9x OH – 7.13 3.17 2.7 2.51 ≥256
9y NH2 – 8.01 (7.85)e 1.93 2.2 1.72 ≥256
Penicillin – – – – – – 0.25
ZnSO4 – – – – – – ≥800 µM
a Determined using ACD labs version 12, unless stated otherwise.
b Determined using an HPLC method, as described.
c Against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4.
d MIC ≥ 64 µg/mL in the absence of 50 µM ZnSO4.
e Determined experimentally using a spectrophotometric titration method, as described.
f Determined experimentally using a spectrophotometric shake-flask method, as described (n = 5).
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Furthermore, given that the surmised metal–ligand coordination pro-
cess would likely involve the participation of both the endocyclic qui-
noline nitrogen and the exocyclic deprotonated sulfonamide nitrogen as
donor atoms, it was anticipated that the acid-dissociation constant of
the sulfonamide group (pKa(NH)) would similarly play a key role in
metal-binding/transport; with the electronic nature (both mesomeric
and inductive effect) of the benzenesulfonamide ring substituent ex-
pected to strongly influence the pKa(NH). Accordingly, it was envisaged
that the pKa(NH) of the sulfonamide group could be fine-tuned by
tailoring the substituent on the benzenesulfonamide. In an effort to
correlate antibacterial activity against S. uberis (in the presence of
50 µM ZnSO4) to these two key physicochemical parameters, a tailored
Craig plot was prepared mapping both the electronic effect (Hammett
constant, σ) and lipophilic contribution (Hansch constant, π) of the
benzenesulfonamide ring substituent against the observed MIC (Fig. 2).
Based on this plot it was apparent that substituent lipophilicity had a
strong influence on antibacterial activity (against the mastitis-causing
pathogen S. uberis) in the presence of supplementary zinc.
Table 2
Antibacterial activity of compounds 10a-p against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4.
Compound R Yield (%) pKa(NH)a Log P calc.a Retention factor (k′)b Log D7.8a MIC (µg/mL)c,d
10a Cl 63 6.28 3.23 10.6 2.77 0.0625
10b CF3 74 6.69 3.31 17.3 2.81 0.0625
10c OCF3 52 6.74 3.89 22.4 3.41 0.0625
10d F 88 6.87 2.79 6.6 2.38 0.125
10e Br 80 6.81 3.42 12.5 2.96 0.125
10f Me 80 7.17 3.05 8.4 2.75 0.25
10g OMe 86 7.12 2.84 6.9 2.52 0.25
10h NO2 40 6.45 2.29 7.0 1.59 0.25
10i CO2Me 64 6.76 2.86 7.0 2.39 0.25
10j CN 51 6.56 2.01 5.0 1.44 1
10k SO2Me 75 6.53 1.94 3.0 1.35 4
10l OH – 7.60 1.97 2.9 1.61 8
10m NHCOMe 16 7.02 2.04 N.D. 1.70 8
10n NH2 – 7.31 1.57 1.4 1.29 16
10o CONH2 77 6.81 1.49 1.7 1.02 16
10p SO2NH2 29 6.64 1.56 2.0 1.02 16
Penicillin – – – – – – 0.25
ZnSO4 – – – – – – ≥800 µM
a Determined using ACD labs version 12, unless stated otherwise.
b Determined using an HPLC method, as described.
c Against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4.
d MIC ≥ 64 µg/mL in the absence of 50 µM ZnSO4; N.D. = not determined.
Table 3
Antibacterial activity of compounds 11a-j against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4.
Compound Yield (%) R2 R3 R4 R5 pKa(NH)a Log P calc.a Retention factor (k′)b Log D7.8a MIC (µg/mL)c,d
11a 45 F H H H 6.28 2.68 4.3 2.18 0.0625
11b 96 H F F H 6.52 3.03 7.4 2.45 0.0625
11c 83 Cl Cl H H 6.39 3.50 10.5 2.83 0.0625
11d 77 Cl H Cl H 6.27 3.59 13.6 2.84 0.0625
11e 97 F H F F 6.14 2.98 7.5 2.06 0.0625
11f 47 Cl H H H 6.66 2.95 5.5 2.43 0.125
11g 31 Br H H H 6.66 2.66 6.8 2.14 0.125
11h 34 CF3 H H H 6.56 3.16 9.3 2.57 0.125
11i 38 OCF3 H H H 6.56 3.31 10.1 2.71 0.125
11j 63 CN H H H 6.37 2.01 3.5 1.31 1
Penicillin – – – – – – – – – 0.25
ZnSO4 – – – – – – – – – ≥800 µM
a Determined using ACD labs version 12, unless stated otherwise.
b Determined using an HPLC method, as described.
c Against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4.
d MIC ≥ 64 µg/mL in the absence of 50 µM ZnSO4.
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Table 4
Antibacterial activity of compounds 12–45 against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4.
Compound R Yield (%) pKa(NH)a Log P calc.a Retention factor (k′)b Log D7.8a MIC (µg/mL)c,d
12 77 6.28 3.59 16.2 2.40 0.0625
13 81 4.67 2.38 3.6 0.36 0.0625
14 62 7.58 2.30 <2.5 0.73 0.125
15 80 5.02 2.26 3.5 0.34 0.125
16 21 6.55 3.31 N.D. 2.63 0.125
17 53 6.41 2.66 3.6 1.91 0.125
18 18 6.40 2.10 4.0 1.41 0.125
19 63 7.58 2.93 3.4 1.41 0.25
20 40 7.57 1.97 <2.5 0.16 0.25
21 53 6.94 2.52 4.1 2.04 0.25
22 51 6.98 2.38 3.6 1.91 0.25
23 48 6.05 2.37 3.9 1.28 0.25
24 34 5.66 2.20 5.3 0.60 0.25
25 33 5.43 1.52 <2.5 −0.18 0.25
26 51 5.87 1.92 <2.5 0.88 0.25
27 25 7.57 2.74 4.6 1.69 0.25
28 40 5.84 2.15 2.4 0.73 0.25
29 22 9.55 2.50 5.1 2.37 0.25
30 79 7.58 2.26 <2.5 0.85 0.5
31 55 5.75 2.34 <2.5 0.95 0.5
32 CF3 48 2.53 3.28 4.5 1.13 0.5
33 25 6.48 0.73 2.8 0.03 0.5
34 68 5.47 1.89 <2.5 0.21 0.5
35 11 9.55 1.97 2.5 1.84 0.5
36 27 7.58 1.79 1.8 0.36 1
37 39 6.55 2.33 5.2 1.66 1
(continued on next page)
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Benzenesulfonamides (both 3- and 4-substituted) bearing lipophilic
chloro (9a and 10a), bromo (9b and 10e), trifluoromethyl (9g and 10b)
and trifluoromethoxy (9d and 10c) substituents all displayed
MICs ≤ 0.125 µg/mL. Conversely, benzenesulfonamides substituted
with polar groups, such as sulfones (9t and 10k), carboxamides (9s, 9u,
10m and 10o) and sulfonamides (9v and 10p), were found to be of
significantly lower activity (MIC ≥ 4 µg/mL), despite having largely
comparable Hammett constants. These trends were generally found to
be in agreement with both in silico (log P) and experimentally de-
termined (retention factor, k′) lipophilicity indicators for the whole
molecule (Tables 1 and 2).
Trends were less apparent with respect to the electronic contribu-
tion of the benzenesulfonamide ring substituent, though a more pro-
nounced electronic influence was observed for para-substituents where
resonance was a significant contributor to their Hammett constant,
namely hydroxy-substituted benzenesulfonamide 9x and amino-sub-
stituted benzenesulfonamide 9y, which were both demonstrated to be
completely inactive against S. uberis in the presence of supplementary
zinc (MIC ≥ 256 µg/mL); conversely, such a phenomena was found to
be absent in their corresponding meta-substituted counterparts, namely
compounds 10l (R = OH) and 10n (NH2) (MIC 8 and 16 µg/mL, re-
spectively) (Tables 1 and 2). Experimentally determined sulfonamide
pKa(NH) values were subsequently generated for compounds 9k (pKa(NH)
exp. 6.99; R = H), 9n (pKa(NH) exp. 6.10; R = NO2) and 9y (pKa(NH)
exp. 7.85; R = NH2); the latter two as exemplars of benzenesulfona-
mides bearing either strongly electron-withdrawing or strongly elec-
tron-donating groups, respectively. In silico generated pKa(NH) values
were found to be in good agreement with their experimentally derived
counterparts across this pKa range (Table 1). To further probe the in-
fluence of the electronic nature of the benzenesulfonamide ring sub-
stituent on the degree of sulfonamide ionization, the proportion of
sulfonamide residing in its ionized state (a presumed pre-requisite for
effective zinc chelation) at pH 7.8 (initial [external] pH of Todd Hewitt
broth media for S. uberis incubation) was calculated for compounds 9k,
9n and 9y (using the Henderson-Hasselbalch equation). Based on their
experimental pKa(NH) values, the sulfonamide moieties present in
compounds 9k, 9n and 9y were calculated as being 86%, 98% and 48%
ionized, respectively, at pH 7.8. More pronounced still was the pre-
dicted proportion of ionized and non-ionized sulfonamide at pH 6.8
(intracellular pH for S. uberis).28 At this lower pH, again taking com-
pounds 9k, 9n and 9y as exemplars, the influence of the sulfonamide
ring substituent on sulfonamide ionization was further amplified (40%,
83% and 9% sulfonamide ionization, respectively); which in theory
could be expected to have an impact on both intracellular zinc release
(through metal-proton exchange), and the rate at which the metal-free
ligand passes back across the bacterial cell membrane and out of the
cell to re-engage with further extracellular zinc.
Finally, in an effort to combine these two key physicochemical
factors (acid-dissociation constant and lipophilicity) into a single
parameter, experimental log D7.8 values were determined for benze-
nesulfonamides 9a, 9g, 9k, 9q and 9u; as exemplars of compounds with
predicted log D7.8 values of approximately 1.0, 1.5, 2.0, 2.5 and 3.0,
respectively (Table 1). While compounds 9k, 9q and 9u largely adhered
to their in silico derived values, a significant discrepancy was noted
between the predicted and experimentally determined values for com-
pounds 9a and 9g; which were revealed to be approximately 1 log unit
lower than predicted. On the grounds that the putative mechanism of
action of these ionophoric compounds centres on the reversible trans-
location of zinc ions across bacterial cell membranes as part of a me-
tal–ligand complex, a degree of caution should be exercised when at-
tempting to directly plot biological activity against compound
lipophilicity.
Of the miscellaneous sulfonamide derivatives evaluated (Table 4)
compounds 12 (R = trifluoromethylbenzyl) and 13 (benzothiadiazole)
displayed the greatest activity (MIC 0.0625 µg/mL), followed by com-
pounds 14 (cyclopropylmethyl), 15 (trifluoropropyl), 16 (chlor-
othiophene), 17 (dimethylisoxazole) and 18 (methoxypyridine), with
MICs a single dilution higher at 0.125 µg/mL; revealing levels of anti-
bacterial activity against S. uberis in the presence of supplementary zinc
comparable to those observed within the parallel substituted benzene-
sulfonamide series (9–11). In the main, and in general accordance with
previous observations, lipophilic heterocyclic sulfonamide derivatives
such as benzothiadiazole 13, and heterocyclic sulfonamides substituted
with lipophilic substituents, for example chlorothiophene 16, were
Table 4 (continued)
Compound R Yield (%) pKa(NH)a Log P calc.a Retention factor (k′)b Log D7.8a MIC (µg/mL)c,d
38 76 6.44 1.65 <2.5 1.00 1
39 20 10.7 1.15 <2.5 1.01 1
40 Me 71 7.58 1.40 <2.5 −0.20 2
41 13 4.51 1.45 <2.5 −0.62 2
42 44 4.44 2.45 <2.5 0.32 2
43 9 6.81 0.61 <2.5 0.15 4
44 27 6.58 1.50 <2.5 0.95 32
45 – 5.04 1.41 <2.5 −1.27 ≥256
Penicillin – – – – – – 0.25
ZnSO4 – – – – – – ≥800 µM
a Determined using ACD labs version 12, unless stated otherwise.
b Determined using an HPLC method, as described.
c Against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4.
d MIC ≥ 64 µg/mL in the absence of 50 µM ZnSO4.
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generally found to exhibit greater activity (MIC ≤ 0.125 µg/mL) than
sulfonamides incorporating polar heterocyclic groups, such as pyrazole
43, imidazole 44 and piperidine 45 (MIC ≥ 4 µg/mL). That said,
anomalies were found to be more prevalent within the heterocyclic
sulfonamide series, for example compounds 25 (tetrahydropyran) and
26 (isoxazole) demonstrated better antibacterial activity than would
have been expected for these relatively polar examples. Interestingly,
trifluoromethylbenzyl-substituted sulfonamide 12 was revealed to be of
comparable activity to trifluoromethylbenzenesulfonamide 9g, despite
the sulfonamide group not being electronically conjugated to the aro-
matic ring (as it is in the case of the latter).
All compounds were similarly evaluated against both S. aureus
strain ATCC 6538 and E. coli strain ATCC 10536, again both in the
presence and absence of 50 µM ZnSO4. Only compounds 9g (MIC 4 µg/
mL) and 11d (MIC 8 µg/mL) were found to have reasonable activity
against S. aureus in the presence of supplementary zinc (all other
compounds, MIC ≥ 32 µg/mL); all compounds were demonstrated to
be relatively inactive against S. aureus in the absence of supplementary
zinc (MIC≥ 32 µg/mL). Likewise, all compounds were confirmed to be
inactive against E. coli (MIC ≥ 256 µg/mL), both in the presence and
absence of supplementary zinc. As such it is evident that of the mastitis
causative pathogens studied, S. uberis would appear to be considerably
more sensitive to these 8-sulfonamidoquinoline-zinc combinations than
either S. aureus or E. coli. Compound 9g was subsequently shown to be
bactericidal in action with an MBC of 0.125 µg/mL against S. uberis
strain ATCC 19436 in the presence of 50 µM ZnSO4; the fractional
inhibitory concentration index (FICI) (used to describe drug interac-
tions) was determined to be< 0.5, indicating synergy between com-
pound 9g and ZnSO4 (see Fig. 2, Supplementary Data). In the absence of
supplementary zinc the MBC of compound 9g against S. uberis was
≥128 µg/mL. Against both S. aureus strain ATCC 6538 and E. coli strain
ATCC 10536 compound 9g was confirmed to be inactive
(MBC ≥ 128 µg/mL, both in the presence and absence of 50 µM
ZnSO4).
To evaluate the ability of compound 9g to be classed as a chemical
disinfectant or antiseptic we developed and validated a modified
quantitative suspension test (BS EN 1656:2009, European Committee
for Standardization, 2009), for use in 96-well microtiter plates, to
evaluate the sanitizing activity of compound 9g in the presence of
supplementary zinc against S. uberis ATCC 19436. The EN1656 stan-
dardised assay specifies strict conditions in which the evaluation of
potential chemical disinfections and antiseptics must be carried out
under. Compounds for testing must be biologically active in the pre-
sence of a well-defined interfering agent (European Committee for
Standardization, 2000). For the validation of teat spray disinfectants
the use of skim milk as an interfering agent is required. Our findings
(Table 5) indicated that under all conditions tested compound 9g was
able to reduce the bacterial load of S. uberis by>5-log10 after 5 min
exposure in the presence of interfering skim milk, indicating the po-
tential for compound 9g (with broader spectrum of activity) to function
as a preventative teat disinfectant for the prevention of bovine mastitis.
Additionally, these results further validate the use of 8-
Fig. 2. Craig plot mapping the electronic effect (Hammett constant, σ) and lipophilicity (Hansch constant, π) of the benzenesulfonamide ring substituent (for
compounds 9–10) versus MIC (against S. uberis strain ATCC 19436 in the presence of 50 µM ZnSO4).
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sulfonamidoquinolines as potential animal-specific sanitizers.
In summary, based on the findings of this study, it is apparent that
this particular family of 8-sulfonamidoquinolines are reliant on the
participation of supplementary zinc for effective antibacterial activity.
As such it is tentatively postulated that, analogous to the aforedescribed
8-HQs, these bioisosteric structural equivalents similarly share the ca-
pacity to form reversible metal–ligand complexes with divalent transi-
tion metal ions such as zinc(II); potentially mimicking the structure of
zinc complexes of PBT2, as described by Nguyen and co-workers.19
Moreover, it is suggested that these lipid-soluble complexes are en-
dowed with the ability to transport zinc ions across bacterial cell
membranes, with ensuing elevated intracellular zinc concentrations
ultimately leading to zinc intoxication. In contrast to metal chelators
and metal shuttles, whereby increasing the metal concentration leads to
either a reversal of a compound’s biological effect or has no influence at
all, respectively, the biological activity of metal ionophores, by defi-
nition, is amplified with increasing metal concentration. By means of a
checkerboard broth dilution assay, using compound 9g, we can also
now confirm that higher zinc concentrations in the assay medium
(which are ineffective on their own) confer greater antibacterial activity
at a pre-determined concentration of 8-sulfonamidoquinoline, as would
be expected for a compound which was functioning as a metal iono-
phore (see Fig. 2, Supplementary Data). A more detailed mechanistic
explanation sits outside the scope of this current manuscript. In con-
clusion, 8-sulfonamidoquinolines, in combination with supplementary
zinc, serve as a potentially promising platform for the design of future
antibacterial therapeutics for use in non-human applications.
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Table 5
Log reduction (cfu/mL) of S. uberis ATCC 19436 in the presence of compound
9g and ZnSO4, as determined by the modified microplate quantitative suspen-
sion test (BS EN 1656:2009) for chemical disinfectants; including EN1656
controls.




9g (10 mg/mL) + ZnSO4 (1.92 mM) 8.54 Pass
9g (5 mg/mL) + ZnSO4 (0.96 mM) 8.54 Pass
9g (1 mg/mL) + ZnSO4 (0.192 mM) 6.36 Pass
Growth control (without 9g and
neutralizers)b
– Pass
Neutralizer toxicity controlc – Pass
Method validation controld – Pass
a Initial S. uberis count at OD625 0.3 equates to approximately
3.45 × 108 CFU/mL. These data are representative of a biological triplicate.
b Growth control: milk and bacteria only (i.e. without compound 9g and
neutralizers), to ensure that the presence of milk does not inhibit the growth of
S. uberis.
c Neutralizer toxicity control: neutralizer and S. uberis cells only (i.e. without
compound 9g and milk), to ensure neutralizer toxicity does not inhibit growth
of S. uberis.
d Method validation control: S. uberis cells are added post compound 9g
neutralization, to ensure that the neutralizer acts against compound 9g, and
that S. uberis can grow in the presence of compound.
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